#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=ADHD and Cannabis Use in Young Adults Examined Using fMRI of a Go/NoGo Task
#Text=Background
#Text=Children diagnosed with attention-deficit/hyperactivity disorder (ADHD) are at increased risk for substance abuse.
1-1	0-4	ADHD	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder
1-2	5-8	and	_
1-3	9-17	Cannabis	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[1]
1-4	18-21	Use	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[1]
1-5	22-24	in	_
1-6	25-30	Young	_
1-7	31-37	Adults	_
1-8	38-46	Examined	_
1-9	47-52	Using	_
1-10	53-57	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
1-11	58-60	of	_
1-12	61-62	a	_
1-13	63-65	Go	http://maven.renci.org/NeuroBridge/neurobridge#GoNoGoTask[2]
1-14	65-66	/	http://maven.renci.org/NeuroBridge/neurobridge#GoNoGoTask[2]
1-15	66-70	NoGo	http://maven.renci.org/NeuroBridge/neurobridge#GoNoGoTask[2]
1-16	71-75	Task	http://maven.renci.org/NeuroBridge/neurobridge#GoNoGoTask[2]
1-17	76-86	Background	_
1-18	87-95	Children	_
1-19	96-105	diagnosed	_
1-20	106-110	with	_
1-21	111-128	attention-deficit	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder[3]
1-22	128-129	/	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder[3]
1-23	129-142	hyperactivity	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder[3]
1-24	143-151	disorder	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder[3]
1-25	152-153	(	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder[3]
1-26	153-157	ADHD	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder[3]
1-27	157-158	)	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder[3]
1-28	159-162	are	_
1-29	163-165	at	_
1-30	166-175	increased	_
1-31	176-180	risk	_
1-32	181-184	for	_
1-33	185-194	substance	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[4]
1-34	195-200	abuse	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[4]
1-35	200-201	.	_

#Text=Response inhibition is a hallmark of ADHD, yet the combined effects of ADHD and regular substance use on neural networks associated with response inhibition are unknown.
2-1	202-210	Response	_
2-2	211-221	inhibition	_
2-3	222-224	is	_
2-4	225-226	a	_
2-5	227-235	hallmark	_
2-6	236-238	of	_
2-7	239-243	ADHD	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder
2-8	243-244	,	_
2-9	245-248	yet	_
2-10	249-252	the	_
2-11	253-261	combined	_
2-12	262-269	effects	_
2-13	270-272	of	_
2-14	273-277	ADHD	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder
2-15	278-281	and	_
2-16	282-289	regular	_
2-17	290-299	substance	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[5]
2-18	300-303	use	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[5]
2-19	304-306	on	_
2-20	307-313	neural	_
2-21	314-322	networks	_
2-22	323-333	associated	_
2-23	334-338	with	_
2-24	339-347	response	_
2-25	348-358	inhibition	_
2-26	359-362	are	_
2-27	363-370	unknown	_
2-28	370-371	.	_

#Text=Methods
#Text=Task-based functional Magnetic Resonance Imaging (fMRI) data from young adults with childhood ADHD with (n=25) and without (n=25) cannabis use ≥ monthly in the past year were compared with a local normative comparison group (LNCG) with (n=11) and without (n=12) cannabis use.
3-1	372-379	Methods	_
3-2	380-390	Task-based	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[6]
3-3	391-401	functional	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[7]
3-4	402-410	Magnetic	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[7]
3-5	411-420	Resonance	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[7]
3-6	421-428	Imaging	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[7]
3-7	429-430	(	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[7]
3-8	430-434	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[7]
3-9	434-435	)	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[7]
3-10	436-440	data	_
3-11	441-445	from	_
3-12	446-451	young	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder[8]
3-13	452-458	adults	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder[8]
3-14	459-463	with	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder[8]
3-15	464-473	childhood	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder[8]
3-16	474-478	ADHD	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder[8]
3-17	479-483	with	_
3-18	484-485	(	_
3-19	485-486	n	_
3-20	486-487	=	_
3-21	487-489	25	_
3-22	489-490	)	_
3-23	491-494	and	_
3-24	495-502	without	_
3-25	503-504	(	_
3-26	504-505	n	_
3-27	505-506	=	_
3-28	506-508	25	_
3-29	508-509	)	_
3-30	510-518	cannabis	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[9]
3-31	519-522	use	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[9]
3-32	523-524	≥	_
3-33	525-532	monthly	_
3-34	533-535	in	_
3-35	536-539	the	_
3-36	540-544	past	_
3-37	545-549	year	_
3-38	550-554	were	_
3-39	555-563	compared	_
3-40	564-568	with	_
3-41	569-570	a	_
3-42	571-576	local	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[10]
3-43	577-586	normative	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[10]
3-44	587-597	comparison	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[10]
3-45	598-603	group	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[10]
3-46	604-605	(	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[10]
3-47	605-609	LNCG	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[10]
3-48	609-610	)	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[10]
3-49	611-615	with	_
3-50	616-617	(	_
3-51	617-618	n	_
3-52	618-619	=	_
3-53	619-621	11	_
3-54	621-622	)	_
3-55	623-626	and	_
3-56	627-634	without	_
3-57	635-636	(	_
3-58	636-637	n	_
3-59	637-638	=	_
3-60	638-640	12	_
3-61	640-641	)	_
3-62	642-650	cannabis	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[11]
3-63	651-654	use	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[11]
3-64	654-655	.	_

#Text=Go/NoGo behavioral and fMRI data were evaluated for main and interaction effects of ADHD diagnosis and cannabis use.
4-1	656-658	Go	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[12]|http://maven.renci.org/NeuroBridge/neurobridge#GoNoGoTask[13]
4-2	658-659	/	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[12]|http://maven.renci.org/NeuroBridge/neurobridge#GoNoGoTask[13]
4-3	659-663	NoGo	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[12]|http://maven.renci.org/NeuroBridge/neurobridge#GoNoGoTask[13]
4-4	664-674	behavioral	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[12]|http://maven.renci.org/NeuroBridge/neurobridge#GoNoGoTask[13]
4-5	675-678	and	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[12]
4-6	679-683	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[12]|http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[14]
4-7	684-688	data	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[12]|http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[14]
4-8	689-693	were	_
4-9	694-703	evaluated	_
4-10	704-707	for	_
4-11	708-712	main	_
4-12	713-716	and	_
4-13	717-728	interaction	_
4-14	729-736	effects	_
4-15	737-739	of	_
4-16	740-744	ADHD	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder
4-17	745-754	diagnosis	_
4-18	755-758	and	_
4-19	759-767	cannabis	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[15]
4-20	768-771	use	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[15]
4-21	771-772	.	_

#Text=Results
#Text=ADHD participants made significantly more commission errors on NoGo trials than controls.
5-1	773-780	Results	_
5-2	781-785	ADHD	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder[16]
5-3	786-798	participants	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder[16]
5-4	799-803	made	_
5-5	804-817	significantly	_
5-6	818-822	more	_
5-7	823-833	commission	_
5-8	834-840	errors	_
5-9	841-843	on	_
5-10	844-848	NoGo	_
5-11	849-855	trials	_
5-12	856-860	than	_
5-13	861-869	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
5-14	869-870	.	_

#Text=ADHD participants also had less frontoparietal and frontostriatal activity, independent of cannabis use.
6-1	871-875	ADHD	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder[17]
6-2	876-888	participants	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder[17]
6-3	889-893	also	_
6-4	894-897	had	_
6-5	898-902	less	_
6-6	903-917	frontoparietal	_
6-7	918-921	and	_
6-8	922-936	frontostriatal	_
6-9	937-945	activity	_
6-10	945-946	,	_
6-11	947-958	independent	_
6-12	959-961	of	_
6-13	962-970	cannabis	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[18]
6-14	971-974	use	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[18]
6-15	974-975	.	_

#Text=No main effects of cannabis use on response inhibition or functional brain activation were observed.
7-1	976-978	No	_
7-2	979-983	main	_
7-3	984-991	effects	_
7-4	992-994	of	_
7-5	995-1003	cannabis	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[19]
7-6	1004-1007	use	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[19]
7-7	1008-1010	on	_
7-8	1011-1019	response	_
7-9	1020-1030	inhibition	_
7-10	1031-1033	or	_
7-11	1034-1044	functional	_
7-12	1045-1050	brain	_
7-13	1051-1061	activation	_
7-14	1062-1066	were	_
7-15	1067-1075	observed	_
7-16	1075-1076	.	_

#Text=An interaction of ADHD diagnosis and cannabis use was found in the right hippocampus and cerebellar vermis, with increased recruitment of these regions in cannabis-using controls during correct response inhibition.
8-1	1077-1079	An	_
8-2	1080-1091	interaction	_
8-3	1092-1094	of	_
8-4	1095-1099	ADHD	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder
8-5	1100-1109	diagnosis	_
8-6	1110-1113	and	_
8-7	1114-1122	cannabis	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[20]
8-8	1123-1126	use	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[20]
8-9	1127-1130	was	_
8-10	1131-1136	found	_
8-11	1137-1139	in	_
8-12	1140-1143	the	_
8-13	1144-1149	right	_
8-14	1150-1161	hippocampus	_
8-15	1162-1165	and	_
8-16	1166-1176	cerebellar	_
8-17	1177-1183	vermis	_
8-18	1183-1184	,	_
8-19	1185-1189	with	_
8-20	1190-1199	increased	_
8-21	1200-1211	recruitment	_
8-22	1212-1214	of	_
8-23	1215-1220	these	_
8-24	1221-1228	regions	_
8-25	1229-1231	in	_
8-26	1232-1246	cannabis-using	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[21]
8-27	1247-1255	controls	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[21]
8-28	1256-1262	during	_
8-29	1263-1270	correct	_
8-30	1271-1279	response	_
8-31	1280-1290	inhibition	_
8-32	1290-1291	.	_

#Text=Conclusions
#Text=ADHD participants had impaired response inhibition combined with less fronto-parietal/striatal activity, regardless of cannabis use history.
9-1	1292-1303	Conclusions	_
9-2	1304-1308	ADHD	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder[22]
9-3	1309-1321	participants	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder[22]
9-4	1322-1325	had	_
9-5	1326-1334	impaired	_
9-6	1335-1343	response	_
9-7	1344-1354	inhibition	_
9-8	1355-1363	combined	_
9-9	1364-1368	with	_
9-10	1369-1373	less	_
9-11	1374-1389	fronto-parietal	_
9-12	1389-1390	/	_
9-13	1390-1398	striatal	_
9-14	1399-1407	activity	_
9-15	1407-1408	,	_
9-16	1409-1419	regardless	_
9-17	1420-1422	of	_
9-18	1423-1431	cannabis	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[23]
9-19	1432-1435	use	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[23]
9-20	1436-1443	history	_
9-21	1443-1444	.	_

#Text=Cannabis use did not impact behavioral response inhibition.
10-1	1445-1453	Cannabis	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[24]
10-2	1454-1457	use	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[24]
10-3	1458-1461	did	_
10-4	1462-1465	not	_
10-5	1466-1472	impact	_
10-6	1473-1483	behavioral	_
10-7	1484-1492	response	_
10-8	1493-1503	inhibition	_
10-9	1503-1504	.	_

#Text=Cannabis use was associated with hippocampal and cerebellar activation, areas rich in cannabinoid receptors, in LNCG but not ADHD participants.
11-1	1505-1513	Cannabis	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[25]
11-2	1514-1517	use	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[25]
11-3	1518-1521	was	_
11-4	1522-1532	associated	_
11-5	1533-1537	with	_
11-6	1538-1549	hippocampal	_
11-7	1550-1553	and	_
11-8	1554-1564	cerebellar	_
11-9	1565-1575	activation	_
11-10	1575-1576	,	_
11-11	1577-1582	areas	_
11-12	1583-1587	rich	_
11-13	1588-1590	in	_
11-14	1591-1602	cannabinoid	_
11-15	1603-1612	receptors	_
11-16	1612-1613	,	_
11-17	1614-1616	in	_
11-18	1617-1621	LNCG	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
11-19	1622-1625	but	_
11-20	1626-1629	not	_
11-21	1630-1634	ADHD	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder[26]
11-22	1635-1647	participants	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder[26]
11-23	1647-1648	.	_

#Text=This may reflect recruitment of compensatory circuitry in cannabis using controls but not ADHD participants.
12-1	1649-1653	This	_
12-2	1654-1657	may	_
12-3	1658-1665	reflect	_
12-4	1666-1677	recruitment	_
12-5	1678-1680	of	_
12-6	1681-1693	compensatory	_
12-7	1694-1703	circuitry	_
12-8	1704-1706	in	_
12-9	1707-1715	cannabis	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[27]|http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[28]
12-10	1716-1721	using	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[27]
12-11	1722-1730	controls	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[27]
12-12	1731-1734	but	_
12-13	1735-1738	not	_
12-14	1739-1743	ADHD	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder[29]
12-15	1744-1756	participants	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder[29]
12-16	1756-1757	.	_

#Text=Future studies targeting hippocampal and cerebellar-dependent function in these groups may provide further insight into how this circuitry is altered by ADHD and cannabis use.
#Text=1 Background
#Text=Children with attention-deficit/hyperactivity disorder (ADHD) are at increased risk of substance use disorder (SUD).
13-1	1758-1764	Future	_
13-2	1765-1772	studies	_
13-3	1773-1782	targeting	_
13-4	1783-1794	hippocampal	_
13-5	1795-1798	and	_
13-6	1799-1819	cerebellar-dependent	_
13-7	1820-1828	function	_
13-8	1829-1831	in	_
13-9	1832-1837	these	_
13-10	1838-1844	groups	_
13-11	1845-1848	may	_
13-12	1849-1856	provide	_
13-13	1857-1864	further	_
13-14	1865-1872	insight	_
13-15	1873-1877	into	_
13-16	1878-1881	how	_
13-17	1882-1886	this	_
13-18	1887-1896	circuitry	_
13-19	1897-1899	is	_
13-20	1900-1907	altered	_
13-21	1908-1910	by	_
13-22	1911-1915	ADHD	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder
13-23	1916-1919	and	_
13-24	1920-1928	cannabis	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[30]
13-25	1929-1932	use	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[30]
13-26	1932-1933	.	_
13-27	1934-1935	1	_
13-28	1936-1946	Background	_
13-29	1947-1955	Children	_
13-30	1956-1960	with	_
13-31	1961-1978	attention-deficit	_
13-32	1978-1979	/	_
13-33	1979-1992	hyperactivity	_
13-34	1993-2001	disorder	_
13-35	2002-2003	(	_
13-36	2003-2007	ADHD	_
13-37	2007-2008	)	_
13-38	2009-2012	are	_
13-39	2013-2015	at	_
13-40	2016-2025	increased	_
13-41	2026-2030	risk	_
13-42	2031-2033	of	_
13-43	2034-2043	substance	_
13-44	2044-2047	use	_
13-45	2048-2056	disorder	_
13-46	2057-2058	(	_
13-47	2058-2061	SUD	_
13-48	2061-2062	)	_
13-49	2062-2063	.	_

#Text=Individuals with ADHD perform poorly on behavioral tests of response inhibition compared to non-ADHD samples, and it has been suggested that impairment in response inhibition may play a role in substance abuse risk.
14-1	2064-2075	Individuals	_
14-2	2076-2080	with	_
14-3	2081-2085	ADHD	_
14-4	2086-2093	perform	_
14-5	2094-2100	poorly	_
14-6	2101-2103	on	_
14-7	2104-2114	behavioral	_
14-8	2115-2120	tests	_
14-9	2121-2123	of	_
14-10	2124-2132	response	_
14-11	2133-2143	inhibition	_
14-12	2144-2152	compared	_
14-13	2153-2155	to	_
14-14	2156-2164	non-ADHD	_
14-15	2165-2172	samples	_
14-16	2172-2173	,	_
14-17	2174-2177	and	_
14-18	2178-2180	it	_
14-19	2181-2184	has	_
14-20	2185-2189	been	_
14-21	2190-2199	suggested	_
14-22	2200-2204	that	_
14-23	2205-2215	impairment	_
14-24	2216-2218	in	_
14-25	2219-2227	response	_
14-26	2228-2238	inhibition	_
14-27	2239-2242	may	_
14-28	2243-2247	play	_
14-29	2248-2249	a	_
14-30	2250-2254	role	_
14-31	2255-2257	in	_
14-32	2258-2267	substance	_
14-33	2268-2273	abuse	_
14-34	2274-2278	risk	_
14-35	2278-2279	.	_

#Text=Cannabis is the most commonly used illicit substance among youths with ADHD.
15-1	2280-2288	Cannabis	_
15-2	2289-2291	is	_
15-3	2292-2295	the	_
15-4	2296-2300	most	_
15-5	2301-2309	commonly	_
15-6	2310-2314	used	_
15-7	2315-2322	illicit	_
15-8	2323-2332	substance	_
15-9	2333-2338	among	_
15-10	2339-2345	youths	_
15-11	2346-2350	with	_
15-12	2351-2355	ADHD	_
15-13	2355-2356	.	_

#Text=Since cannabis use reduces levels of striatal dopamine synthesis and is associated with executive function deficits, the use of cannabis coupled with the pre-existing low levels of dopamine associated with ADHD may predict a synergistic reduction of dopamine.
16-1	2357-2362	Since	_
16-2	2363-2371	cannabis	_
16-3	2372-2375	use	_
16-4	2376-2383	reduces	_
16-5	2384-2390	levels	_
16-6	2391-2393	of	_
16-7	2394-2402	striatal	_
16-8	2403-2411	dopamine	_
16-9	2412-2421	synthesis	_
16-10	2422-2425	and	_
16-11	2426-2428	is	_
16-12	2429-2439	associated	_
16-13	2440-2444	with	_
16-14	2445-2454	executive	_
16-15	2455-2463	function	_
16-16	2464-2472	deficits	_
16-17	2472-2473	,	_
16-18	2474-2477	the	_
16-19	2478-2481	use	_
16-20	2482-2484	of	_
16-21	2485-2493	cannabis	_
16-22	2494-2501	coupled	_
16-23	2502-2506	with	_
16-24	2507-2510	the	_
16-25	2511-2523	pre-existing	_
16-26	2524-2527	low	_
16-27	2528-2534	levels	_
16-28	2535-2537	of	_
16-29	2538-2546	dopamine	_
16-30	2547-2557	associated	_
16-31	2558-2562	with	_
16-32	2563-2567	ADHD	_
16-33	2568-2571	may	_
16-34	2572-2579	predict	_
16-35	2580-2581	a	_
16-36	2582-2593	synergistic	_
16-37	2594-2603	reduction	_
16-38	2604-2606	of	_
16-39	2607-2615	dopamine	_
16-40	2615-2616	.	_

#Text=This reduction may result in exacerbation of ADHD- and/or cannabis-related cognitive deficits.
17-1	2617-2621	This	_
17-2	2622-2631	reduction	_
17-3	2632-2635	may	_
17-4	2636-2642	result	_
17-5	2643-2645	in	_
17-6	2646-2658	exacerbation	_
17-7	2659-2661	of	_
17-8	2662-2666	ADHD	_
17-9	2666-2667	-	_
17-10	2668-2671	and	_
17-11	2671-2672	/	_
17-12	2672-2674	or	_
17-13	2675-2691	cannabis-related	_
17-14	2692-2701	cognitive	_
17-15	2702-2710	deficits	_
17-16	2710-2711	.	_

#Text=Increased impulsivity in rapid stimulus evaluation-response tasks has also been characteristic of individuals with histories of drug use.
18-1	2712-2721	Increased	_
18-2	2722-2733	impulsivity	_
18-3	2734-2736	in	_
18-4	2737-2742	rapid	_
18-5	2743-2751	stimulus	_
18-6	2752-2771	evaluation-response	_
18-7	2772-2777	tasks	_
18-8	2778-2781	has	_
18-9	2782-2786	also	_
18-10	2787-2791	been	_
18-11	2792-2806	characteristic	_
18-12	2807-2809	of	_
18-13	2810-2821	individuals	_
18-14	2822-2826	with	_
18-15	2827-2836	histories	_
18-16	2837-2839	of	_
18-17	2840-2844	drug	_
18-18	2845-2848	use	_
18-19	2848-2849	.	_

#Text=For example, cannabis users were found to have greater reflection impulsivity, a variant of impulsivity characterized by a lower threshold of processing/evaluating stimuli before committing to a response.
19-1	2850-2853	For	_
19-2	2854-2861	example	_
19-3	2861-2862	,	_
19-4	2863-2871	cannabis	_
19-5	2872-2877	users	_
19-6	2878-2882	were	_
19-7	2883-2888	found	_
19-8	2889-2891	to	_
19-9	2892-2896	have	_
19-10	2897-2904	greater	_
19-11	2905-2915	reflection	_
19-12	2916-2927	impulsivity	_
19-13	2927-2928	,	_
19-14	2929-2930	a	_
19-15	2931-2938	variant	_
19-16	2939-2941	of	_
19-17	2942-2953	impulsivity	_
19-18	2954-2967	characterized	_
19-19	2968-2970	by	_
19-20	2971-2972	a	_
19-21	2973-2978	lower	_
19-22	2979-2988	threshold	_
19-23	2989-2991	of	_
19-24	2992-3002	processing	_
19-25	3002-3003	/	_
19-26	3003-3013	evaluating	_
19-27	3014-3021	stimuli	_
19-28	3022-3028	before	_
19-29	3029-3039	committing	_
19-30	3040-3042	to	_
19-31	3043-3044	a	_
19-32	3045-3053	response	_
19-33	3053-3054	.	_

#Text=Accordingly, cannabis users were found to produce more commission errors in Go/NoGo and Stroop tasks, perhaps by virtue of incomplete processing of visual stimuli.
20-1	3055-3066	Accordingly	_
20-2	3066-3067	,	_
20-3	3068-3076	cannabis	_
20-4	3077-3082	users	_
20-5	3083-3087	were	_
20-6	3088-3093	found	_
20-7	3094-3096	to	_
20-8	3097-3104	produce	_
20-9	3105-3109	more	_
20-10	3110-3120	commission	_
20-11	3121-3127	errors	_
20-12	3128-3130	in	_
20-13	3131-3133	Go	_
20-14	3133-3134	/	_
20-15	3134-3138	NoGo	_
20-16	3139-3142	and	_
20-17	3143-3149	Stroop	_
20-18	3150-3155	tasks	_
20-19	3155-3156	,	_
20-20	3157-3164	perhaps	_
20-21	3165-3167	by	_
20-22	3168-3174	virtue	_
20-23	3175-3177	of	_
20-24	3178-3188	incomplete	_
20-25	3189-3199	processing	_
20-26	3200-3202	of	_
20-27	3203-3209	visual	_
20-28	3210-3217	stimuli	_
20-29	3217-3218	.	_

#Text=A potential exists, therefore, for a deleterious interaction between ADHD neurodevelopment, combined with cannabis exposure, to result in especially increased rapid-response impulsivity.
21-1	3219-3220	A	_
21-2	3221-3230	potential	_
21-3	3231-3237	exists	_
21-4	3237-3238	,	_
21-5	3239-3248	therefore	_
21-6	3248-3249	,	_
21-7	3250-3253	for	_
21-8	3254-3255	a	_
21-9	3256-3267	deleterious	_
21-10	3268-3279	interaction	_
21-11	3280-3287	between	_
21-12	3288-3292	ADHD	_
21-13	3293-3309	neurodevelopment	_
21-14	3309-3310	,	_
21-15	3311-3319	combined	_
21-16	3320-3324	with	_
21-17	3325-3333	cannabis	_
21-18	3334-3342	exposure	_
21-19	3342-3343	,	_
21-20	3344-3346	to	_
21-21	3347-3353	result	_
21-22	3354-3356	in	_
21-23	3357-3367	especially	_
21-24	3368-3377	increased	_
21-25	3378-3392	rapid-response	_
21-26	3393-3404	impulsivity	_
21-27	3404-3405	.	_

#Text=A recent publication characterized the impact of childhood ADHD and subsequent cannabis use on executive functioning in young adults.
22-1	3406-3407	A	_
22-2	3408-3414	recent	_
22-3	3415-3426	publication	_
22-4	3427-3440	characterized	_
22-5	3441-3444	the	_
22-6	3445-3451	impact	_
22-7	3452-3454	of	_
22-8	3455-3464	childhood	_
22-9	3465-3469	ADHD	_
22-10	3470-3473	and	_
22-11	3474-3484	subsequent	_
22-12	3485-3493	cannabis	_
22-13	3494-3497	use	_
22-14	3498-3500	on	_
22-15	3501-3510	executive	_
22-16	3511-3522	functioning	_
22-17	3523-3525	in	_
22-18	3526-3531	young	_
22-19	3532-3538	adults	_
22-20	3538-3539	.	_

#Text=ADHD diagnosis was predictive of performance deficits on a number of cognitive tasks including working memory and response inhibition.
23-1	3540-3544	ADHD	_
23-2	3545-3554	diagnosis	_
23-3	3555-3558	was	_
23-4	3559-3569	predictive	_
23-5	3570-3572	of	_
23-6	3573-3584	performance	_
23-7	3585-3593	deficits	_
23-8	3594-3596	on	_
23-9	3597-3598	a	_
23-10	3599-3605	number	_
23-11	3606-3608	of	_
23-12	3609-3618	cognitive	_
23-13	3619-3624	tasks	_
23-14	3625-3634	including	_
23-15	3635-3642	working	_
23-16	3643-3649	memory	_
23-17	3650-3653	and	_
23-18	3654-3662	response	_
23-19	3663-3673	inhibition	_
23-20	3673-3674	.	_

#Text=There were no significant main effects of cannabis use.
24-1	3675-3680	There	_
24-2	3681-3685	were	_
24-3	3686-3688	no	_
24-4	3689-3700	significant	_
24-5	3701-3705	main	_
24-6	3706-3713	effects	_
24-7	3714-3716	of	_
24-8	3717-3725	cannabis	_
24-9	3726-3729	use	_
24-10	3729-3730	.	_

#Text=However, exploratory analyses suggested that earlier, regular use of cannabis (before age 16) was associated with poorer executive functioning than later use of cannabis.
25-1	3731-3738	However	_
25-2	3738-3739	,	_
25-3	3740-3751	exploratory	_
25-4	3752-3760	analyses	_
25-5	3761-3770	suggested	_
25-6	3771-3775	that	_
25-7	3776-3783	earlier	_
25-8	3783-3784	,	_
25-9	3785-3792	regular	_
25-10	3793-3796	use	_
25-11	3797-3799	of	_
25-12	3800-3808	cannabis	_
25-13	3809-3810	(	_
25-14	3810-3816	before	_
25-15	3817-3820	age	_
25-16	3821-3823	16	_
25-17	3823-3824	)	_
25-18	3825-3828	was	_
25-19	3829-3839	associated	_
25-20	3840-3844	with	_
25-21	3845-3851	poorer	_
25-22	3852-3861	executive	_
25-23	3862-3873	functioning	_
25-24	3874-3878	than	_
25-25	3879-3884	later	_
25-26	3885-3888	use	_
25-27	3889-3891	of	_
25-28	3892-3900	cannabis	_
25-29	3900-3901	.	_

#Text=The current functional brain imaging study makes use of data collected in the same study to examine whether childhood ADHD and cannabis use history relate differentially, or interactively, to behavioral response inhibition and associated neural activity.
26-1	3902-3905	The	_
26-2	3906-3913	current	_
26-3	3914-3924	functional	_
26-4	3925-3930	brain	_
26-5	3931-3938	imaging	_
26-6	3939-3944	study	_
26-7	3945-3950	makes	_
26-8	3951-3954	use	_
26-9	3955-3957	of	_
26-10	3958-3962	data	_
26-11	3963-3972	collected	_
26-12	3973-3975	in	_
26-13	3976-3979	the	_
26-14	3980-3984	same	_
26-15	3985-3990	study	_
26-16	3991-3993	to	_
26-17	3994-4001	examine	_
26-18	4002-4009	whether	_
26-19	4010-4019	childhood	_
26-20	4020-4024	ADHD	_
26-21	4025-4028	and	_
26-22	4029-4037	cannabis	_
26-23	4038-4041	use	_
26-24	4042-4049	history	_
26-25	4050-4056	relate	_
26-26	4057-4071	differentially	_
26-27	4071-4072	,	_
26-28	4073-4075	or	_
26-29	4076-4089	interactively	_
26-30	4089-4090	,	_
26-31	4091-4093	to	_
26-32	4094-4104	behavioral	_
26-33	4105-4113	response	_
26-34	4114-4124	inhibition	_
26-35	4125-4128	and	_
26-36	4129-4139	associated	_
26-37	4140-4146	neural	_
26-38	4147-4155	activity	_
26-39	4155-4156	.	_

#Text=The Go/NoGo task has been used extensively to study inhibitory control in ADHD patients, who typically show hypoactivation of frontostriatal and frontoparietal networks thought to integrate external information with internal representations and actions.
27-1	4157-4160	The	_
27-2	4161-4163	Go	_
27-3	4163-4164	/	_
27-4	4164-4168	NoGo	_
27-5	4169-4173	task	_
27-6	4174-4177	has	_
27-7	4178-4182	been	_
27-8	4183-4187	used	_
27-9	4188-4199	extensively	_
27-10	4200-4202	to	_
27-11	4203-4208	study	_
27-12	4209-4219	inhibitory	_
27-13	4220-4227	control	_
27-14	4228-4230	in	_
27-15	4231-4235	ADHD	_
27-16	4236-4244	patients	_
27-17	4244-4245	,	_
27-18	4246-4249	who	_
27-19	4250-4259	typically	_
27-20	4260-4264	show	_
27-21	4265-4279	hypoactivation	_
27-22	4280-4282	of	_
27-23	4283-4297	frontostriatal	_
27-24	4298-4301	and	_
27-25	4302-4316	frontoparietal	_
27-26	4317-4325	networks	_
27-27	4326-4333	thought	_
27-28	4334-4336	to	_
27-29	4337-4346	integrate	_
27-30	4347-4355	external	_
27-31	4356-4367	information	_
27-32	4368-4372	with	_
27-33	4373-4381	internal	_
27-34	4382-4397	representations	_
27-35	4398-4401	and	_
27-36	4402-4409	actions	_
27-37	4409-4410	.	_

#Text=While Go/NoGo behavioral task performance has shown little susceptibility to acute substance use, cannabis dose dependence on functional activation of the thalamus during a Go/NoGo task has been observed.
28-1	4411-4416	While	_
28-2	4417-4419	Go	_
28-3	4419-4420	/	_
28-4	4420-4424	NoGo	_
28-5	4425-4435	behavioral	_
28-6	4436-4440	task	_
28-7	4441-4452	performance	_
28-8	4453-4456	has	_
28-9	4457-4462	shown	_
28-10	4463-4469	little	_
28-11	4470-4484	susceptibility	_
28-12	4485-4487	to	_
28-13	4488-4493	acute	_
28-14	4494-4503	substance	_
28-15	4504-4507	use	_
28-16	4507-4508	,	_
28-17	4509-4517	cannabis	_
28-18	4518-4522	dose	_
28-19	4523-4533	dependence	_
28-20	4534-4536	on	_
28-21	4537-4547	functional	_
28-22	4548-4558	activation	_
28-23	4559-4561	of	_
28-24	4562-4565	the	_
28-25	4566-4574	thalamus	_
28-26	4575-4581	during	_
28-27	4582-4583	a	_
28-28	4584-4586	Go	_
28-29	4586-4587	/	_
28-30	4587-4591	NoGo	_
28-31	4592-4596	task	_
28-32	4597-4600	has	_
28-33	4601-4605	been	_
28-34	4606-4614	observed	_
28-35	4614-4615	.	_

#Text=A cohort of abstinent (28 day washout) cannabis users showed increased activation during a Go/NoGo task in inferior frontal gyrus and superior parietal lobule, a well-described inhibition network.
29-1	4616-4617	A	_
29-2	4618-4624	cohort	_
29-3	4625-4627	of	_
29-4	4628-4637	abstinent	_
29-5	4638-4639	(	_
29-6	4639-4641	28	_
29-7	4642-4645	day	_
29-8	4646-4653	washout	_
29-9	4653-4654	)	_
29-10	4655-4663	cannabis	_
29-11	4664-4669	users	_
29-12	4670-4676	showed	_
29-13	4677-4686	increased	_
29-14	4687-4697	activation	_
29-15	4698-4704	during	_
29-16	4705-4706	a	_
29-17	4707-4709	Go	_
29-18	4709-4710	/	_
29-19	4710-4714	NoGo	_
29-20	4715-4719	task	_
29-21	4720-4722	in	_
29-22	4723-4731	inferior	_
29-23	4732-4739	frontal	_
29-24	4740-4745	gyrus	_
29-25	4746-4749	and	_
29-26	4750-4758	superior	_
29-27	4759-4767	parietal	_
29-28	4768-4774	lobule	_
29-29	4774-4775	,	_
29-30	4776-4777	a	_
29-31	4778-4792	well-described	_
29-32	4793-4803	inhibition	_
29-33	4804-4811	network	_
29-34	4811-4812	.	_

#Text=One additional study using the Go/NoGo task has demonstrated decreased right inferior frontal gyrus and anterior cingulate cortex activation during inhibition following administration of THC in contrast to placebo.
30-1	4813-4816	One	_
30-2	4817-4827	additional	_
30-3	4828-4833	study	_
30-4	4834-4839	using	_
30-5	4840-4843	the	_
30-6	4844-4846	Go	_
30-7	4846-4847	/	_
30-8	4847-4851	NoGo	_
30-9	4852-4856	task	_
30-10	4857-4860	has	_
30-11	4861-4873	demonstrated	_
30-12	4874-4883	decreased	_
30-13	4884-4889	right	_
30-14	4890-4898	inferior	_
30-15	4899-4906	frontal	_
30-16	4907-4912	gyrus	_
30-17	4913-4916	and	_
30-18	4917-4925	anterior	_
30-19	4926-4935	cingulate	_
30-20	4936-4942	cortex	_
30-21	4943-4953	activation	_
30-22	4954-4960	during	_
30-23	4961-4971	inhibition	_
30-24	4972-4981	following	_
30-25	4982-4996	administration	_
30-26	4997-4999	of	_
30-27	5000-5003	THC	_
30-28	5004-5006	in	_
30-29	5007-5015	contrast	_
30-30	5016-5018	to	_
30-31	5019-5026	placebo	_
30-32	5026-5027	.	_

#Text=Using a large multi-site cohort, the current study employed a Go/NoGo fMRI task to examine effects of cannabis use history on the inhibition circuitry in young adults with and without a childhood diagnosis of ADHD.
#Text=2 Methods
#Text=This study was approved by the Institutional Review Board at each of four participating sites that collected fMRI data.
31-1	5028-5033	Using	_
31-2	5034-5035	a	_
31-3	5036-5041	large	_
31-4	5042-5052	multi-site	_
31-5	5053-5059	cohort	_
31-6	5059-5060	,	_
31-7	5061-5064	the	_
31-8	5065-5072	current	_
31-9	5073-5078	study	_
31-10	5079-5087	employed	_
31-11	5088-5089	a	_
31-12	5090-5092	Go	_
31-13	5092-5093	/	_
31-14	5093-5097	NoGo	_
31-15	5098-5102	fMRI	_
31-16	5103-5107	task	_
31-17	5108-5110	to	_
31-18	5111-5118	examine	_
31-19	5119-5126	effects	_
31-20	5127-5129	of	_
31-21	5130-5138	cannabis	_
31-22	5139-5142	use	_
31-23	5143-5150	history	_
31-24	5151-5153	on	_
31-25	5154-5157	the	_
31-26	5158-5168	inhibition	_
31-27	5169-5178	circuitry	_
31-28	5179-5181	in	_
31-29	5182-5187	young	_
31-30	5188-5194	adults	_
31-31	5195-5199	with	_
31-32	5200-5203	and	_
31-33	5204-5211	without	_
31-34	5212-5213	a	_
31-35	5214-5223	childhood	_
31-36	5224-5233	diagnosis	_
31-37	5234-5236	of	_
31-38	5237-5241	ADHD	_
31-39	5241-5242	.	_
31-40	5243-5244	2	_
31-41	5245-5252	Methods	http://www.case.edu/ProvCaRe/provcare#StudyMethod
31-42	5253-5257	This	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]
31-43	5258-5263	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]
31-44	5264-5267	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]
31-45	5268-5276	approved	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]
31-46	5277-5279	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]
31-47	5280-5283	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]
31-48	5284-5297	Institutional	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]
31-49	5298-5304	Review	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]
31-50	5305-5310	Board	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]
31-51	5311-5313	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]
31-52	5314-5318	each	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]
31-53	5319-5321	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]
31-54	5322-5326	four	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]
31-55	5327-5340	participating	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]
31-56	5341-5346	sites	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]
31-57	5347-5351	that	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]
31-58	5352-5361	collected	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]
31-59	5362-5366	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]|http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[32]
31-60	5367-5371	data	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]|http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[32]
31-61	5371-5372	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]

#Text=Informed consent was obtained from all participants prior to participation.
#Text=2.1 Participants
#Text=Participants were recruited from the longitudinal follow-up of the Multimodal Treatment Study of ADHD (MTA) to participate in the current study.
32-1	5373-5381	Informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]
32-2	5382-5389	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]
32-3	5390-5393	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]
32-4	5394-5402	obtained	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]
32-5	5403-5407	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]
32-6	5408-5411	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]
32-7	5412-5424	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]
32-8	5425-5430	prior	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]
32-9	5431-5433	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]
32-10	5434-5447	participation	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]
32-11	5447-5448	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
32-12	5449-5452	2.1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
32-13	5453-5465	Participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
32-14	5466-5478	Participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
32-15	5479-5483	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
32-16	5484-5493	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
32-17	5494-5498	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
32-18	5499-5502	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
32-19	5503-5515	longitudinal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
32-20	5516-5525	follow-up	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
32-21	5526-5528	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
32-22	5529-5532	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
32-23	5533-5543	Multimodal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]|http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder[36]
32-24	5544-5553	Treatment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]|http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder[36]
32-25	5554-5559	Study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]|http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder[36]
32-26	5560-5562	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]|http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder[36]
32-27	5563-5567	ADHD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]|http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder[36]|http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder[37]
32-28	5568-5569	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]|http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder[36]
32-29	5569-5572	MTA	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]|http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder[36]
32-30	5572-5573	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]|http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder[36]
32-31	5574-5576	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
32-32	5577-5588	participate	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
32-33	5589-5591	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
32-34	5592-5595	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
32-35	5596-5603	current	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
32-36	5604-5609	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
32-37	5609-5610	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]

#Text=Recruitment took place at either the 14- or 16-year follow-up assessments (i.e., 14 or 16 years after study enrollment in childhood).
33-1	5611-5622	Recruitment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
33-2	5623-5627	took	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
33-3	5628-5633	place	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
33-4	5634-5636	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
33-5	5637-5643	either	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
33-6	5644-5647	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
33-7	5648-5650	14	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
33-8	5650-5651	-	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
33-9	5652-5654	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
33-10	5655-5657	16	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
33-11	5657-5658	-	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
33-12	5658-5662	year	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
33-13	5663-5672	follow-up	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
33-14	5673-5684	assessments	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
33-15	5685-5686	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
33-16	5686-5689	i.e	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
33-17	5689-5690	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
33-18	5690-5691	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
33-19	5692-5694	14	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
33-20	5695-5697	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
33-21	5698-5700	16	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
33-22	5701-5706	years	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
33-23	5707-5712	after	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
33-24	5713-5718	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
33-25	5719-5729	enrollment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
33-26	5730-5732	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
33-27	5733-5742	childhood	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
33-28	5742-5743	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
33-29	5743-5744	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]

#Text=Original MTA participants included 579 children aged 7.0 to 9.9 years diagnosed in childhood with ADHD Combined Type.
34-1	5745-5753	Original	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
34-2	5754-5757	MTA	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
34-3	5758-5770	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
34-4	5771-5779	included	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
34-5	5780-5783	579	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
34-6	5784-5792	children	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
34-7	5793-5797	aged	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
34-8	5798-5801	7.0	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
34-9	5802-5804	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
34-10	5805-5808	9.9	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
34-11	5809-5814	years	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
34-12	5815-5824	diagnosed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
34-13	5825-5827	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
34-14	5828-5837	childhood	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
34-15	5838-5842	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
34-16	5843-5847	ADHD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]|http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder[38]
34-17	5848-5856	Combined	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]|http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder[38]
34-18	5857-5861	Type	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]|http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder[38]
34-19	5861-5862	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]

#Text=The MTA procedures for diagnosis, treatment specifics, and sample demographics have been described elsewhere.
35-1	5863-5866	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
35-2	5867-5870	MTA	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
35-3	5871-5881	procedures	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
35-4	5882-5885	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
35-5	5886-5895	diagnosis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
35-6	5895-5896	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
35-7	5897-5906	treatment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
35-8	5907-5916	specifics	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
35-9	5916-5917	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
35-10	5918-5921	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
35-11	5922-5928	sample	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
35-12	5929-5941	demographics	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
35-13	5942-5946	have	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
35-14	5947-5951	been	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
35-15	5952-5961	described	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
35-16	5962-5971	elsewhere	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
35-17	5971-5972	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]

#Text=A local normative comparison group (LNCG, n=289) was recruited to reflect the local populations from which the ADHD sample was drawn.
36-1	5973-5974	A	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
36-2	5975-5980	local	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[39]
36-3	5981-5990	normative	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[39]
36-4	5991-6001	comparison	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[39]
36-5	6002-6007	group	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[39]
36-6	6008-6009	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[39]
36-7	6009-6013	LNCG	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[39]
36-8	6013-6014	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
36-9	6015-6016	n	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
36-10	6016-6017	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
36-11	6017-6020	289	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
36-12	6020-6021	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
36-13	6022-6025	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
36-14	6026-6035	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
36-15	6036-6038	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
36-16	6039-6046	reflect	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
36-17	6047-6050	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
36-18	6051-6056	local	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
36-19	6057-6068	populations	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
36-20	6069-6073	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
36-21	6074-6079	which	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
36-22	6080-6083	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
36-23	6084-6088	ADHD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]|http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder[40]
36-24	6089-6095	sample	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
36-25	6096-6099	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
36-26	6100-6105	drawn	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
36-27	6105-6106	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]

#Text=ADHD and LNCG participants have been followed longitudinally with visits at 36-months, and 6, 8, 10, 12, 14, and 16 years after baseline assessment.
37-1	6107-6111	ADHD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]|http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder[41]
37-2	6112-6115	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
37-3	6116-6120	LNCG	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[42]
37-4	6121-6133	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[42]
37-5	6134-6138	have	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
37-6	6139-6143	been	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
37-7	6144-6152	followed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
37-8	6153-6167	longitudinally	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
37-9	6168-6172	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
37-10	6173-6179	visits	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
37-11	6180-6182	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
37-12	6183-6185	36	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
37-13	6185-6186	-	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
37-14	6186-6192	months	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
37-15	6192-6193	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
37-16	6194-6197	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
37-17	6198-6199	6	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
37-18	6199-6200	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
37-19	6201-6202	8	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
37-20	6202-6203	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
37-21	6204-6206	10	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
37-22	6206-6207	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
37-23	6208-6210	12	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
37-24	6210-6211	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
37-25	6212-6214	14	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
37-26	6214-6215	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
37-27	6216-6219	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
37-28	6220-6222	16	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
37-29	6223-6228	years	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
37-30	6229-6234	after	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
37-31	6235-6243	baseline	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
37-32	6244-6254	assessment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
37-33	6254-6255	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]

#Text=Imaging performed in this work occurred during supplemental visits to the 14- or 16-year follow-up visits.
38-1	6256-6263	Imaging	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
38-2	6264-6273	performed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
38-3	6274-6276	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
38-4	6277-6281	this	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
38-5	6282-6286	work	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
38-6	6287-6295	occurred	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
38-7	6296-6302	during	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
38-8	6303-6315	supplemental	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
38-9	6316-6322	visits	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
38-10	6323-6325	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
38-11	6326-6329	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
38-12	6330-6332	14	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
38-13	6332-6333	-	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
38-14	6334-6336	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
38-15	6337-6339	16	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
38-16	6339-6340	-	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
38-17	6340-6344	year	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
38-18	6345-6354	follow-up	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
38-19	6355-6361	visits	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]
38-20	6361-6362	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]

#Text=Cannabis use history was defined from self-report on the Substance Use Questionnaire (SUQ).
39-1	6363-6371	Cannabis	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[43]
39-2	6372-6375	use	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[43]
39-3	6376-6383	history	_
39-4	6384-6387	was	_
39-5	6388-6395	defined	_
39-6	6396-6400	from	_
39-7	6401-6412	self-report	_
39-8	6413-6415	on	_
39-9	6416-6419	the	_
39-10	6420-6429	Substance	http://www.case.edu/ProvCaRe/provcare#Questionnaire[44]
39-11	6430-6433	Use	http://www.case.edu/ProvCaRe/provcare#Questionnaire[44]
39-12	6434-6447	Questionnaire	http://www.case.edu/ProvCaRe/provcare#Questionnaire[44]
39-13	6448-6449	(	http://www.case.edu/ProvCaRe/provcare#Questionnaire[44]
39-14	6449-6452	SUQ	http://www.case.edu/ProvCaRe/provcare#Questionnaire[44]
39-15	6452-6453	)	http://www.case.edu/ProvCaRe/provcare#Questionnaire[44]
39-16	6453-6454	.	_

#Text=Cannabis users reported greater than or equal to monthly cannabis use over the past year, and non-users reported having used cannabis fewer than 4 times during the previous year.
40-1	6455-6463	Cannabis	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[45]
40-2	6464-6469	users	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[45]
40-3	6470-6478	reported	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[45]
40-4	6479-6486	greater	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[45]
40-5	6487-6491	than	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[45]
40-6	6492-6494	or	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[45]
40-7	6495-6500	equal	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[45]
40-8	6501-6503	to	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[45]
40-9	6504-6511	monthly	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[45]
40-10	6512-6520	cannabis	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[45]
40-11	6521-6524	use	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[45]
40-12	6525-6529	over	_
40-13	6530-6533	the	_
40-14	6534-6538	past	_
40-15	6539-6543	year	_
40-16	6543-6544	,	_
40-17	6545-6548	and	_
40-18	6549-6558	non-users	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[46]
40-19	6559-6567	reported	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[46]
40-20	6568-6574	having	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[46]
40-21	6575-6579	used	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[46]
40-22	6580-6588	cannabis	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[46]
40-23	6589-6594	fewer	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[46]
40-24	6595-6599	than	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[46]
40-25	6600-6601	4	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[46]
40-26	6602-6607	times	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[46]
40-27	6608-6614	during	_
40-28	6615-6618	the	_
40-29	6619-6627	previous	_
40-30	6628-6632	year	_
40-31	6632-6633	.	_

#Text=Exclusion criteria included self-reported binge drinking (> 4 drinks in a single session on a weekly basis or more over the past year), recreational use of other substances (monthly or more often), history of traumatic brain injury with loss of consciousness, contraindications for MRI exposure, and/or psychotropic medication use other than for ADHD.
41-1	6634-6643	Exclusion	_
41-2	6644-6652	criteria	_
41-3	6653-6661	included	_
41-4	6662-6675	self-reported	_
41-5	6676-6681	binge	_
41-6	6682-6690	drinking	_
41-7	6691-6692	(	_
41-8	6692-6693	>	_
41-9	6694-6695	4	_
41-10	6696-6702	drinks	_
41-11	6703-6705	in	_
41-12	6706-6707	a	_
41-13	6708-6714	single	_
41-14	6715-6722	session	_
41-15	6723-6725	on	_
41-16	6726-6727	a	_
41-17	6728-6734	weekly	_
41-18	6735-6740	basis	_
41-19	6741-6743	or	_
41-20	6744-6748	more	_
41-21	6749-6753	over	_
41-22	6754-6757	the	_
41-23	6758-6762	past	_
41-24	6763-6767	year	_
41-25	6767-6768	)	_
41-26	6768-6769	,	_
41-27	6770-6782	recreational	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[47]
41-28	6783-6786	use	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[47]
41-29	6787-6789	of	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[47]
41-30	6790-6795	other	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[47]
41-31	6796-6806	substances	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[47]
41-32	6807-6808	(	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[47]
41-33	6808-6815	monthly	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[47]
41-34	6816-6818	or	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[47]
41-35	6819-6823	more	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[47]
41-36	6824-6829	often	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[47]
41-37	6829-6830	)	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[47]
41-38	6830-6831	,	_
41-39	6832-6839	history	_
41-40	6840-6842	of	_
41-41	6843-6852	traumatic	_
41-42	6853-6858	brain	_
41-43	6859-6865	injury	_
41-44	6866-6870	with	_
41-45	6871-6875	loss	_
41-46	6876-6878	of	_
41-47	6879-6892	consciousness	_
41-48	6892-6893	,	_
41-49	6894-6911	contraindications	_
41-50	6912-6915	for	_
41-51	6916-6919	MRI	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[48]
41-52	6920-6928	exposure	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[48]
41-53	6928-6929	,	_
41-54	6930-6933	and	_
41-55	6933-6934	/	_
41-56	6934-6936	or	_
41-57	6937-6949	psychotropic	http://maven.renci.org/NeuroBridge/neurobridge#MedicationStatus[49]
41-58	6950-6960	medication	http://maven.renci.org/NeuroBridge/neurobridge#MedicationStatus[49]
41-59	6961-6964	use	_
41-60	6965-6970	other	_
41-61	6971-6975	than	_
41-62	6976-6979	for	_
41-63	6980-6984	ADHD	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder
41-64	6984-6985	.	_

#Text=All participants observed a 24-hour washout for all medications and a 36-hour washout for other substances, including cannabis and alcohol, prior to the scan.
42-1	6986-6989	All	_
42-2	6990-7002	participants	_
42-3	7003-7011	observed	_
42-4	7012-7013	a	_
42-5	7014-7016	24	http://maven.renci.org/NeuroBridge/neurobridge#MedicationStatus[50]
42-6	7016-7017	-	http://maven.renci.org/NeuroBridge/neurobridge#MedicationStatus[50]
42-7	7017-7021	hour	http://maven.renci.org/NeuroBridge/neurobridge#MedicationStatus[50]
42-8	7022-7029	washout	http://maven.renci.org/NeuroBridge/neurobridge#MedicationStatus[50]
42-9	7030-7033	for	http://maven.renci.org/NeuroBridge/neurobridge#MedicationStatus[50]
42-10	7034-7037	all	http://maven.renci.org/NeuroBridge/neurobridge#MedicationStatus[50]
42-11	7038-7049	medications	http://maven.renci.org/NeuroBridge/neurobridge#MedicationStatus[50]
42-12	7050-7053	and	_
42-13	7054-7055	a	_
42-14	7056-7058	36	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[51]
42-15	7058-7059	-	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[51]
42-16	7059-7063	hour	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[51]
42-17	7064-7071	washout	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[51]
42-18	7072-7075	for	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[51]
42-19	7076-7081	other	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[51]
42-20	7082-7092	substances	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[51]
42-21	7092-7093	,	_
42-22	7094-7103	including	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[52]
42-23	7104-7112	cannabis	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[52]
42-24	7113-7116	and	_
42-25	7117-7124	alcohol	_
42-26	7124-7125	,	_
42-27	7126-7131	prior	_
42-28	7132-7134	to	_
42-29	7135-7138	the	_
42-30	7139-7143	scan	_
42-31	7143-7144	.	_

#Text=In addition, participants refrained from smoking and caffeine intake for at least one-hour prior to the scan.
43-1	7145-7147	In	_
43-2	7148-7156	addition	_
43-3	7156-7157	,	_
43-4	7158-7170	participants	_
43-5	7171-7180	refrained	_
43-6	7181-7185	from	_
43-7	7186-7193	smoking	_
43-8	7194-7197	and	_
43-9	7198-7206	caffeine	_
43-10	7207-7213	intake	_
43-11	7214-7217	for	_
43-12	7218-7220	at	_
43-13	7221-7226	least	_
43-14	7227-7235	one-hour	_
43-15	7236-7241	prior	_
43-16	7242-7244	to	_
43-17	7245-7248	the	_
43-18	7249-7253	scan	_
43-19	7253-7254	.	_

#Text=All abstinence measures were based on self-report.
44-1	7255-7258	All	_
44-2	7259-7269	abstinence	_
44-3	7270-7278	measures	_
44-4	7279-7283	were	_
44-5	7284-7289	based	_
44-6	7290-7292	on	_
44-7	7293-7304	self-report	_
44-8	7304-7305	.	_

#Text=The final sample across all four imaging sites included 62 ADHD (31 users, 31 non-users) and 26 LNCG (12 users, 14 non-users).
45-1	7306-7309	The	_
45-2	7310-7315	final	_
45-3	7316-7322	sample	_
45-4	7323-7329	across	_
45-5	7330-7333	all	_
45-6	7334-7338	four	_
45-7	7339-7346	imaging	_
45-8	7347-7352	sites	_
45-9	7353-7361	included	_
45-10	7362-7364	62	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder[53]
45-11	7365-7369	ADHD	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder[53]|http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder[54]
45-12	7370-7371	(	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder[53]
45-13	7371-7373	31	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder[53]
45-14	7374-7379	users	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder[53]
45-15	7379-7380	,	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder[53]
45-16	7381-7383	31	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder[53]
45-17	7384-7393	non-users	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder[53]
45-18	7393-7394	)	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder[53]
45-19	7395-7398	and	_
45-20	7399-7401	26	_
45-21	7402-7406	LNCG	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
45-22	7407-7408	(	_
45-23	7408-7410	12	_
45-24	7411-7416	users	_
45-25	7416-7417	,	_
45-26	7418-7420	14	_
45-27	7421-7430	non-users	_
45-28	7430-7431	)	_
45-29	7431-7432	.	_

#Text=After data quality screening for sufficient behavioral performance during the in-scanner task and temporal signal-to-noise-ratio of acquired fMRI data, participants included 50 ADHD (25 users, 25 non-users) and 23 LNCG (11 users, 12 non-users).
46-1	7433-7438	After	_
46-2	7439-7443	data	_
46-3	7444-7451	quality	_
46-4	7452-7461	screening	_
46-5	7462-7465	for	_
46-6	7466-7476	sufficient	_
46-7	7477-7487	behavioral	_
46-8	7488-7499	performance	_
46-9	7500-7506	during	_
46-10	7507-7510	the	_
46-11	7511-7521	in-scanner	_
46-12	7522-7526	task	_
46-13	7527-7530	and	_
46-14	7531-7539	temporal	_
46-15	7540-7561	signal-to-noise-ratio	_
46-16	7562-7564	of	_
46-17	7565-7573	acquired	_
46-18	7574-7578	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[55]
46-19	7579-7583	data	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[55]
46-20	7583-7584	,	_
46-21	7585-7597	participants	_
46-22	7598-7606	included	_
46-23	7607-7609	50	_
46-24	7610-7614	ADHD	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder
46-25	7615-7616	(	_
46-26	7616-7618	25	_
46-27	7619-7624	users	_
46-28	7624-7625	,	_
46-29	7626-7628	25	_
46-30	7629-7638	non-users	_
46-31	7638-7639	)	_
46-32	7640-7643	and	_
46-33	7644-7646	23	_
46-34	7647-7651	LNCG	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
46-35	7652-7653	(	_
46-36	7653-7655	11	_
46-37	7656-7661	users	_
46-38	7661-7662	,	_
46-39	7663-7665	12	_
46-40	7666-7675	non-users	_
46-41	7675-7676	)	_
46-42	7676-7677	.	_

#Text=Participants included in analyses ranged in age from 21 to 27 years.
47-1	7678-7690	Participants	_
47-2	7691-7699	included	_
47-3	7700-7702	in	_
47-4	7703-7711	analyses	_
47-5	7712-7718	ranged	_
47-6	7719-7721	in	_
47-7	7722-7725	age	_
47-8	7726-7730	from	_
47-9	7731-7733	21	_
47-10	7734-7736	to	_
47-11	7737-7739	27	_
47-12	7740-7745	years	_
47-13	7745-7746	.	_

#Text=Demographic characteristics for the sample are provided in Table 1.
#Text=2.2 Task and fMRI Acquisition Parameters
#Text=Each of the participants performed four runs of an appetitive Go/NoGo task.
48-1	7747-7758	Demographic	_
48-2	7759-7774	characteristics	_
48-3	7775-7778	for	_
48-4	7779-7782	the	_
48-5	7783-7789	sample	_
48-6	7790-7793	are	_
48-7	7794-7802	provided	_
48-8	7803-7805	in	_
48-9	7806-7811	Table	_
48-10	7812-7813	1	_
48-11	7813-7814	.	_
48-12	7815-7818	2.2	_
48-13	7819-7823	Task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
48-14	7824-7827	and	_
48-15	7828-7832	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[56]
48-16	7833-7844	Acquisition	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[56]
48-17	7845-7855	Parameters	_
48-18	7856-7860	Each	_
48-19	7861-7863	of	_
48-20	7864-7867	the	_
48-21	7868-7880	participants	_
48-22	7881-7890	performed	_
48-23	7891-7895	four	_
48-24	7896-7900	runs	_
48-25	7901-7903	of	_
48-26	7904-7906	an	_
48-27	7907-7917	appetitive	_
48-28	7918-7920	Go	http://maven.renci.org/NeuroBridge/neurobridge#GoNoGoTask[57]
48-29	7920-7921	/	http://maven.renci.org/NeuroBridge/neurobridge#GoNoGoTask[57]
48-30	7921-7925	NoGo	http://maven.renci.org/NeuroBridge/neurobridge#GoNoGoTask[57]
48-31	7926-7930	task	http://maven.renci.org/NeuroBridge/neurobridge#GoNoGoTask[57]
48-32	7930-7931	.	_

#Text=The task consisted of responding with a right index finger button press when presented with a target (Go) cue and withholding a button press when presented with a non-target (NoGo) cue.
49-1	7932-7935	The	_
49-2	7936-7940	task	_
49-3	7941-7950	consisted	_
49-4	7951-7953	of	_
49-5	7954-7964	responding	_
49-6	7965-7969	with	_
49-7	7970-7971	a	_
49-8	7972-7977	right	_
49-9	7978-7983	index	_
49-10	7984-7990	finger	_
49-11	7991-7997	button	_
49-12	7998-8003	press	_
49-13	8004-8008	when	_
49-14	8009-8018	presented	_
49-15	8019-8023	with	_
49-16	8024-8025	a	_
49-17	8026-8032	target	_
49-18	8033-8034	(	_
49-19	8034-8036	Go	_
49-20	8036-8037	)	_
49-21	8038-8041	cue	_
49-22	8042-8045	and	_
49-23	8046-8057	withholding	_
49-24	8058-8059	a	_
49-25	8060-8066	button	_
49-26	8067-8072	press	_
49-27	8073-8077	when	_
49-28	8078-8087	presented	_
49-29	8088-8092	with	_
49-30	8093-8094	a	_
49-31	8095-8105	non-target	_
49-32	8106-8107	(	_
49-33	8107-8111	NoGo	_
49-34	8111-8112	)	_
49-35	8113-8116	cue	_
49-36	8116-8117	.	_

#Text=Targets appeared in 500ms durations with an inter-stimulus interval (ISI) jittered in duration from 2–14.5s (mean 5.2s).
50-1	8118-8125	Targets	_
50-2	8126-8134	appeared	_
50-3	8135-8137	in	_
50-4	8138-8143	500ms	_
50-5	8144-8153	durations	_
50-6	8154-8158	with	_
50-7	8159-8161	an	_
50-8	8162-8176	inter-stimulus	_
50-9	8177-8185	interval	_
50-10	8186-8187	(	_
50-11	8187-8190	ISI	_
50-12	8190-8191	)	_
50-13	8192-8200	jittered	_
50-14	8201-8203	in	_
50-15	8204-8212	duration	_
50-16	8213-8217	from	_
50-17	8218-8219	2	_
50-18	8219-8220	–	_
50-19	8220-8225	14.5s	_
50-20	8226-8227	(	_
50-21	8227-8231	mean	_
50-22	8232-8236	5.2s	_
50-23	8236-8237	)	_
50-24	8237-8238	.	_

#Text=All four runs each contained 36 Go and 12 NoGo trials for a total of 192 trials per subject.
51-1	8239-8242	All	_
51-2	8243-8247	four	_
51-3	8248-8252	runs	_
51-4	8253-8257	each	_
51-5	8258-8267	contained	_
51-6	8268-8270	36	_
51-7	8271-8273	Go	_
51-8	8274-8277	and	_
51-9	8278-8280	12	_
51-10	8281-8285	NoGo	_
51-11	8286-8292	trials	_
51-12	8293-8296	for	_
51-13	8297-8298	a	_
51-14	8299-8304	total	_
51-15	8305-8307	of	_
51-16	8308-8311	192	_
51-17	8312-8318	trials	_
51-18	8319-8322	per	_
51-19	8323-8330	subject	_
51-20	8330-8331	.	_

#Text=The targets and non-targets were pseudo-randomized in presentation order within each run and defined for the participant via an instructional screen prior to the start of each run.
52-1	8332-8335	The	_
52-2	8336-8343	targets	_
52-3	8344-8347	and	_
52-4	8348-8359	non-targets	_
52-5	8360-8364	were	_
52-6	8365-8382	pseudo-randomized	_
52-7	8383-8385	in	_
52-8	8386-8398	presentation	_
52-9	8399-8404	order	_
52-10	8405-8411	within	_
52-11	8412-8416	each	_
52-12	8417-8420	run	_
52-13	8421-8424	and	_
52-14	8425-8432	defined	_
52-15	8433-8436	for	_
52-16	8437-8440	the	_
52-17	8441-8452	participant	_
52-18	8453-8456	via	_
52-19	8457-8459	an	_
52-20	8460-8473	instructional	_
52-21	8474-8480	screen	_
52-22	8481-8486	prior	_
52-23	8487-8489	to	_
52-24	8490-8493	the	_
52-25	8494-8499	start	_
52-26	8500-8502	of	_
52-27	8503-8507	each	_
52-28	8508-8511	run	_
52-29	8511-8512	.	_

#Text=Human faces with emotional content (happy or neutral) were used as the primary stimulus, and fixation crosses for the ISI.
53-1	8513-8518	Human	_
53-2	8519-8524	faces	_
53-3	8525-8529	with	_
53-4	8530-8539	emotional	_
53-5	8540-8547	content	_
53-6	8548-8549	(	_
53-7	8549-8554	happy	_
53-8	8555-8557	or	_
53-9	8558-8565	neutral	_
53-10	8565-8566	)	_
53-11	8567-8571	were	_
53-12	8572-8576	used	_
53-13	8577-8579	as	_
53-14	8580-8583	the	_
53-15	8584-8591	primary	_
53-16	8592-8600	stimulus	_
53-17	8600-8601	,	_
53-18	8602-8605	and	_
53-19	8606-8614	fixation	_
53-20	8615-8622	crosses	_
53-21	8623-8626	for	_
53-22	8627-8630	the	_
53-23	8631-8634	ISI	_
53-24	8634-8635	.	_

#Text=The task instructions read: “Press your index finger as fast as you can whenever you see the PLAIN [HAPPY] faces.
54-1	8636-8639	The	_
54-2	8640-8644	task	_
54-3	8645-8657	instructions	_
54-4	8658-8662	read	_
54-5	8662-8663	:	_
54-6	8664-8665	“	_
54-7	8665-8670	Press	_
54-8	8671-8675	your	_
54-9	8676-8681	index	_
54-10	8682-8688	finger	_
54-11	8689-8691	as	_
54-12	8692-8696	fast	_
54-13	8697-8699	as	_
54-14	8700-8703	you	_
54-15	8704-8707	can	_
54-16	8708-8716	whenever	_
54-17	8717-8720	you	_
54-18	8721-8724	see	_
54-19	8725-8728	the	_
54-20	8729-8734	PLAIN	_
54-21	8735-8736	[	_
54-22	8736-8741	HAPPY	_
54-23	8741-8742	]	_
54-24	8743-8748	faces	_
54-25	8748-8749	.	_

#Text=Don’t press for other faces, only the PLAIN [HAPPY] faces.”
55-1	8750-8753	Don	_
55-2	8753-8754	’	_
55-3	8754-8755	t	_
55-4	8756-8761	press	_
55-5	8762-8765	for	_
55-6	8766-8771	other	_
55-7	8772-8777	faces	_
55-8	8777-8778	,	_
55-9	8779-8783	only	_
55-10	8784-8787	the	_
55-11	8788-8793	PLAIN	_
55-12	8794-8795	[	_
55-13	8795-8800	HAPPY	_
55-14	8800-8801	]	_
55-15	8802-8807	faces	_
55-16	8807-8808	.	_
55-17	8808-8809	”	_

#Text=Each participant had, in a pseudo-randomized order, two runs of happy and two runs of neutral faces as a target.
56-1	8810-8814	Each	_
56-2	8815-8826	participant	_
56-3	8827-8830	had	_
56-4	8830-8831	,	_
56-5	8832-8834	in	_
56-6	8835-8836	a	_
56-7	8837-8854	pseudo-randomized	_
56-8	8855-8860	order	_
56-9	8860-8861	,	_
56-10	8862-8865	two	_
56-11	8866-8870	runs	_
56-12	8871-8873	of	_
56-13	8874-8879	happy	_
56-14	8880-8883	and	_
56-15	8884-8887	two	_
56-16	8888-8892	runs	_
56-17	8893-8895	of	_
56-18	8896-8903	neutral	_
56-19	8904-8909	faces	_
56-20	8910-8912	as	_
56-21	8913-8914	a	_
56-22	8915-8921	target	_
56-23	8921-8922	.	_

#Text=Human faces as a no-go stimulus have been well validated in prior work.
57-1	8923-8928	Human	_
57-2	8929-8934	faces	_
57-3	8935-8937	as	_
57-4	8938-8939	a	_
57-5	8940-8945	no-go	_
57-6	8946-8954	stimulus	_
57-7	8955-8959	have	_
57-8	8960-8964	been	_
57-9	8965-8969	well	_
57-10	8970-8979	validated	_
57-11	8980-8982	in	_
57-12	8983-8988	prior	_
57-13	8989-8993	work	_
57-14	8993-8994	.	_

#Text=Echo planar images (EPI) were acquired over 154 volumes for a total of 5m and 12s per run (TR/TE=2000ms/30ms, 32 axial slices, AC-PC aligned, TH=4mm, Slice Gap=1mm, In-plane resolution=3.4×3.4mm).
58-1	8995-8999	Echo	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[58]
58-2	9000-9006	planar	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[58]
58-3	9007-9013	images	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[58]
58-4	9014-9015	(	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[58]
58-5	9015-9018	EPI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[58]
58-6	9018-9019	)	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[58]
58-7	9020-9024	were	_
58-8	9025-9033	acquired	_
58-9	9034-9038	over	_
58-10	9039-9042	154	_
58-11	9043-9050	volumes	_
58-12	9051-9054	for	_
58-13	9055-9056	a	_
58-14	9057-9062	total	_
58-15	9063-9065	of	_
58-16	9066-9068	5m	_
58-17	9069-9072	and	_
58-18	9073-9076	12s	_
58-19	9077-9080	per	_
58-20	9081-9084	run	_
58-21	9085-9086	(	_
58-22	9086-9088	TR	_
58-23	9088-9089	/	_
58-24	9089-9091	TE	_
58-25	9091-9092	=	_
58-26	9092-9098	2000ms	_
58-27	9098-9099	/	_
58-28	9099-9103	30ms	_
58-29	9103-9104	,	_
58-30	9105-9107	32	_
58-31	9108-9113	axial	_
58-32	9114-9120	slices	_
58-33	9120-9121	,	_
58-34	9122-9127	AC-PC	_
58-35	9128-9135	aligned	_
58-36	9135-9136	,	_
58-37	9137-9139	TH	_
58-38	9139-9140	=	_
58-39	9140-9143	4mm	_
58-40	9143-9144	,	_
58-41	9145-9150	Slice	_
58-42	9151-9154	Gap	_
58-43	9154-9155	=	_
58-44	9155-9158	1mm	_
58-45	9158-9159	,	_
58-46	9160-9168	In-plane	_
58-47	9169-9179	resolution	_
58-48	9179-9180	=	_
58-49	9180-9183	3.4	_
58-50	9183-9184	×	_
58-51	9184-9189	3.4mm	_
58-52	9189-9190	)	_
58-53	9190-9191	.	_

#Text=High-resolution anatomical MPRAGE T1-weighted images (TR/TE/TI=2170/5.56/1100ms, 160 sagittal slices, TH=1.2mm, In-plane resolution=1×1mm) were acquired along with T2-weighted images (TR/TE=6440/67ms) co-planar to the functional acquisitions.
59-1	9192-9207	High-resolution	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[59]
59-2	9208-9218	anatomical	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[59]
59-3	9219-9225	MPRAGE	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[59]
59-4	9226-9228	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[59]
59-5	9228-9229	-	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[59]
59-6	9229-9237	weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[59]
59-7	9238-9244	images	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[59]
59-8	9245-9246	(	_
59-9	9246-9248	TR	_
59-10	9248-9249	/	_
59-11	9249-9251	TE	_
59-12	9251-9252	/	_
59-13	9252-9254	TI	_
59-14	9254-9255	=	_
59-15	9255-9259	2170	_
59-16	9259-9260	/	_
59-17	9260-9264	5.56	_
59-18	9264-9265	/	_
59-19	9265-9271	1100ms	_
59-20	9271-9272	,	_
59-21	9273-9276	160	_
59-22	9277-9285	sagittal	_
59-23	9286-9292	slices	_
59-24	9292-9293	,	_
59-25	9294-9296	TH	_
59-26	9296-9297	=	_
59-27	9297-9302	1.2mm	_
59-28	9302-9303	,	_
59-29	9304-9312	In-plane	_
59-30	9313-9323	resolution	_
59-31	9323-9324	=	_
59-32	9324-9325	1	_
59-33	9325-9326	×	_
59-34	9326-9329	1mm	_
59-35	9329-9330	)	_
59-36	9331-9335	were	_
59-37	9336-9344	acquired	_
59-38	9345-9350	along	_
59-39	9351-9355	with	_
59-40	9356-9358	T2	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging[60]
59-41	9358-9359	-	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging[60]
59-42	9359-9367	weighted	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging[60]
59-43	9368-9374	images	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging[60]
59-44	9375-9376	(	_
59-45	9376-9378	TR	_
59-46	9378-9379	/	_
59-47	9379-9381	TE	_
59-48	9381-9382	=	_
59-49	9382-9386	6440	_
59-50	9386-9387	/	_
59-51	9387-9391	67ms	_
59-52	9391-9392	)	_
59-53	9393-9402	co-planar	_
59-54	9403-9405	to	_
59-55	9406-9409	the	_
59-56	9410-9420	functional	_
59-57	9421-9433	acquisitions	_
59-58	9433-9434	.	_

#Text=For distortion correction, a dual-echo B0 mapping scan (TR/TE1/TE2=500/3.03/5.49) was acquired co-planar with the functional acquisitions.
#Text=2.3 Pre-Processing
#Text=Functional and task behavioral data underwent a quality control evaluation and initial pre-processing using FBIRN tools and dashboard monitoring (www.birncommunity.org).
60-1	9435-9438	For	_
60-2	9439-9449	distortion	_
60-3	9450-9460	correction	_
60-4	9460-9461	,	_
60-5	9462-9463	a	_
60-6	9464-9473	dual-echo	_
60-7	9474-9476	B0	_
60-8	9477-9484	mapping	_
60-9	9485-9489	scan	_
60-10	9490-9491	(	_
60-11	9491-9493	TR	_
60-12	9493-9494	/	_
60-13	9494-9497	TE1	_
60-14	9497-9498	/	_
60-15	9498-9501	TE2	_
60-16	9501-9502	=	_
60-17	9502-9505	500	_
60-18	9505-9506	/	_
60-19	9506-9510	3.03	_
60-20	9510-9511	/	_
60-21	9511-9515	5.49	_
60-22	9515-9516	)	_
60-23	9517-9520	was	_
60-24	9521-9529	acquired	_
60-25	9530-9539	co-planar	_
60-26	9540-9544	with	_
60-27	9545-9548	the	_
60-28	9549-9559	functional	_
60-29	9560-9572	acquisitions	_
60-30	9572-9573	.	_
60-31	9574-9577	2.3	_
60-32	9578-9592	Pre-Processing	_
60-33	9593-9603	Functional	_
60-34	9604-9607	and	_
60-35	9608-9612	task	_
60-36	9613-9623	behavioral	_
60-37	9624-9628	data	_
60-38	9629-9638	underwent	_
60-39	9639-9640	a	_
60-40	9641-9648	quality	_
60-41	9649-9656	control	_
60-42	9657-9667	evaluation	_
60-43	9668-9671	and	_
60-44	9672-9679	initial	_
60-45	9680-9694	pre-processing	_
60-46	9695-9700	using	_
60-47	9701-9706	FBIRN	_
60-48	9707-9712	tools	_
60-49	9713-9716	and	_
60-50	9717-9726	dashboard	_
60-51	9727-9737	monitoring	_
60-52	9738-9739	(	_
60-53	9739-9760	www.birncommunity.org	_
60-54	9760-9761	)	_
60-55	9761-9762	.	_

#Text=Quality control ensured adequate data quality and consistency throughout the study.
61-1	9763-9770	Quality	_
61-2	9771-9778	control	_
61-3	9779-9786	ensured	_
61-4	9787-9795	adequate	_
61-5	9796-9800	data	_
61-6	9801-9808	quality	_
61-7	9809-9812	and	_
61-8	9813-9824	consistency	_
61-9	9825-9835	throughout	_
61-10	9836-9839	the	_
61-11	9840-9845	study	_
61-12	9845-9846	.	_

#Text=Errant subjects were flagged for removal for either of two reasons: 1) average task performance at or below chance levels (<60% accuracy, 4 total subjects), or 2) the concurrence of excessive motion (Signal-To-Noise-Fluctuation<65) and null functional activation in occipital lobes during visual stimuli (11 total subjects).
62-1	9847-9853	Errant	_
62-2	9854-9862	subjects	_
62-3	9863-9867	were	_
62-4	9868-9875	flagged	_
62-5	9876-9879	for	_
62-6	9880-9887	removal	_
62-7	9888-9891	for	_
62-8	9892-9898	either	_
62-9	9899-9901	of	_
62-10	9902-9905	two	_
62-11	9906-9913	reasons	_
62-12	9913-9914	:	_
62-13	9915-9916	1	_
62-14	9916-9917	)	_
62-15	9918-9925	average	_
62-16	9926-9930	task	_
62-17	9931-9942	performance	_
62-18	9943-9945	at	_
62-19	9946-9948	or	_
62-20	9949-9954	below	_
62-21	9955-9961	chance	_
62-22	9962-9968	levels	_
62-23	9969-9970	(	_
62-24	9970-9971	<	_
62-25	9971-9974	60%	_
62-26	9975-9983	accuracy	_
62-27	9983-9984	,	_
62-28	9985-9986	4	_
62-29	9987-9992	total	_
62-30	9993-10001	subjects	_
62-31	10001-10002	)	_
62-32	10002-10003	,	_
62-33	10004-10006	or	_
62-34	10007-10008	2	_
62-35	10008-10009	)	_
62-36	10010-10013	the	_
62-37	10014-10025	concurrence	_
62-38	10026-10028	of	_
62-39	10029-10038	excessive	_
62-40	10039-10045	motion	_
62-41	10046-10047	(	_
62-42	10047-10074	Signal-To-Noise-Fluctuation	_
62-43	10074-10075	<	_
62-44	10075-10077	65	_
62-45	10077-10078	)	_
62-46	10079-10082	and	_
62-47	10083-10087	null	_
62-48	10088-10098	functional	_
62-49	10099-10109	activation	_
62-50	10110-10112	in	_
62-51	10113-10122	occipital	_
62-52	10123-10128	lobes	_
62-53	10129-10135	during	_
62-54	10136-10142	visual	_
62-55	10143-10150	stimuli	_
62-56	10151-10152	(	_
62-57	10152-10154	11	_
62-58	10155-10160	total	_
62-59	10161-10169	subjects	_
62-60	10169-10170	)	_
62-61	10170-10171	.	_

#Text=An initial preprocessing stream was applied: B0 and slice time correction followed by motion correction, brain extraction, spatial smoothing (FWHM=5mm), intensity normalization and high-pass temporal filtering (sigma=50s) in FSL.
63-1	10172-10174	An	_
63-2	10175-10182	initial	_
63-3	10183-10196	preprocessing	_
63-4	10197-10203	stream	_
63-5	10204-10207	was	_
63-6	10208-10215	applied	_
63-7	10215-10216	:	_
63-8	10217-10219	B0	_
63-9	10220-10223	and	_
63-10	10224-10229	slice	_
63-11	10230-10234	time	_
63-12	10235-10245	correction	_
63-13	10246-10254	followed	_
63-14	10255-10257	by	_
63-15	10258-10264	motion	_
63-16	10265-10275	correction	_
63-17	10275-10276	,	_
63-18	10277-10282	brain	_
63-19	10283-10293	extraction	_
63-20	10293-10294	,	_
63-21	10295-10302	spatial	_
63-22	10303-10312	smoothing	_
63-23	10313-10314	(	_
63-24	10314-10318	FWHM	_
63-25	10318-10319	=	_
63-26	10319-10322	5mm	_
63-27	10322-10323	)	_
63-28	10323-10324	,	_
63-29	10325-10334	intensity	_
63-30	10335-10348	normalization	_
63-31	10349-10352	and	_
63-32	10353-10362	high-pass	_
63-33	10363-10371	temporal	_
63-34	10372-10381	filtering	_
63-35	10382-10383	(	_
63-36	10383-10388	sigma	_
63-37	10388-10389	=	_
63-38	10389-10392	50s	_
63-39	10392-10393	)	_
63-40	10394-10396	in	_
63-41	10397-10400	FSL	_
63-42	10400-10401	.	_

#Text=A General Linear Model for each of the four runs was performed using FSL, predicting fMRI time series data with correct Go and NoGo trials, convolved with a double gamma hemodynamic response function, along with their temporal derivatives.
64-1	10402-10403	A	_
64-2	10404-10411	General	_
64-3	10412-10418	Linear	_
64-4	10419-10424	Model	_
64-5	10425-10428	for	_
64-6	10429-10433	each	_
64-7	10434-10436	of	_
64-8	10437-10440	the	_
64-9	10441-10445	four	_
64-10	10446-10450	runs	_
64-11	10451-10454	was	_
64-12	10455-10464	performed	_
64-13	10465-10470	using	_
64-14	10471-10474	FSL	_
64-15	10474-10475	,	_
64-16	10476-10486	predicting	_
64-17	10487-10491	fMRI	_
64-18	10492-10496	time	_
64-19	10497-10503	series	_
64-20	10504-10508	data	_
64-21	10509-10513	with	_
64-22	10514-10521	correct	_
64-23	10522-10524	Go	_
64-24	10525-10528	and	_
64-25	10529-10533	NoGo	_
64-26	10534-10540	trials	_
64-27	10540-10541	,	_
64-28	10542-10551	convolved	_
64-29	10552-10556	with	_
64-30	10557-10558	a	_
64-31	10559-10565	double	_
64-32	10566-10571	gamma	_
64-33	10572-10583	hemodynamic	_
64-34	10584-10592	response	_
64-35	10593-10601	function	_
64-36	10601-10602	,	_
64-37	10603-10608	along	_
64-38	10609-10613	with	_
64-39	10614-10619	their	_
64-40	10620-10628	temporal	_
64-41	10629-10640	derivatives	_
64-42	10640-10641	.	_

#Text=This model included the time derivative to account for variance in trial onset times as well as covariates for motion (rotation and translation).
65-1	10642-10646	This	_
65-2	10647-10652	model	_
65-3	10653-10661	included	_
65-4	10662-10665	the	_
65-5	10666-10670	time	_
65-6	10671-10681	derivative	_
65-7	10682-10684	to	_
65-8	10685-10692	account	_
65-9	10693-10696	for	_
65-10	10697-10705	variance	_
65-11	10706-10708	in	_
65-12	10709-10714	trial	_
65-13	10715-10720	onset	_
65-14	10721-10726	times	_
65-15	10727-10729	as	_
65-16	10730-10734	well	_
65-17	10735-10737	as	_
65-18	10738-10748	covariates	_
65-19	10749-10752	for	_
65-20	10753-10759	motion	_
65-21	10760-10761	(	_
65-22	10761-10769	rotation	_
65-23	10770-10773	and	_
65-24	10774-10785	translation	_
65-25	10785-10786	)	_
65-26	10786-10787	.	_

#Text=A three-step (EPI to T2, T2 to T1, T1 to template) registration from native space to template space was performed using the T2-coplanar and T1-high resolution anatomical scans as references.
66-1	10788-10789	A	_
66-2	10790-10800	three-step	_
66-3	10801-10802	(	_
66-4	10802-10805	EPI	_
66-5	10806-10808	to	_
66-6	10809-10811	T2	_
66-7	10811-10812	,	_
66-8	10813-10815	T2	_
66-9	10816-10818	to	_
66-10	10819-10821	T1	_
66-11	10821-10822	,	_
66-12	10823-10825	T1	_
66-13	10826-10828	to	_
66-14	10829-10837	template	_
66-15	10837-10838	)	_
66-16	10839-10851	registration	_
66-17	10852-10856	from	_
66-18	10857-10863	native	_
66-19	10864-10869	space	_
66-20	10870-10872	to	_
66-21	10873-10881	template	_
66-22	10882-10887	space	_
66-23	10888-10891	was	_
66-24	10892-10901	performed	_
66-25	10902-10907	using	_
66-26	10908-10911	the	_
66-27	10912-10914	T2	_
66-28	10914-10915	-	_
66-29	10915-10923	coplanar	_
66-30	10924-10927	and	_
66-31	10928-10930	T1	_
66-32	10930-10931	-	_
66-33	10931-10935	high	_
66-34	10936-10946	resolution	_
66-35	10947-10957	anatomical	_
66-36	10958-10963	scans	_
66-37	10964-10966	as	_
66-38	10967-10977	references	_
66-39	10977-10978	.	_

#Text=The four runs were then collapsed into visit level maps using fixed effects prior to calculating voxelwise group statistics using FSLs FLAME 1 mixed effects analysis with correction for multiple comparisons.
#Text=2.4 Analyses
#Text=A 2-way ANOVA (diagnosis, cannabis use) model with interactions was used to analyze behavioral performance measures, including errors of commission, errors of omission, and response times.
67-1	10979-10982	The	_
67-2	10983-10987	four	_
67-3	10988-10992	runs	_
67-4	10993-10997	were	_
67-5	10998-11002	then	_
67-6	11003-11012	collapsed	_
67-7	11013-11017	into	_
67-8	11018-11023	visit	_
67-9	11024-11029	level	_
67-10	11030-11034	maps	_
67-11	11035-11040	using	_
67-12	11041-11046	fixed	_
67-13	11047-11054	effects	_
67-14	11055-11060	prior	_
67-15	11061-11063	to	_
67-16	11064-11075	calculating	_
67-17	11076-11085	voxelwise	_
67-18	11086-11091	group	_
67-19	11092-11102	statistics	_
67-20	11103-11108	using	_
67-21	11109-11113	FSLs	_
67-22	11114-11119	FLAME	_
67-23	11120-11121	1	_
67-24	11122-11127	mixed	_
67-25	11128-11135	effects	_
67-26	11136-11144	analysis	_
67-27	11145-11149	with	_
67-28	11150-11160	correction	_
67-29	11161-11164	for	_
67-30	11165-11173	multiple	_
67-31	11174-11185	comparisons	_
67-32	11185-11186	.	_
67-33	11187-11190	2.4	_
67-34	11191-11199	Analyses	_
67-35	11200-11201	A	_
67-36	11202-11203	2	_
67-37	11203-11204	-	_
67-38	11204-11207	way	_
67-39	11208-11213	ANOVA	_
67-40	11214-11215	(	_
67-41	11215-11224	diagnosis	_
67-42	11224-11225	,	_
67-43	11226-11234	cannabis	_
67-44	11235-11238	use	_
67-45	11238-11239	)	_
67-46	11240-11245	model	_
67-47	11246-11250	with	_
67-48	11251-11263	interactions	_
67-49	11264-11267	was	_
67-50	11268-11272	used	_
67-51	11273-11275	to	_
67-52	11276-11283	analyze	_
67-53	11284-11294	behavioral	_
67-54	11295-11306	performance	_
67-55	11307-11315	measures	_
67-56	11315-11316	,	_
67-57	11317-11326	including	_
67-58	11327-11333	errors	_
67-59	11334-11336	of	_
67-60	11337-11347	commission	_
67-61	11347-11348	,	_
67-62	11349-11355	errors	_
67-63	11356-11358	of	_
67-64	11359-11367	omission	_
67-65	11367-11368	,	_
67-66	11369-11372	and	_
67-67	11373-11381	response	_
67-68	11382-11387	times	_
67-69	11387-11388	.	_

#Text=In this analysis, the NoGo vs.
68-1	11389-11391	In	_
68-2	11392-11396	this	_
68-3	11397-11405	analysis	_
68-4	11405-11406	,	_
68-5	11407-11410	the	_
68-6	11411-11415	NoGo	_
68-7	11416-11418	vs	_
68-8	11418-11419	.	_

#Text=Go imaging contrast collapsed across emotional content was used to measure inhibitory control.
69-1	11420-11422	Go	_
69-2	11423-11430	imaging	_
69-3	11431-11439	contrast	_
69-4	11440-11449	collapsed	_
69-5	11450-11456	across	_
69-6	11457-11466	emotional	_
69-7	11467-11474	content	_
69-8	11475-11478	was	_
69-9	11479-11483	used	_
69-10	11484-11486	to	_
69-11	11487-11494	measure	_
69-12	11495-11505	inhibitory	_
69-13	11506-11513	control	_
69-14	11513-11514	.	_

#Text=The inhibition contrast (NoGo vs.
70-1	11515-11518	The	_
70-2	11519-11529	inhibition	_
70-3	11530-11538	contrast	_
70-4	11539-11540	(	_
70-5	11540-11544	NoGo	_
70-6	11545-11547	vs	_
70-7	11547-11548	.	_

#Text=Go) identifies functional activation, defined here as an increase in the BOLD signal, during NoGo trials (inhibiting a response) relative to Go trials (making a response).
71-1	11549-11551	Go	_
71-2	11551-11552	)	_
71-3	11553-11563	identifies	_
71-4	11564-11574	functional	_
71-5	11575-11585	activation	_
71-6	11585-11586	,	_
71-7	11587-11594	defined	_
71-8	11595-11599	here	_
71-9	11600-11602	as	_
71-10	11603-11605	an	_
71-11	11606-11614	increase	_
71-12	11615-11617	in	_
71-13	11618-11621	the	_
71-14	11622-11626	BOLD	_
71-15	11627-11633	signal	_
71-16	11633-11634	,	_
71-17	11635-11641	during	_
71-18	11642-11646	NoGo	_
71-19	11647-11653	trials	_
71-20	11654-11655	(	_
71-21	11655-11665	inhibiting	_
71-22	11666-11667	a	_
71-23	11668-11676	response	_
71-24	11676-11677	)	_
71-25	11678-11686	relative	_
71-26	11687-11689	to	_
71-27	11690-11692	Go	_
71-28	11693-11699	trials	_
71-29	11700-11701	(	_
71-30	11701-11707	making	_
71-31	11708-11709	a	_
71-32	11710-11718	response	_
71-33	11718-11719	)	_
71-34	11719-11720	.	_

#Text=The analysis consisted of all successful trials.
72-1	11721-11724	The	_
72-2	11725-11733	analysis	_
72-3	11734-11743	consisted	_
72-4	11744-11746	of	_
72-5	11747-11750	all	_
72-6	11751-11761	successful	_
72-7	11762-11768	trials	_
72-8	11768-11769	.	_

#Text=Primary group contrasts included the main effect of diagnosis (ADHD vs.
73-1	11770-11777	Primary	_
73-2	11778-11783	group	_
73-3	11784-11793	contrasts	_
73-4	11794-11802	included	_
73-5	11803-11806	the	_
73-6	11807-11811	main	_
73-7	11812-11818	effect	_
73-8	11819-11821	of	_
73-9	11822-11831	diagnosis	_
73-10	11832-11833	(	_
73-11	11833-11837	ADHD	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder
73-12	11838-11840	vs	_
73-13	11840-11841	.	_

#Text=LNCG), cannabis use (cannabis user vs. non-user) and their two-way interaction (diagnosis x cannabis use).
74-1	11842-11846	LNCG	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
74-2	11846-11847	)	_
74-3	11847-11848	,	_
74-4	11849-11857	cannabis	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[61]
74-5	11858-11861	use	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[61]
74-6	11862-11863	(	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[61]
74-7	11863-11871	cannabis	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[61]
74-8	11872-11876	user	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[61]
74-9	11877-11879	vs	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[61]
74-10	11879-11880	.	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[61]
74-11	11881-11889	non-user	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[61]
74-12	11889-11890	)	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[61]
74-13	11891-11894	and	_
74-14	11895-11900	their	_
74-15	11901-11908	two-way	_
74-16	11909-11920	interaction	_
74-17	11921-11922	(	_
74-18	11922-11931	diagnosis	_
74-19	11932-11933	x	_
74-20	11934-11942	cannabis	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[62]
74-21	11943-11946	use	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[62]
74-22	11946-11947	)	_
74-23	11947-11948	.	_

#Text=In addition to voxelwise analyses, native space analyses were performed using Freesurfer segmented ROIs of subcortical anatomy including caudate, putamen, pallidum, thalamus and accumbens.
75-1	11949-11951	In	_
75-2	11952-11960	addition	_
75-3	11961-11963	to	_
75-4	11964-11973	voxelwise	_
75-5	11974-11982	analyses	_
75-6	11982-11983	,	_
75-7	11984-11990	native	_
75-8	11991-11996	space	_
75-9	11997-12005	analyses	_
75-10	12006-12010	were	_
75-11	12011-12020	performed	_
75-12	12021-12026	using	_
75-13	12027-12037	Freesurfer	_
75-14	12038-12047	segmented	_
75-15	12048-12052	ROIs	_
75-16	12053-12055	of	_
75-17	12056-12067	subcortical	_
75-18	12068-12075	anatomy	_
75-19	12076-12085	including	_
75-20	12086-12093	caudate	_
75-21	12093-12094	,	_
75-22	12095-12102	putamen	_
75-23	12102-12103	,	_
75-24	12104-12112	pallidum	_
75-25	12112-12113	,	_
75-26	12114-12122	thalamus	_
75-27	12123-12126	and	_
75-28	12127-12136	accumbens	_
75-29	12136-12137	.	_

#Text=Native space analysis allows for more precise interrogation of data that is less dependent on subject-to-template registration accuracy.
76-1	12138-12144	Native	_
76-2	12145-12150	space	_
76-3	12151-12159	analysis	_
76-4	12160-12166	allows	_
76-5	12167-12170	for	_
76-6	12171-12175	more	_
76-7	12176-12183	precise	_
76-8	12184-12197	interrogation	_
76-9	12198-12200	of	_
76-10	12201-12205	data	_
76-11	12206-12210	that	_
76-12	12211-12213	is	_
76-13	12214-12218	less	_
76-14	12219-12228	dependent	_
76-15	12229-12231	on	_
76-16	12232-12251	subject-to-template	_
76-17	12252-12264	registration	_
76-18	12265-12273	accuracy	_
76-19	12273-12274	.	_

#Text=To address threshold ambiguity of the findings and define the overlap with previous reports of activation differences in adults, a sliding z-score threshold was used in increments of 0.1 (from z=1 to z=4) to quantify the relative global distribution of activation across threshold values in 7 functionally connected networks previously identified by Yeo et. al..
77-1	12275-12277	To	_
77-2	12278-12285	address	_
77-3	12286-12295	threshold	_
77-4	12296-12305	ambiguity	_
77-5	12306-12308	of	_
77-6	12309-12312	the	_
77-7	12313-12321	findings	_
77-8	12322-12325	and	_
77-9	12326-12332	define	_
77-10	12333-12336	the	_
77-11	12337-12344	overlap	_
77-12	12345-12349	with	_
77-13	12350-12358	previous	_
77-14	12359-12366	reports	_
77-15	12367-12369	of	_
77-16	12370-12380	activation	_
77-17	12381-12392	differences	_
77-18	12393-12395	in	_
77-19	12396-12402	adults	_
77-20	12402-12403	,	_
77-21	12404-12405	a	_
77-22	12406-12413	sliding	_
77-23	12414-12421	z-score	_
77-24	12422-12431	threshold	_
77-25	12432-12435	was	_
77-26	12436-12440	used	_
77-27	12441-12443	in	_
77-28	12444-12454	increments	_
77-29	12455-12457	of	_
77-30	12458-12461	0.1	_
77-31	12462-12463	(	_
77-32	12463-12467	from	_
77-33	12468-12469	z	_
77-34	12469-12470	=	_
77-35	12470-12471	1	_
77-36	12472-12474	to	_
77-37	12475-12476	z	_
77-38	12476-12477	=	_
77-39	12477-12478	4	_
77-40	12478-12479	)	_
77-41	12480-12482	to	_
77-42	12483-12491	quantify	_
77-43	12492-12495	the	_
77-44	12496-12504	relative	_
77-45	12505-12511	global	_
77-46	12512-12524	distribution	_
77-47	12525-12527	of	_
77-48	12528-12538	activation	_
77-49	12539-12545	across	_
77-50	12546-12555	threshold	_
77-51	12556-12562	values	_
77-52	12563-12565	in	_
77-53	12566-12567	7	_
77-54	12568-12580	functionally	_
77-55	12581-12590	connected	_
77-56	12591-12599	networks	_
77-57	12600-12610	previously	_
77-58	12611-12621	identified	_
77-59	12622-12624	by	_
77-60	12625-12628	Yeo	_
77-61	12629-12631	et	_
77-62	12631-12632	.	_
77-63	12633-12635	al	_
77-64	12635-12636	.	_
77-65	12636-12637	.	_

#Text=A secondary analysis including age and gender as covariates was performed to assess the confounding effects of significantly different demographic factors on the outcomes highlighted in the sample.
78-1	12638-12639	A	_
78-2	12640-12649	secondary	_
78-3	12650-12658	analysis	_
78-4	12659-12668	including	_
78-5	12669-12672	age	_
78-6	12673-12676	and	_
78-7	12677-12683	gender	_
78-8	12684-12686	as	_
78-9	12687-12697	covariates	_
78-10	12698-12701	was	_
78-11	12702-12711	performed	_
78-12	12712-12714	to	_
78-13	12715-12721	assess	_
78-14	12722-12725	the	_
78-15	12726-12737	confounding	_
78-16	12738-12745	effects	_
78-17	12746-12748	of	_
78-18	12749-12762	significantly	_
78-19	12763-12772	different	_
78-20	12773-12784	demographic	_
78-21	12785-12792	factors	_
78-22	12793-12795	on	_
78-23	12796-12799	the	_
78-24	12800-12808	outcomes	_
78-25	12809-12820	highlighted	_
78-26	12821-12823	in	_
78-27	12824-12827	the	_
78-28	12828-12834	sample	_
78-29	12834-12835	.	_

#Text=To address relative withdrawal differences during washout between groups, a statistical comparison of total withdrawal symptoms on a continuous withdrawal scale (Budney 2012) was performed.
79-1	12836-12838	To	_
79-2	12839-12846	address	_
79-3	12847-12855	relative	_
79-4	12856-12866	withdrawal	_
79-5	12867-12878	differences	_
79-6	12879-12885	during	_
79-7	12886-12893	washout	_
79-8	12894-12901	between	_
79-9	12902-12908	groups	_
79-10	12908-12909	,	_
79-11	12910-12911	a	_
79-12	12912-12923	statistical	_
79-13	12924-12934	comparison	_
79-14	12935-12937	of	_
79-15	12938-12943	total	_
79-16	12944-12954	withdrawal	_
79-17	12955-12963	symptoms	_
79-18	12964-12966	on	_
79-19	12967-12968	a	_
79-20	12969-12979	continuous	_
79-21	12980-12990	withdrawal	_
79-22	12991-12996	scale	_
79-23	12997-12998	(	_
79-24	12998-13004	Budney	_
79-25	13005-13009	2012	_
79-26	13009-13010	)	_
79-27	13011-13014	was	_
79-28	13015-13024	performed	_
79-29	13024-13025	.	_

#Text=Finally, to support the main results, a post-hoc analysis using the significant regions of interest (ROI) highlighted in the results section of this work (six ROIs for main effect of diagnosis, 2 ROIs for interaction effect of diagnosis x cannabis use) were interrogated for additional main effects of nicotine use and current medication status.
#Text=3 Results
#Text=3.1 Demographics
#Text=LNCG participants had a lower mean age than those with an ADHD diagnosis (LNCG=24.1±1.2 years; ADHD 24.8±1.3 years, p<.05).
80-1	13026-13033	Finally	_
80-2	13033-13034	,	_
80-3	13035-13037	to	_
80-4	13038-13045	support	_
80-5	13046-13049	the	_
80-6	13050-13054	main	_
80-7	13055-13062	results	_
80-8	13062-13063	,	_
80-9	13064-13065	a	_
80-10	13066-13074	post-hoc	_
80-11	13075-13083	analysis	_
80-12	13084-13089	using	_
80-13	13090-13093	the	_
80-14	13094-13105	significant	_
80-15	13106-13113	regions	_
80-16	13114-13116	of	_
80-17	13117-13125	interest	_
80-18	13126-13127	(	_
80-19	13127-13130	ROI	_
80-20	13130-13131	)	_
80-21	13132-13143	highlighted	_
80-22	13144-13146	in	_
80-23	13147-13150	the	_
80-24	13151-13158	results	_
80-25	13159-13166	section	_
80-26	13167-13169	of	_
80-27	13170-13174	this	_
80-28	13175-13179	work	_
80-29	13180-13181	(	_
80-30	13181-13184	six	_
80-31	13185-13189	ROIs	_
80-32	13190-13193	for	_
80-33	13194-13198	main	_
80-34	13199-13205	effect	_
80-35	13206-13208	of	_
80-36	13209-13218	diagnosis	_
80-37	13218-13219	,	_
80-38	13220-13221	2	_
80-39	13222-13226	ROIs	_
80-40	13227-13230	for	_
80-41	13231-13242	interaction	_
80-42	13243-13249	effect	_
80-43	13250-13252	of	_
80-44	13253-13262	diagnosis	_
80-45	13263-13264	x	_
80-46	13265-13273	cannabis	_
80-47	13274-13277	use	_
80-48	13277-13278	)	_
80-49	13279-13283	were	_
80-50	13284-13296	interrogated	_
80-51	13297-13300	for	_
80-52	13301-13311	additional	_
80-53	13312-13316	main	_
80-54	13317-13324	effects	_
80-55	13325-13327	of	_
80-56	13328-13336	nicotine	_
80-57	13337-13340	use	_
80-58	13341-13344	and	_
80-59	13345-13352	current	_
80-60	13353-13363	medication	_
80-61	13364-13370	status	_
80-62	13370-13371	.	_
80-63	13372-13373	3	_
80-64	13374-13381	Results	_
80-65	13382-13385	3.1	_
80-66	13386-13398	Demographics	_
80-67	13399-13403	LNCG	_
80-68	13404-13416	participants	_
80-69	13417-13420	had	_
80-70	13421-13422	a	_
80-71	13423-13428	lower	_
80-72	13429-13433	mean	_
80-73	13434-13437	age	_
80-74	13438-13442	than	_
80-75	13443-13448	those	_
80-76	13449-13453	with	_
80-77	13454-13456	an	_
80-78	13457-13461	ADHD	_
80-79	13462-13471	diagnosis	_
80-80	13472-13473	(	_
80-81	13473-13477	LNCG	_
80-82	13477-13478	=	_
80-83	13478-13482	24.1	_
80-84	13482-13483	±	_
80-85	13483-13486	1.2	_
80-86	13487-13492	years	_
80-87	13492-13493	;	_
80-88	13494-13498	ADHD	_
80-89	13499-13503	24.8	_
80-90	13503-13504	±	_
80-91	13504-13507	1.3	_
80-92	13508-13513	years	_
80-93	13513-13514	,	_
80-94	13515-13516	p	_
80-95	13516-13517	<	_
80-96	13517-13520	.05	_
80-97	13520-13521	)	_
80-98	13521-13522	.	_

#Text=Cannabis users were more likely to be male than non-cannabis using participants (users 94% male, non-user 62% male).
81-1	13523-13531	Cannabis	_
81-2	13532-13537	users	_
81-3	13538-13542	were	_
81-4	13543-13547	more	_
81-5	13548-13554	likely	_
81-6	13555-13557	to	_
81-7	13558-13560	be	_
81-8	13561-13565	male	_
81-9	13566-13570	than	_
81-10	13571-13583	non-cannabis	_
81-11	13584-13589	using	_
81-12	13590-13602	participants	_
81-13	13603-13604	(	_
81-14	13604-13609	users	_
81-15	13610-13613	94%	_
81-16	13614-13618	male	_
81-17	13618-13619	,	_
81-18	13620-13628	non-user	_
81-19	13629-13632	62%	_
81-20	13633-13637	male	_
81-21	13637-13638	)	_
81-22	13638-13639	.	_

#Text=These demographic factors appeared to have little effect on the results of this study when included as covariates.
82-1	13640-13645	These	_
82-2	13646-13657	demographic	_
82-3	13658-13665	factors	_
82-4	13666-13674	appeared	_
82-5	13675-13677	to	_
82-6	13678-13682	have	_
82-7	13683-13689	little	_
82-8	13690-13696	effect	_
82-9	13697-13699	on	_
82-10	13700-13703	the	_
82-11	13704-13711	results	_
82-12	13712-13714	of	_
82-13	13715-13719	this	_
82-14	13720-13725	study	_
82-15	13726-13730	when	_
82-16	13731-13739	included	_
82-17	13740-13742	as	_
82-18	13743-13753	covariates	_
82-19	13753-13754	.	_

#Text=There were no other significant demographic differences between any of the 4 groups (LNCG/ADHD, User/Non-User) with respect to race/ethnicity, IQ, nicotine use (greater than once per day), age of first regular cannabis use within identified users or current medication status within ADHD participants.
#Text=3.2 Behavioral results
#Text=Participants with ADHD made significantly more errors of commission (mean inhibition accuracy = 89.1±7.6% for LNCG; 84.4±9.8% for ADHD; p<0.05; Figure 1).
83-1	13755-13760	There	_
83-2	13761-13765	were	_
83-3	13766-13768	no	_
83-4	13769-13774	other	_
83-5	13775-13786	significant	_
83-6	13787-13798	demographic	_
83-7	13799-13810	differences	_
83-8	13811-13818	between	_
83-9	13819-13822	any	_
83-10	13823-13825	of	_
83-11	13826-13829	the	_
83-12	13830-13831	4	_
83-13	13832-13838	groups	_
83-14	13839-13840	(	_
83-15	13840-13844	LNCG	_
83-16	13844-13845	/	_
83-17	13845-13849	ADHD	_
83-18	13849-13850	,	_
83-19	13851-13855	User	_
83-20	13855-13856	/	_
83-21	13856-13864	Non-User	_
83-22	13864-13865	)	_
83-23	13866-13870	with	_
83-24	13871-13878	respect	_
83-25	13879-13881	to	_
83-26	13882-13886	race	_
83-27	13886-13887	/	_
83-28	13887-13896	ethnicity	_
83-29	13896-13897	,	_
83-30	13898-13900	IQ	_
83-31	13900-13901	,	_
83-32	13902-13910	nicotine	_
83-33	13911-13914	use	_
83-34	13915-13916	(	_
83-35	13916-13923	greater	_
83-36	13924-13928	than	_
83-37	13929-13933	once	_
83-38	13934-13937	per	_
83-39	13938-13941	day	_
83-40	13941-13942	)	_
83-41	13942-13943	,	_
83-42	13944-13947	age	_
83-43	13948-13950	of	_
83-44	13951-13956	first	_
83-45	13957-13964	regular	_
83-46	13965-13973	cannabis	_
83-47	13974-13977	use	_
83-48	13978-13984	within	_
83-49	13985-13995	identified	_
83-50	13996-14001	users	_
83-51	14002-14004	or	_
83-52	14005-14012	current	_
83-53	14013-14023	medication	_
83-54	14024-14030	status	_
83-55	14031-14037	within	_
83-56	14038-14042	ADHD	_
83-57	14043-14055	participants	_
83-58	14055-14056	.	_
83-59	14057-14060	3.2	_
83-60	14061-14071	Behavioral	_
83-61	14072-14079	results	_
83-62	14080-14092	Participants	_
83-63	14093-14097	with	_
83-64	14098-14102	ADHD	_
83-65	14103-14107	made	_
83-66	14108-14121	significantly	_
83-67	14122-14126	more	_
83-68	14127-14133	errors	_
83-69	14134-14136	of	_
83-70	14137-14147	commission	_
83-71	14148-14149	(	_
83-72	14149-14153	mean	_
83-73	14154-14164	inhibition	_
83-74	14165-14173	accuracy	_
83-75	14174-14175	=	_
83-76	14176-14180	89.1	_
83-77	14180-14181	±	_
83-78	14181-14185	7.6%	_
83-79	14186-14189	for	_
83-80	14190-14194	LNCG	_
83-81	14194-14195	;	_
83-82	14196-14200	84.4	_
83-83	14200-14201	±	_
83-84	14201-14205	9.8%	_
83-85	14206-14209	for	_
83-86	14210-14214	ADHD	_
83-87	14214-14215	;	_
83-88	14216-14217	p	_
83-89	14217-14218	<	_
83-90	14218-14222	0.05	_
83-91	14222-14223	;	_
83-92	14224-14230	Figure	_
83-93	14231-14232	1	_
83-94	14232-14233	)	_
83-95	14233-14234	.	_

#Text=No significant main effect of cannabis use or diagnosis-by-use interaction effects were observed for errors of commission.
84-1	14235-14237	No	_
84-2	14238-14249	significant	_
84-3	14250-14254	main	_
84-4	14255-14261	effect	_
84-5	14262-14264	of	_
84-6	14265-14273	cannabis	_
84-7	14274-14277	use	_
84-8	14278-14280	or	_
84-9	14281-14297	diagnosis-by-use	_
84-10	14298-14309	interaction	_
84-11	14310-14317	effects	_
84-12	14318-14322	were	_
84-13	14323-14331	observed	_
84-14	14332-14335	for	_
84-15	14336-14342	errors	_
84-16	14343-14345	of	_
84-17	14346-14356	commission	_
84-18	14356-14357	.	_

#Text=There were no statistically significant main effects of diagnosis or cannabis use, or their interactions, for Go response times and NoGo errors of omission.
#Text=3.3 fMRI results
#Text=3.3.1 Main Effects of Diagnosis and Cannabis Use during Response Inhibition
#Text=Participants with a childhood diagnosis of ADHD showed widespread decreases in cortical activation during the NoGo>Go contrast compared with the LNCG for correct trials (Table 2 and Figure 2).
85-1	14358-14363	There	_
85-2	14364-14368	were	_
85-3	14369-14371	no	_
85-4	14372-14385	statistically	_
85-5	14386-14397	significant	_
85-6	14398-14402	main	_
85-7	14403-14410	effects	_
85-8	14411-14413	of	_
85-9	14414-14423	diagnosis	_
85-10	14424-14426	or	_
85-11	14427-14435	cannabis	_
85-12	14436-14439	use	_
85-13	14439-14440	,	_
85-14	14441-14443	or	_
85-15	14444-14449	their	_
85-16	14450-14462	interactions	_
85-17	14462-14463	,	_
85-18	14464-14467	for	_
85-19	14468-14470	Go	_
85-20	14471-14479	response	_
85-21	14480-14485	times	_
85-22	14486-14489	and	_
85-23	14490-14494	NoGo	_
85-24	14495-14501	errors	_
85-25	14502-14504	of	_
85-26	14505-14513	omission	_
85-27	14513-14514	.	_
85-28	14515-14518	3.3	_
85-29	14519-14523	fMRI	_
85-30	14524-14531	results	_
85-31	14532-14537	3.3.1	_
85-32	14538-14542	Main	_
85-33	14543-14550	Effects	_
85-34	14551-14553	of	_
85-35	14554-14563	Diagnosis	_
85-36	14564-14567	and	_
85-37	14568-14576	Cannabis	_
85-38	14577-14580	Use	_
85-39	14581-14587	during	_
85-40	14588-14596	Response	_
85-41	14597-14607	Inhibition	_
85-42	14608-14620	Participants	_
85-43	14621-14625	with	_
85-44	14626-14627	a	_
85-45	14628-14637	childhood	_
85-46	14638-14647	diagnosis	_
85-47	14648-14650	of	_
85-48	14651-14655	ADHD	_
85-49	14656-14662	showed	_
85-50	14663-14673	widespread	_
85-51	14674-14683	decreases	_
85-52	14684-14686	in	_
85-53	14687-14695	cortical	_
85-54	14696-14706	activation	_
85-55	14707-14713	during	_
85-56	14714-14717	the	_
85-57	14718-14722	NoGo	_
85-58	14722-14723	>	_
85-59	14723-14725	Go	_
85-60	14726-14734	contrast	_
85-61	14735-14743	compared	_
85-62	14744-14748	with	_
85-63	14749-14752	the	_
85-64	14753-14757	LNCG	_
85-65	14758-14761	for	_
85-66	14762-14769	correct	_
85-67	14770-14776	trials	_
85-68	14777-14778	(	_
85-69	14778-14783	Table	_
85-70	14784-14785	2	_
85-71	14786-14789	and	_
85-72	14790-14796	Figure	_
85-73	14797-14798	2	_
85-74	14798-14799	)	_
85-75	14799-14800	.	_

#Text=These regions included those in right frontostriatal and frontoparietal networks.
86-1	14801-14806	These	_
86-2	14807-14814	regions	_
86-3	14815-14823	included	_
86-4	14824-14829	those	_
86-5	14830-14832	in	_
86-6	14833-14838	right	_
86-7	14839-14853	frontostriatal	_
86-8	14854-14857	and	_
86-9	14858-14872	frontoparietal	_
86-10	14873-14881	networks	_
86-11	14881-14882	.	_

#Text=Activation differences were visually most prominent in the right hemisphere with the exception of pre- and post-central gyrus, which showed a stronger effect in the left hemisphere.
87-1	14883-14893	Activation	_
87-2	14894-14905	differences	_
87-3	14906-14910	were	_
87-4	14911-14919	visually	_
87-5	14920-14924	most	_
87-6	14925-14934	prominent	_
87-7	14935-14937	in	_
87-8	14938-14941	the	_
87-9	14942-14947	right	_
87-10	14948-14958	hemisphere	_
87-11	14959-14963	with	_
87-12	14964-14967	the	_
87-13	14968-14977	exception	_
87-14	14978-14980	of	_
87-15	14981-14984	pre	_
87-16	14984-14985	-	_
87-17	14986-14989	and	_
87-18	14990-15002	post-central	_
87-19	15003-15008	gyrus	_
87-20	15008-15009	,	_
87-21	15010-15015	which	_
87-22	15016-15022	showed	_
87-23	15023-15024	a	_
87-24	15025-15033	stronger	_
87-25	15034-15040	effect	_
87-26	15041-15043	in	_
87-27	15044-15047	the	_
87-28	15048-15052	left	_
87-29	15053-15063	hemisphere	_
87-30	15063-15064	.	_

#Text=Significant clusters in the precuneus cortex and posterior cingulate gyrus were also right lateralized.
88-1	15065-15076	Significant	_
88-2	15077-15085	clusters	_
88-3	15086-15088	in	_
88-4	15089-15092	the	_
88-5	15093-15102	precuneus	_
88-6	15103-15109	cortex	_
88-7	15110-15113	and	_
88-8	15114-15123	posterior	_
88-9	15124-15133	cingulate	_
88-10	15134-15139	gyrus	_
88-11	15140-15144	were	_
88-12	15145-15149	also	_
88-13	15150-15155	right	_
88-14	15156-15167	lateralized	_
88-15	15167-15168	.	_

#Text=To address possible threshold confounds and to compare with literature in children and adults a sensitivity analysis using a sliding z-score threshold was performed with 0.1 increments in z-threshold (from z=1 to z=4) to quantify the relative global distribution of activation across threshold values in 7 functionally connected networks previously identified by Yeo et. al..
89-1	15169-15171	To	_
89-2	15172-15179	address	_
89-3	15180-15188	possible	_
89-4	15189-15198	threshold	_
89-5	15199-15208	confounds	_
89-6	15209-15212	and	_
89-7	15213-15215	to	_
89-8	15216-15223	compare	_
89-9	15224-15228	with	_
89-10	15229-15239	literature	_
89-11	15240-15242	in	_
89-12	15243-15251	children	_
89-13	15252-15255	and	_
89-14	15256-15262	adults	_
89-15	15263-15264	a	_
89-16	15265-15276	sensitivity	_
89-17	15277-15285	analysis	_
89-18	15286-15291	using	_
89-19	15292-15293	a	_
89-20	15294-15301	sliding	_
89-21	15302-15309	z-score	_
89-22	15310-15319	threshold	_
89-23	15320-15323	was	_
89-24	15324-15333	performed	_
89-25	15334-15338	with	_
89-26	15339-15342	0.1	_
89-27	15343-15353	increments	_
89-28	15354-15356	in	_
89-29	15357-15368	z-threshold	_
89-30	15369-15370	(	_
89-31	15370-15374	from	_
89-32	15375-15376	z	_
89-33	15376-15377	=	_
89-34	15377-15378	1	_
89-35	15379-15381	to	_
89-36	15382-15383	z	_
89-37	15383-15384	=	_
89-38	15384-15385	4	_
89-39	15385-15386	)	_
89-40	15387-15389	to	_
89-41	15390-15398	quantify	_
89-42	15399-15402	the	_
89-43	15403-15411	relative	_
89-44	15412-15418	global	_
89-45	15419-15431	distribution	_
89-46	15432-15434	of	_
89-47	15435-15445	activation	_
89-48	15446-15452	across	_
89-49	15453-15462	threshold	_
89-50	15463-15469	values	_
89-51	15470-15472	in	_
89-52	15473-15474	7	_
89-53	15475-15487	functionally	_
89-54	15488-15497	connected	_
89-55	15498-15506	networks	_
89-56	15507-15517	previously	_
89-57	15518-15528	identified	_
89-58	15529-15531	by	_
89-59	15532-15535	Yeo	_
89-60	15536-15538	et	_
89-61	15538-15539	.	_
89-62	15540-15542	al	_
89-63	15542-15543	.	_
89-64	15543-15544	.	_

#Text=This analysis observed that the group differences were primarily located in regions associated with frontoparietal connectivity (see Supplemental Figure 1).
90-1	15545-15549	This	_
90-2	15550-15558	analysis	_
90-3	15559-15567	observed	_
90-4	15568-15572	that	_
90-5	15573-15576	the	_
90-6	15577-15582	group	_
90-7	15583-15594	differences	_
90-8	15595-15599	were	_
90-9	15600-15609	primarily	_
90-10	15610-15617	located	_
90-11	15618-15620	in	_
90-12	15621-15628	regions	_
90-13	15629-15639	associated	_
90-14	15640-15644	with	_
90-15	15645-15659	frontoparietal	_
90-16	15660-15672	connectivity	_
90-17	15673-15674	(	_
90-18	15674-15677	see	_
90-19	15678-15690	Supplemental	_
90-20	15691-15697	Figure	_
90-21	15698-15699	1	_
90-22	15699-15700	)	_
90-23	15700-15701	.	_

#Text=Voxelwise analyses of subcortical regions revealed that the right caudate and right thalamus were significantly less active in the ADHD than LNCG.
91-1	15702-15711	Voxelwise	_
91-2	15712-15720	analyses	_
91-3	15721-15723	of	_
91-4	15724-15735	subcortical	_
91-5	15736-15743	regions	_
91-6	15744-15752	revealed	_
91-7	15753-15757	that	_
91-8	15758-15761	the	_
91-9	15762-15767	right	_
91-10	15768-15775	caudate	_
91-11	15776-15779	and	_
91-12	15780-15785	right	_
91-13	15786-15794	thalamus	_
91-14	15795-15799	were	_
91-15	15800-15813	significantly	_
91-16	15814-15818	less	_
91-17	15819-15825	active	_
91-18	15826-15828	in	_
91-19	15829-15832	the	_
91-20	15833-15837	ADHD	_
91-21	15838-15842	than	_
91-22	15843-15847	LNCG	_
91-23	15847-15848	.	_

#Text=Native space subcortical ROI analyses confirmed significant group differences in right caudate (p=0.01), thalamus (p=0.05) and putamen (p=0.04), as well as left pallidum (p=0.05) (Figure 3).
92-1	15849-15855	Native	_
92-2	15856-15861	space	_
92-3	15862-15873	subcortical	_
92-4	15874-15877	ROI	_
92-5	15878-15886	analyses	_
92-6	15887-15896	confirmed	_
92-7	15897-15908	significant	_
92-8	15909-15914	group	_
92-9	15915-15926	differences	_
92-10	15927-15929	in	_
92-11	15930-15935	right	_
92-12	15936-15943	caudate	_
92-13	15944-15945	(	_
92-14	15945-15946	p	_
92-15	15946-15947	=	_
92-16	15947-15951	0.01	_
92-17	15951-15952	)	_
92-18	15952-15953	,	_
92-19	15954-15962	thalamus	_
92-20	15963-15964	(	_
92-21	15964-15965	p	_
92-22	15965-15966	=	_
92-23	15966-15970	0.05	_
92-24	15970-15971	)	_
92-25	15972-15975	and	_
92-26	15976-15983	putamen	_
92-27	15984-15985	(	_
92-28	15985-15986	p	_
92-29	15986-15987	=	_
92-30	15987-15991	0.04	_
92-31	15991-15992	)	_
92-32	15992-15993	,	_
92-33	15994-15996	as	_
92-34	15997-16001	well	_
92-35	16002-16004	as	_
92-36	16005-16009	left	_
92-37	16010-16018	pallidum	_
92-38	16019-16020	(	_
92-39	16020-16021	p	_
92-40	16021-16022	=	_
92-41	16022-16026	0.05	_
92-42	16026-16027	)	_
92-43	16028-16029	(	_
92-44	16029-16035	Figure	_
92-45	16036-16037	3	_
92-46	16037-16038	)	_
92-47	16038-16039	.	_

#Text=With the exception of the frontal pole, all significant cortical regions showed NoGo>Go activation in the LNCGs and relatively null NoGo>Go activation in ADHD participants.
93-1	16040-16044	With	_
93-2	16045-16048	the	_
93-3	16049-16058	exception	_
93-4	16059-16061	of	_
93-5	16062-16065	the	_
93-6	16066-16073	frontal	_
93-7	16074-16078	pole	_
93-8	16078-16079	,	_
93-9	16080-16083	all	_
93-10	16084-16095	significant	_
93-11	16096-16104	cortical	_
93-12	16105-16112	regions	_
93-13	16113-16119	showed	_
93-14	16120-16124	NoGo	_
93-15	16124-16125	>	_
93-16	16125-16127	Go	_
93-17	16128-16138	activation	_
93-18	16139-16141	in	_
93-19	16142-16145	the	_
93-20	16146-16151	LNCGs	_
93-21	16152-16155	and	_
93-22	16156-16166	relatively	_
93-23	16167-16171	null	_
93-24	16172-16176	NoGo	_
93-25	16176-16177	>	_
93-26	16177-16179	Go	_
93-27	16180-16190	activation	_
93-28	16191-16193	in	_
93-29	16194-16198	ADHD	_
93-30	16199-16211	participants	_
93-31	16211-16212	.	_

#Text=There were no significant clusters in which ADHD participants demonstrated greater inhibition-related activation than the control group.
94-1	16213-16218	There	_
94-2	16219-16223	were	_
94-3	16224-16226	no	_
94-4	16227-16238	significant	_
94-5	16239-16247	clusters	_
94-6	16248-16250	in	_
94-7	16251-16256	which	_
94-8	16257-16261	ADHD	_
94-9	16262-16274	participants	_
94-10	16275-16287	demonstrated	_
94-11	16288-16295	greater	_
94-12	16296-16314	inhibition-related	_
94-13	16315-16325	activation	_
94-14	16326-16330	than	_
94-15	16331-16334	the	_
94-16	16335-16342	control	_
94-17	16343-16348	group	_
94-18	16348-16349	.	_

#Text=No main effects of cannabis use on response inhibition were observed.
95-1	16350-16352	No	_
95-2	16353-16357	main	_
95-3	16358-16365	effects	_
95-4	16366-16368	of	_
95-5	16369-16377	cannabis	_
95-6	16378-16381	use	_
95-7	16382-16384	on	_
95-8	16385-16393	response	_
95-9	16394-16404	inhibition	_
95-10	16405-16409	were	_
95-11	16410-16418	observed	_
95-12	16418-16419	.	_

#Text=A secondary analysis that included age and gender as covariates found a similar pattern of group differences.
96-1	16420-16421	A	_
96-2	16422-16431	secondary	_
96-3	16432-16440	analysis	_
96-4	16441-16445	that	_
96-5	16446-16454	included	_
96-6	16455-16458	age	_
96-7	16459-16462	and	_
96-8	16463-16469	gender	_
96-9	16470-16472	as	_
96-10	16473-16483	covariates	_
96-11	16484-16489	found	_
96-12	16490-16491	a	_
96-13	16492-16499	similar	_
96-14	16500-16507	pattern	_
96-15	16508-16510	of	_
96-16	16511-16516	group	_
96-17	16517-16528	differences	_
96-18	16528-16529	.	_

#Text=No significant difference in total withdrawal symptoms between ADHD cannabis users and LNCG cannabis users was found.
#Text=3.3.2 Diagnosis by Cannabis Use Interaction Effects during Response Inhibition
#Text=There was a significant ADHD diagnosis by cannabis use interaction in the right hippocampus and cerebellar vermis during successful response inhibition (Table 2 and Figure 4).
97-1	16530-16532	No	_
97-2	16533-16544	significant	_
97-3	16545-16555	difference	_
97-4	16556-16558	in	_
97-5	16559-16564	total	_
97-6	16565-16575	withdrawal	_
97-7	16576-16584	symptoms	_
97-8	16585-16592	between	_
97-9	16593-16597	ADHD	_
97-10	16598-16606	cannabis	_
97-11	16607-16612	users	_
97-12	16613-16616	and	_
97-13	16617-16621	LNCG	_
97-14	16622-16630	cannabis	_
97-15	16631-16636	users	_
97-16	16637-16640	was	_
97-17	16641-16646	found	_
97-18	16646-16647	.	_
97-19	16648-16653	3.3.2	_
97-20	16654-16663	Diagnosis	_
97-21	16664-16666	by	_
97-22	16667-16675	Cannabis	_
97-23	16676-16679	Use	_
97-24	16680-16691	Interaction	_
97-25	16692-16699	Effects	_
97-26	16700-16706	during	_
97-27	16707-16715	Response	_
97-28	16716-16726	Inhibition	_
97-29	16727-16732	There	_
97-30	16733-16736	was	_
97-31	16737-16738	a	_
97-32	16739-16750	significant	_
97-33	16751-16755	ADHD	_
97-34	16756-16765	diagnosis	_
97-35	16766-16768	by	_
97-36	16769-16777	cannabis	_
97-37	16778-16781	use	_
97-38	16782-16793	interaction	_
97-39	16794-16796	in	_
97-40	16797-16800	the	_
97-41	16801-16806	right	_
97-42	16807-16818	hippocampus	_
97-43	16819-16822	and	_
97-44	16823-16833	cerebellar	_
97-45	16834-16840	vermis	_
97-46	16841-16847	during	_
97-47	16848-16858	successful	_
97-48	16859-16867	response	_
97-49	16868-16878	inhibition	_
97-50	16879-16880	(	_
97-51	16880-16885	Table	_
97-52	16886-16887	2	_
97-53	16888-16891	and	_
97-54	16892-16898	Figure	_
97-55	16899-16900	4	_
97-56	16900-16901	)	_
97-57	16901-16902	.	_

#Text=The LNCG cannabis users showed significantly more activation (NoGo>Go) in these regions than LNCG non-users (Hippocampus p<.001; Cerebellar Vermis p<.01), whereas ADHD cannabis users showed non-significantly lower activation in these regions than ADHD cannabis non-users.
98-1	16903-16906	The	_
98-2	16907-16911	LNCG	_
98-3	16912-16920	cannabis	_
98-4	16921-16926	users	_
98-5	16927-16933	showed	_
98-6	16934-16947	significantly	_
98-7	16948-16952	more	_
98-8	16953-16963	activation	_
98-9	16964-16965	(	_
98-10	16965-16969	NoGo	_
98-11	16969-16970	>	_
98-12	16970-16972	Go	_
98-13	16972-16973	)	_
98-14	16974-16976	in	_
98-15	16977-16982	these	_
98-16	16983-16990	regions	_
98-17	16991-16995	than	_
98-18	16996-17000	LNCG	_
98-19	17001-17010	non-users	_
98-20	17011-17012	(	_
98-21	17012-17023	Hippocampus	_
98-22	17024-17025	p	_
98-23	17025-17026	<	_
98-24	17026-17030	.001	_
98-25	17030-17031	;	_
98-26	17032-17042	Cerebellar	_
98-27	17043-17049	Vermis	_
98-28	17050-17051	p	_
98-29	17051-17052	<	_
98-30	17052-17055	.01	_
98-31	17055-17056	)	_
98-32	17056-17057	,	_
98-33	17058-17065	whereas	_
98-34	17066-17070	ADHD	_
98-35	17071-17079	cannabis	_
98-36	17080-17085	users	_
98-37	17086-17092	showed	_
98-38	17093-17110	non-significantly	_
98-39	17111-17116	lower	_
98-40	17117-17127	activation	_
98-41	17128-17130	in	_
98-42	17131-17136	these	_
98-43	17137-17144	regions	_
98-44	17145-17149	than	_
98-45	17150-17154	ADHD	_
98-46	17155-17163	cannabis	_
98-47	17164-17173	non-users	_
98-48	17173-17174	.	_

#Text=In addition, among cannabis users, the LNCG participants activated these regions more than the ADHD participants (Hippocampus p<.001; Cerebellar Vermis p<.01), whereas among non-users, ADHD participants activated these regions non-significantly more than LNCG participants.
99-1	17175-17177	In	_
99-2	17178-17186	addition	_
99-3	17186-17187	,	_
99-4	17188-17193	among	_
99-5	17194-17202	cannabis	_
99-6	17203-17208	users	_
99-7	17208-17209	,	_
99-8	17210-17213	the	_
99-9	17214-17218	LNCG	_
99-10	17219-17231	participants	_
99-11	17232-17241	activated	_
99-12	17242-17247	these	_
99-13	17248-17255	regions	_
99-14	17256-17260	more	_
99-15	17261-17265	than	_
99-16	17266-17269	the	_
99-17	17270-17274	ADHD	_
99-18	17275-17287	participants	_
99-19	17288-17289	(	_
99-20	17289-17300	Hippocampus	_
99-21	17301-17302	p	_
99-22	17302-17303	<	_
99-23	17303-17307	.001	_
99-24	17307-17308	;	_
99-25	17309-17319	Cerebellar	_
99-26	17320-17326	Vermis	_
99-27	17327-17328	p	_
99-28	17328-17329	<	_
99-29	17329-17332	.01	_
99-30	17332-17333	)	_
99-31	17333-17334	,	_
99-32	17335-17342	whereas	_
99-33	17343-17348	among	_
99-34	17349-17358	non-users	_
99-35	17358-17359	,	_
99-36	17360-17364	ADHD	_
99-37	17365-17377	participants	_
99-38	17378-17387	activated	_
99-39	17388-17393	these	_
99-40	17394-17401	regions	_
99-41	17402-17419	non-significantly	_
99-42	17420-17424	more	_
99-43	17425-17429	than	_
99-44	17430-17434	LNCG	_
99-45	17435-17447	participants	_
99-46	17447-17448	.	_

#Text=Go versus Rest (inter stimulus interval) and NoGo versus rest contrasts indicate that the interaction effects between diagnosis and cannabis use were dominated by the NoGo (inhibition) trial activations (Figure 5).
#Text=3.4 Post-hoc Analyses of Nicotine Use and Medication Status
#Text=Post-hoc analyses of the ROIs identified as having main or interaction effects of cannabis use and diagnosis were tested for confounding effects of tobacco use and current medication status.
100-1	17449-17451	Go	_
100-2	17452-17458	versus	_
100-3	17459-17463	Rest	_
100-4	17464-17465	(	_
100-5	17465-17470	inter	_
100-6	17471-17479	stimulus	_
100-7	17480-17488	interval	_
100-8	17488-17489	)	_
100-9	17490-17493	and	_
100-10	17494-17498	NoGo	_
100-11	17499-17505	versus	_
100-12	17506-17510	rest	_
100-13	17511-17520	contrasts	_
100-14	17521-17529	indicate	_
100-15	17530-17534	that	_
100-16	17535-17538	the	_
100-17	17539-17550	interaction	_
100-18	17551-17558	effects	_
100-19	17559-17566	between	_
100-20	17567-17576	diagnosis	_
100-21	17577-17580	and	_
100-22	17581-17589	cannabis	_
100-23	17590-17593	use	_
100-24	17594-17598	were	_
100-25	17599-17608	dominated	_
100-26	17609-17611	by	_
100-27	17612-17615	the	_
100-28	17616-17620	NoGo	_
100-29	17621-17622	(	_
100-30	17622-17632	inhibition	_
100-31	17632-17633	)	_
100-32	17634-17639	trial	_
100-33	17640-17651	activations	_
100-34	17652-17653	(	_
100-35	17653-17659	Figure	_
100-36	17660-17661	5	_
100-37	17661-17662	)	_
100-38	17662-17663	.	_
100-39	17664-17667	3.4	_
100-40	17668-17676	Post-hoc	_
100-41	17677-17685	Analyses	_
100-42	17686-17688	of	_
100-43	17689-17697	Nicotine	_
100-44	17698-17701	Use	_
100-45	17702-17705	and	_
100-46	17706-17716	Medication	_
100-47	17717-17723	Status	_
100-48	17724-17732	Post-hoc	_
100-49	17733-17741	analyses	_
100-50	17742-17744	of	_
100-51	17745-17748	the	_
100-52	17749-17753	ROIs	_
100-53	17754-17764	identified	_
100-54	17765-17767	as	_
100-55	17768-17774	having	_
100-56	17775-17779	main	_
100-57	17780-17782	or	_
100-58	17783-17794	interaction	_
100-59	17795-17802	effects	_
100-60	17803-17805	of	_
100-61	17806-17814	cannabis	_
100-62	17815-17818	use	_
100-63	17819-17822	and	_
100-64	17823-17832	diagnosis	_
100-65	17833-17837	were	_
100-66	17838-17844	tested	_
100-67	17845-17848	for	_
100-68	17849-17860	confounding	_
100-69	17861-17868	effects	_
100-70	17869-17871	of	_
100-71	17872-17879	tobacco	_
100-72	17880-17883	use	_
100-73	17884-17887	and	_
100-74	17888-17895	current	_
100-75	17896-17906	medication	_
100-76	17907-17913	status	_
100-77	17913-17914	.	_

#Text=All six ROIs showing a main effect of diagnosis remained significant when including medication status and nicotine use as covariates (LNCG>ADHD: R Frontal Pole p<10−4; R Parietal Lobe p<10−3; R Caudate p<10−3; R/L Precuneus p=0.005; L Parietal Lobe p<0.005; R Inferior Frontal Gyrus p<10−5).
#Text=4 Discussion
#Text=The main findings of this study are twofold.
101-1	17915-17918	All	_
101-2	17919-17922	six	_
101-3	17923-17927	ROIs	_
101-4	17928-17935	showing	_
101-5	17936-17937	a	_
101-6	17938-17942	main	_
101-7	17943-17949	effect	_
101-8	17950-17952	of	_
101-9	17953-17962	diagnosis	_
101-10	17963-17971	remained	_
101-11	17972-17983	significant	_
101-12	17984-17988	when	_
101-13	17989-17998	including	_
101-14	17999-18009	medication	_
101-15	18010-18016	status	_
101-16	18017-18020	and	_
101-17	18021-18029	nicotine	_
101-18	18030-18033	use	_
101-19	18034-18036	as	_
101-20	18037-18047	covariates	_
101-21	18048-18049	(	_
101-22	18049-18053	LNCG	_
101-23	18053-18054	>	_
101-24	18054-18058	ADHD	_
101-25	18058-18059	:	_
101-26	18060-18061	R	_
101-27	18062-18069	Frontal	_
101-28	18070-18074	Pole	_
101-29	18075-18076	p	_
101-30	18076-18077	<	_
101-31	18077-18079	10	_
101-32	18079-18080	−	_
101-33	18080-18081	4	_
101-34	18081-18082	;	_
101-35	18083-18084	R	_
101-36	18085-18093	Parietal	_
101-37	18094-18098	Lobe	_
101-38	18099-18100	p	_
101-39	18100-18101	<	_
101-40	18101-18103	10	_
101-41	18103-18104	−	_
101-42	18104-18105	3	_
101-43	18105-18106	;	_
101-44	18107-18108	R	_
101-45	18109-18116	Caudate	_
101-46	18117-18118	p	_
101-47	18118-18119	<	_
101-48	18119-18121	10	_
101-49	18121-18122	−	_
101-50	18122-18123	3	_
101-51	18123-18124	;	_
101-52	18125-18126	R	_
101-53	18126-18127	/	_
101-54	18127-18128	L	_
101-55	18129-18138	Precuneus	_
101-56	18139-18140	p	_
101-57	18140-18141	=	_
101-58	18141-18146	0.005	_
101-59	18146-18147	;	_
101-60	18148-18149	L	_
101-61	18150-18158	Parietal	_
101-62	18159-18163	Lobe	_
101-63	18164-18165	p	_
101-64	18165-18166	<	_
101-65	18166-18171	0.005	_
101-66	18171-18172	;	_
101-67	18173-18174	R	_
101-68	18175-18183	Inferior	_
101-69	18184-18191	Frontal	_
101-70	18192-18197	Gyrus	_
101-71	18198-18199	p	_
101-72	18199-18200	<	_
101-73	18200-18202	10	_
101-74	18202-18203	−	_
101-75	18203-18204	5	_
101-76	18204-18205	)	_
101-77	18205-18206	.	_
101-78	18207-18208	4	_
101-79	18209-18219	Discussion	_
101-80	18220-18223	The	_
101-81	18224-18228	main	_
101-82	18229-18237	findings	_
101-83	18238-18240	of	_
101-84	18241-18245	this	_
101-85	18246-18251	study	_
101-86	18252-18255	are	_
101-87	18256-18263	twofold	_
101-88	18263-18264	.	_

#Text=First, young adults with a childhood diagnosis of ADHD show a higher likelihood of commission errors (i.e., response inhibition deficits) and lower activation in frontostriatal and frontoparietal circuits associated with successful response inhibition during a Go/NoGo task irrespective of cannabis use history.
102-1	18265-18270	First	_
102-2	18270-18271	,	_
102-3	18272-18277	young	_
102-4	18278-18284	adults	_
102-5	18285-18289	with	_
102-6	18290-18291	a	_
102-7	18292-18301	childhood	_
102-8	18302-18311	diagnosis	_
102-9	18312-18314	of	_
102-10	18315-18319	ADHD	_
102-11	18320-18324	show	_
102-12	18325-18326	a	_
102-13	18327-18333	higher	_
102-14	18334-18344	likelihood	_
102-15	18345-18347	of	_
102-16	18348-18358	commission	_
102-17	18359-18365	errors	_
102-18	18366-18367	(	_
102-19	18367-18370	i.e	_
102-20	18370-18371	.	_
102-21	18371-18372	,	_
102-22	18373-18381	response	_
102-23	18382-18392	inhibition	_
102-24	18393-18401	deficits	_
102-25	18401-18402	)	_
102-26	18403-18406	and	_
102-27	18407-18412	lower	_
102-28	18413-18423	activation	_
102-29	18424-18426	in	_
102-30	18427-18441	frontostriatal	_
102-31	18442-18445	and	_
102-32	18446-18460	frontoparietal	_
102-33	18461-18469	circuits	_
102-34	18470-18480	associated	_
102-35	18481-18485	with	_
102-36	18486-18496	successful	_
102-37	18497-18505	response	_
102-38	18506-18516	inhibition	_
102-39	18517-18523	during	_
102-40	18524-18525	a	_
102-41	18526-18528	Go	_
102-42	18528-18529	/	_
102-43	18529-18533	NoGo	_
102-44	18534-18538	task	_
102-45	18539-18551	irrespective	_
102-46	18552-18554	of	_
102-47	18555-18563	cannabis	_
102-48	18564-18567	use	_
102-49	18568-18575	history	_
102-50	18575-18576	.	_

#Text=Second, cannabis use by young adults without ADHD leads to greater recruitment of the hippocampus and cerebellar vermis when correctly inhibiting a response, an effect not observed in the ADHD subjects.
103-1	18577-18583	Second	_
103-2	18583-18584	,	_
103-3	18585-18593	cannabis	_
103-4	18594-18597	use	_
103-5	18598-18600	by	_
103-6	18601-18606	young	_
103-7	18607-18613	adults	_
103-8	18614-18621	without	_
103-9	18622-18626	ADHD	_
103-10	18627-18632	leads	_
103-11	18633-18635	to	_
103-12	18636-18643	greater	_
103-13	18644-18655	recruitment	_
103-14	18656-18658	of	_
103-15	18659-18662	the	_
103-16	18663-18674	hippocampus	_
103-17	18675-18678	and	_
103-18	18679-18689	cerebellar	_
103-19	18690-18696	vermis	_
103-20	18697-18701	when	_
103-21	18702-18711	correctly	_
103-22	18712-18722	inhibiting	_
103-23	18723-18724	a	_
103-24	18725-18733	response	_
103-25	18733-18734	,	_
103-26	18735-18737	an	_
103-27	18738-18744	effect	_
103-28	18745-18748	not	_
103-29	18749-18757	observed	_
103-30	18758-18760	in	_
103-31	18761-18764	the	_
103-32	18765-18769	ADHD	_
103-33	18770-18778	subjects	_
103-34	18778-18779	.	_

#Text=Our findings of diminished cognitive control in ADHD and hypoactivity of prefrontal circuitry are consistent with previous work in ADHD.
104-1	18780-18783	Our	_
104-2	18784-18792	findings	_
104-3	18793-18795	of	_
104-4	18796-18806	diminished	_
104-5	18807-18816	cognitive	_
104-6	18817-18824	control	_
104-7	18825-18827	in	_
104-8	18828-18832	ADHD	_
104-9	18833-18836	and	_
104-10	18837-18849	hypoactivity	_
104-11	18850-18852	of	_
104-12	18853-18863	prefrontal	_
104-13	18864-18873	circuitry	_
104-14	18874-18877	are	_
104-15	18878-18888	consistent	_
104-16	18889-18893	with	_
104-17	18894-18902	previous	_
104-18	18903-18907	work	_
104-19	18908-18910	in	_
104-20	18911-18915	ADHD	_
104-21	18915-18916	.	_

#Text=Specifically, the in-scanner behavioral performance is consistent with studies that have defined response inhibition deficits as being characteristic of ADHD, both in children, who exhibit a significantly higher likelihood of false positive responses, and across development.
105-1	18917-18929	Specifically	_
105-2	18929-18930	,	_
105-3	18931-18934	the	_
105-4	18935-18945	in-scanner	_
105-5	18946-18956	behavioral	_
105-6	18957-18968	performance	_
105-7	18969-18971	is	_
105-8	18972-18982	consistent	_
105-9	18983-18987	with	_
105-10	18988-18995	studies	_
105-11	18996-19000	that	_
105-12	19001-19005	have	_
105-13	19006-19013	defined	_
105-14	19014-19022	response	_
105-15	19023-19033	inhibition	_
105-16	19034-19042	deficits	_
105-17	19043-19045	as	_
105-18	19046-19051	being	_
105-19	19052-19066	characteristic	_
105-20	19067-19069	of	_
105-21	19070-19074	ADHD	_
105-22	19074-19075	,	_
105-23	19076-19080	both	_
105-24	19081-19083	in	_
105-25	19084-19092	children	_
105-26	19092-19093	,	_
105-27	19094-19097	who	_
105-28	19098-19105	exhibit	_
105-29	19106-19107	a	_
105-30	19108-19121	significantly	_
105-31	19122-19128	higher	_
105-32	19129-19139	likelihood	_
105-33	19140-19142	of	_
105-34	19143-19148	false	_
105-35	19149-19157	positive	_
105-36	19158-19167	responses	_
105-37	19167-19168	,	_
105-38	19169-19172	and	_
105-39	19173-19179	across	_
105-40	19180-19191	development	_
105-41	19191-19192	.	_

#Text=While response inhibition in adults with a history of ADHD has been less-studied, there is evidence that response inhibition deficits persist into adulthood as shown by a correlation between response time variability (another hallmark of ADHD) and failed inhibition.
106-1	19193-19198	While	_
106-2	19199-19207	response	_
106-3	19208-19218	inhibition	_
106-4	19219-19221	in	_
106-5	19222-19228	adults	_
106-6	19229-19233	with	_
106-7	19234-19235	a	_
106-8	19236-19243	history	_
106-9	19244-19246	of	_
106-10	19247-19251	ADHD	_
106-11	19252-19255	has	_
106-12	19256-19260	been	_
106-13	19261-19273	less-studied	_
106-14	19273-19274	,	_
106-15	19275-19280	there	_
106-16	19281-19283	is	_
106-17	19284-19292	evidence	_
106-18	19293-19297	that	_
106-19	19298-19306	response	_
106-20	19307-19317	inhibition	_
106-21	19318-19326	deficits	_
106-22	19327-19334	persist	_
106-23	19335-19339	into	_
106-24	19340-19349	adulthood	_
106-25	19350-19352	as	_
106-26	19353-19358	shown	_
106-27	19359-19361	by	_
106-28	19362-19363	a	_
106-29	19364-19375	correlation	_
106-30	19376-19383	between	_
106-31	19384-19392	response	_
106-32	19393-19397	time	_
106-33	19398-19409	variability	_
106-34	19410-19411	(	_
106-35	19411-19418	another	_
106-36	19419-19427	hallmark	_
106-37	19428-19430	of	_
106-38	19431-19435	ADHD	_
106-39	19435-19436	)	_
106-40	19437-19440	and	_
106-41	19441-19447	failed	_
106-42	19448-19458	inhibition	_
106-43	19458-19459	.	_

#Text=Also, a meta-analysis investigating neuropsychological traits in adults with ADHD compared to normal controls reported medium to large effect sizes for response inhibition deficits in adult ADHD participants.
107-1	19460-19464	Also	_
107-2	19464-19465	,	_
107-3	19466-19467	a	_
107-4	19468-19481	meta-analysis	_
107-5	19482-19495	investigating	_
107-6	19496-19514	neuropsychological	_
107-7	19515-19521	traits	_
107-8	19522-19524	in	_
107-9	19525-19531	adults	_
107-10	19532-19536	with	_
107-11	19537-19541	ADHD	_
107-12	19542-19550	compared	_
107-13	19551-19553	to	_
107-14	19554-19560	normal	_
107-15	19561-19569	controls	_
107-16	19570-19578	reported	_
107-17	19579-19585	medium	_
107-18	19586-19588	to	_
107-19	19589-19594	large	_
107-20	19595-19601	effect	_
107-21	19602-19607	sizes	_
107-22	19608-19611	for	_
107-23	19612-19620	response	_
107-24	19621-19631	inhibition	_
107-25	19632-19640	deficits	_
107-26	19641-19643	in	_
107-27	19644-19649	adult	_
107-28	19650-19654	ADHD	_
107-29	19655-19667	participants	_
107-30	19667-19668	.	_

#Text=Not surprisingly, our results are consistent with the out-of-scanner cognitive battery results obtained on a superset of the individuals included in the current study, which showed cognitive control impairments in ADHD subjects independent of cannabis use.
108-1	19669-19672	Not	_
108-2	19673-19685	surprisingly	_
108-3	19685-19686	,	_
108-4	19687-19690	our	_
108-5	19691-19698	results	_
108-6	19699-19702	are	_
108-7	19703-19713	consistent	_
108-8	19714-19718	with	_
108-9	19719-19722	the	_
108-10	19723-19737	out-of-scanner	_
108-11	19738-19747	cognitive	_
108-12	19748-19755	battery	_
108-13	19756-19763	results	_
108-14	19764-19772	obtained	_
108-15	19773-19775	on	_
108-16	19776-19777	a	_
108-17	19778-19786	superset	_
108-18	19787-19789	of	_
108-19	19790-19793	the	_
108-20	19794-19805	individuals	_
108-21	19806-19814	included	_
108-22	19815-19817	in	_
108-23	19818-19821	the	_
108-24	19822-19829	current	_
108-25	19830-19835	study	_
108-26	19835-19836	,	_
108-27	19837-19842	which	_
108-28	19843-19849	showed	_
108-29	19850-19859	cognitive	_
108-30	19860-19867	control	_
108-31	19868-19879	impairments	_
108-32	19880-19882	in	_
108-33	19883-19887	ADHD	_
108-34	19888-19896	subjects	_
108-35	19897-19908	independent	_
108-36	19909-19911	of	_
108-37	19912-19920	cannabis	_
108-38	19921-19924	use	_
108-39	19924-19925	.	_

#Text=The context of these findings in a sample of individuals with a childhood ADHD diagnosis followed longitudinally may not be directly comparable to studies of individuals who are diagnosed with ADHD as adults, as these populations are only partially overlapping.
109-1	19926-19929	The	_
109-2	19930-19937	context	_
109-3	19938-19940	of	_
109-4	19941-19946	these	_
109-5	19947-19955	findings	_
109-6	19956-19958	in	_
109-7	19959-19960	a	_
109-8	19961-19967	sample	_
109-9	19968-19970	of	_
109-10	19971-19982	individuals	_
109-11	19983-19987	with	_
109-12	19988-19989	a	_
109-13	19990-19999	childhood	_
109-14	20000-20004	ADHD	_
109-15	20005-20014	diagnosis	_
109-16	20015-20023	followed	_
109-17	20024-20038	longitudinally	_
109-18	20039-20042	may	_
109-19	20043-20046	not	_
109-20	20047-20049	be	_
109-21	20050-20058	directly	_
109-22	20059-20069	comparable	_
109-23	20070-20072	to	_
109-24	20073-20080	studies	_
109-25	20081-20083	of	_
109-26	20084-20095	individuals	_
109-27	20096-20099	who	_
109-28	20100-20103	are	_
109-29	20104-20113	diagnosed	_
109-30	20114-20118	with	_
109-31	20119-20123	ADHD	_
109-32	20124-20126	as	_
109-33	20127-20133	adults	_
109-34	20133-20134	,	_
109-35	20135-20137	as	_
109-36	20138-20143	these	_
109-37	20144-20155	populations	_
109-38	20156-20159	are	_
109-39	20160-20164	only	_
109-40	20165-20174	partially	_
109-41	20175-20186	overlapping	_
109-42	20186-20187	.	_

#Text=The hypoactivity in prefrontal, parietal and striatal regions of ADHD individuals in our study is largely consistent with existing literature.
110-1	20188-20191	The	_
110-2	20192-20204	hypoactivity	_
110-3	20205-20207	in	_
110-4	20208-20218	prefrontal	_
110-5	20218-20219	,	_
110-6	20220-20228	parietal	_
110-7	20229-20232	and	_
110-8	20233-20241	striatal	_
110-9	20242-20249	regions	_
110-10	20250-20252	of	_
110-11	20253-20257	ADHD	_
110-12	20258-20269	individuals	_
110-13	20270-20272	in	_
110-14	20273-20276	our	_
110-15	20277-20282	study	_
110-16	20283-20285	is	_
110-17	20286-20293	largely	_
110-18	20294-20304	consistent	_
110-19	20305-20309	with	_
110-20	20310-20318	existing	_
110-21	20319-20329	literature	_
110-22	20329-20330	.	_

#Text=While there is evidence of parietal ADHD hyperactivation in children, the majority of studies cited in recent meta-analyses indicate frontoparietal and frontostriatal hypoactivity in the ADHD population.
111-1	20331-20336	While	_
111-2	20337-20342	there	_
111-3	20343-20345	is	_
111-4	20346-20354	evidence	_
111-5	20355-20357	of	_
111-6	20358-20366	parietal	_
111-7	20367-20371	ADHD	_
111-8	20372-20387	hyperactivation	_
111-9	20388-20390	in	_
111-10	20391-20399	children	_
111-11	20399-20400	,	_
111-12	20401-20404	the	_
111-13	20405-20413	majority	_
111-14	20414-20416	of	_
111-15	20417-20424	studies	_
111-16	20425-20430	cited	_
111-17	20431-20433	in	_
111-18	20434-20440	recent	_
111-19	20441-20454	meta-analyses	_
111-20	20455-20463	indicate	_
111-21	20464-20478	frontoparietal	_
111-22	20479-20482	and	_
111-23	20483-20497	frontostriatal	_
111-24	20498-20510	hypoactivity	_
111-25	20511-20513	in	_
111-26	20514-20517	the	_
111-27	20518-20522	ADHD	_
111-28	20523-20533	population	_
111-29	20533-20534	.	_

#Text=Specifically, our findings of hypoactivity in the left precentral, middle frontal, inferior frontal, and posterior cingulate gyrus; right postcentral, insula, parietal and thalamus regions are consistent with those reported as being involved in ADHD during inhibition tasks in the meta-analysis by Dickstein et al.
112-1	20535-20547	Specifically	_
112-2	20547-20548	,	_
112-3	20549-20552	our	_
112-4	20553-20561	findings	_
112-5	20562-20564	of	_
112-6	20565-20577	hypoactivity	_
112-7	20578-20580	in	_
112-8	20581-20584	the	_
112-9	20585-20589	left	_
112-10	20590-20600	precentral	_
112-11	20600-20601	,	_
112-12	20602-20608	middle	_
112-13	20609-20616	frontal	_
112-14	20616-20617	,	_
112-15	20618-20626	inferior	_
112-16	20627-20634	frontal	_
112-17	20634-20635	,	_
112-18	20636-20639	and	_
112-19	20640-20649	posterior	_
112-20	20650-20659	cingulate	_
112-21	20660-20665	gyrus	_
112-22	20665-20666	;	_
112-23	20667-20672	right	_
112-24	20673-20684	postcentral	_
112-25	20684-20685	,	_
112-26	20686-20692	insula	_
112-27	20692-20693	,	_
112-28	20694-20702	parietal	_
112-29	20703-20706	and	_
112-30	20707-20715	thalamus	_
112-31	20716-20723	regions	_
112-32	20724-20727	are	_
112-33	20728-20738	consistent	_
112-34	20739-20743	with	_
112-35	20744-20749	those	_
112-36	20750-20758	reported	_
112-37	20759-20761	as	_
112-38	20762-20767	being	_
112-39	20768-20776	involved	_
112-40	20777-20779	in	_
112-41	20780-20784	ADHD	_
112-42	20785-20791	during	_
112-43	20792-20802	inhibition	_
112-44	20803-20808	tasks	_
112-45	20809-20811	in	_
112-46	20812-20815	the	_
112-47	20816-20829	meta-analysis	_
112-48	20830-20832	by	_
112-49	20833-20842	Dickstein	_
112-50	20843-20845	et	_
112-51	20846-20848	al	_
112-52	20848-20849	.	_

#Text=Similarly, the Hart et al. meta-analysis investigating attentional tasks in ADHD reported involvement of networks similar to the right lateralized frontoparietal/frontostriatal activation differences reported here (i.e., right middle frontal gyrus, inferior parietal, precuneus, thalamus, caudate and insula).
113-1	20850-20859	Similarly	_
113-2	20859-20860	,	_
113-3	20861-20864	the	_
113-4	20865-20869	Hart	_
113-5	20870-20872	et	_
113-6	20873-20875	al	_
113-7	20875-20876	.	_
113-8	20877-20890	meta-analysis	_
113-9	20891-20904	investigating	_
113-10	20905-20916	attentional	_
113-11	20917-20922	tasks	_
113-12	20923-20925	in	_
113-13	20926-20930	ADHD	_
113-14	20931-20939	reported	_
113-15	20940-20951	involvement	_
113-16	20952-20954	of	_
113-17	20955-20963	networks	_
113-18	20964-20971	similar	_
113-19	20972-20974	to	_
113-20	20975-20978	the	_
113-21	20979-20984	right	_
113-22	20985-20996	lateralized	_
113-23	20997-21011	frontoparietal	_
113-24	21011-21012	/	_
113-25	21012-21026	frontostriatal	_
113-26	21027-21037	activation	_
113-27	21038-21049	differences	_
113-28	21050-21058	reported	_
113-29	21059-21063	here	_
113-30	21064-21065	(	_
113-31	21065-21068	i.e	_
113-32	21068-21069	.	_
113-33	21069-21070	,	_
113-34	21071-21076	right	_
113-35	21077-21083	middle	_
113-36	21084-21091	frontal	_
113-37	21092-21097	gyrus	_
113-38	21097-21098	,	_
113-39	21099-21107	inferior	_
113-40	21108-21116	parietal	_
113-41	21116-21117	,	_
113-42	21118-21127	precuneus	_
113-43	21127-21128	,	_
113-44	21129-21137	thalamus	_
113-45	21137-21138	,	_
113-46	21139-21146	caudate	_
113-47	21147-21150	and	_
113-48	21151-21157	insula	_
113-49	21157-21158	)	_
113-50	21158-21159	.	_

#Text=Finally, in a recent review of 55 fMRI studies of ADHD, 97% of hypoactivity in adults with ADHD was located in frontoparietal connectivity networks as defined by the seven-network model proposed by Yeo et al., consistent with our findings.
114-1	21160-21167	Finally	_
114-2	21167-21168	,	_
114-3	21169-21171	in	_
114-4	21172-21173	a	_
114-5	21174-21180	recent	_
114-6	21181-21187	review	_
114-7	21188-21190	of	_
114-8	21191-21193	55	_
114-9	21194-21198	fMRI	_
114-10	21199-21206	studies	_
114-11	21207-21209	of	_
114-12	21210-21214	ADHD	_
114-13	21214-21215	,	_
114-14	21216-21219	97%	_
114-15	21220-21222	of	_
114-16	21223-21235	hypoactivity	_
114-17	21236-21238	in	_
114-18	21239-21245	adults	_
114-19	21246-21250	with	_
114-20	21251-21255	ADHD	_
114-21	21256-21259	was	_
114-22	21260-21267	located	_
114-23	21268-21270	in	_
114-24	21271-21285	frontoparietal	_
114-25	21286-21298	connectivity	_
114-26	21299-21307	networks	_
114-27	21308-21310	as	_
114-28	21311-21318	defined	_
114-29	21319-21321	by	_
114-30	21322-21325	the	_
114-31	21326-21339	seven-network	_
114-32	21340-21345	model	_
114-33	21346-21354	proposed	_
114-34	21355-21357	by	_
114-35	21358-21361	Yeo	_
114-36	21362-21364	et	_
114-37	21365-21367	al	_
114-38	21367-21368	.	_
114-39	21368-21369	,	_
114-40	21370-21380	consistent	_
114-41	21381-21385	with	_
114-42	21386-21389	our	_
114-43	21390-21398	findings	_
114-44	21398-21399	.	_

#Text=Significant hypoactivation of the right insula was observed, but not the left thalamus and anterior cingulate cortex, as reported in the recent meta-analysis by Hart et al.
115-1	21400-21411	Significant	_
115-2	21412-21426	hypoactivation	_
115-3	21427-21429	of	_
115-4	21430-21433	the	_
115-5	21434-21439	right	_
115-6	21440-21446	insula	_
115-7	21447-21450	was	_
115-8	21451-21459	observed	_
115-9	21459-21460	,	_
115-10	21461-21464	but	_
115-11	21465-21468	not	_
115-12	21469-21472	the	_
115-13	21473-21477	left	_
115-14	21478-21486	thalamus	_
115-15	21487-21490	and	_
115-16	21491-21499	anterior	_
115-17	21500-21509	cingulate	_
115-18	21510-21516	cortex	_
115-19	21516-21517	,	_
115-20	21518-21520	as	_
115-21	21521-21529	reported	_
115-22	21530-21532	in	_
115-23	21533-21536	the	_
115-24	21537-21543	recent	_
115-25	21544-21557	meta-analysis	_
115-26	21558-21560	by	_
115-27	21561-21565	Hart	_
115-28	21566-21568	et	_
115-29	21569-21571	al	_
115-30	21571-21572	.	_

#Text=The co-occurrence of regular cannabis exposure with ADHD histories was not associated with increased commission errors or the degree of brain recruitment relative to ADHD subjects with minimal or no cannabis exposure.
116-1	21573-21576	The	_
116-2	21577-21590	co-occurrence	_
116-3	21591-21593	of	_
116-4	21594-21601	regular	_
116-5	21602-21610	cannabis	_
116-6	21611-21619	exposure	_
116-7	21620-21624	with	_
116-8	21625-21629	ADHD	_
116-9	21630-21639	histories	_
116-10	21640-21643	was	_
116-11	21644-21647	not	_
116-12	21648-21658	associated	_
116-13	21659-21663	with	_
116-14	21664-21673	increased	_
116-15	21674-21684	commission	_
116-16	21685-21691	errors	_
116-17	21692-21694	or	_
116-18	21695-21698	the	_
116-19	21699-21705	degree	_
116-20	21706-21708	of	_
116-21	21709-21714	brain	_
116-22	21715-21726	recruitment	_
116-23	21727-21735	relative	_
116-24	21736-21738	to	_
116-25	21739-21743	ADHD	_
116-26	21744-21752	subjects	_
116-27	21753-21757	with	_
116-28	21758-21765	minimal	_
116-29	21766-21768	or	_
116-30	21769-21771	no	_
116-31	21772-21780	cannabis	_
116-32	21781-21789	exposure	_
116-33	21789-21790	.	_

#Text=In sum, the neurodevelopmental effect of an ADHD history appears to exert a markedly more pronounced effect on behavioral and brain signatures of impulsivity than cannabis exposure.
117-1	21791-21793	In	_
117-2	21794-21797	sum	_
117-3	21797-21798	,	_
117-4	21799-21802	the	_
117-5	21803-21821	neurodevelopmental	_
117-6	21822-21828	effect	_
117-7	21829-21831	of	_
117-8	21832-21834	an	_
117-9	21835-21839	ADHD	_
117-10	21840-21847	history	_
117-11	21848-21855	appears	_
117-12	21856-21858	to	_
117-13	21859-21864	exert	_
117-14	21865-21866	a	_
117-15	21867-21875	markedly	_
117-16	21876-21880	more	_
117-17	21881-21891	pronounced	_
117-18	21892-21898	effect	_
117-19	21899-21901	on	_
117-20	21902-21912	behavioral	_
117-21	21913-21916	and	_
117-22	21917-21922	brain	_
117-23	21923-21933	signatures	_
117-24	21934-21936	of	_
117-25	21937-21948	impulsivity	_
117-26	21949-21953	than	_
117-27	21954-21962	cannabis	_
117-28	21963-21971	exposure	_
117-29	21971-21972	.	_

#Text=This pattern is supported by separate cross-sectional studies of ADHD and of cannabis exposure.
118-1	21973-21977	This	_
118-2	21978-21985	pattern	_
118-3	21986-21988	is	_
118-4	21989-21998	supported	_
118-5	21999-22001	by	_
118-6	22002-22010	separate	_
118-7	22011-22026	cross-sectional	_
118-8	22027-22034	studies	_
118-9	22035-22037	of	_
118-10	22038-22042	ADHD	_
118-11	22043-22046	and	_
118-12	22047-22049	of	_
118-13	22050-22058	cannabis	_
118-14	22059-22067	exposure	_
118-15	22067-22068	.	_

#Text=Greater commission errors during inhibition tasks in ADHD subjects have been generally replicated, often in tandem with neurophysiological performance reflecting reduced recruitment.
119-1	22069-22076	Greater	_
119-2	22077-22087	commission	_
119-3	22088-22094	errors	_
119-4	22095-22101	during	_
119-5	22102-22112	inhibition	_
119-6	22113-22118	tasks	_
119-7	22119-22121	in	_
119-8	22122-22126	ADHD	_
119-9	22127-22135	subjects	_
119-10	22136-22140	have	_
119-11	22141-22145	been	_
119-12	22146-22155	generally	_
119-13	22156-22166	replicated	_
119-14	22166-22167	,	_
119-15	22168-22173	often	_
119-16	22174-22176	in	_
119-17	22177-22183	tandem	_
119-18	22184-22188	with	_
119-19	22189-22207	neurophysiological	_
119-20	22208-22219	performance	_
119-21	22220-22230	reflecting	_
119-22	22231-22238	reduced	_
119-23	22239-22250	recruitment	_
119-24	22250-22251	.	_

#Text=However, analogous findings of cross-sectional differences between cannabis users and controls are mixed, with some studies finding impaired inhibition in non-dependent cannabis-using groups, but other studies showing no significant differences in commission errors even using difficult variants of the Go/NoGo paradigm or in populations meeting criteria for cannabis abuse or dependence.
120-1	22252-22259	However	_
120-2	22259-22260	,	_
120-3	22261-22270	analogous	_
120-4	22271-22279	findings	_
120-5	22280-22282	of	_
120-6	22283-22298	cross-sectional	_
120-7	22299-22310	differences	_
120-8	22311-22318	between	_
120-9	22319-22327	cannabis	_
120-10	22328-22333	users	_
120-11	22334-22337	and	_
120-12	22338-22346	controls	_
120-13	22347-22350	are	_
120-14	22351-22356	mixed	_
120-15	22356-22357	,	_
120-16	22358-22362	with	_
120-17	22363-22367	some	_
120-18	22368-22375	studies	_
120-19	22376-22383	finding	_
120-20	22384-22392	impaired	_
120-21	22393-22403	inhibition	_
120-22	22404-22406	in	_
120-23	22407-22420	non-dependent	_
120-24	22421-22435	cannabis-using	_
120-25	22436-22442	groups	_
120-26	22442-22443	,	_
120-27	22444-22447	but	_
120-28	22448-22453	other	_
120-29	22454-22461	studies	_
120-30	22462-22469	showing	_
120-31	22470-22472	no	_
120-32	22473-22484	significant	_
120-33	22485-22496	differences	_
120-34	22497-22499	in	_
120-35	22500-22510	commission	_
120-36	22511-22517	errors	_
120-37	22518-22522	even	_
120-38	22523-22528	using	_
120-39	22529-22538	difficult	_
120-40	22539-22547	variants	_
120-41	22548-22550	of	_
120-42	22551-22554	the	_
120-43	22555-22557	Go	_
120-44	22557-22558	/	_
120-45	22558-22562	NoGo	_
120-46	22563-22571	paradigm	_
120-47	22572-22574	or	_
120-48	22575-22577	in	_
120-49	22578-22589	populations	_
120-50	22590-22597	meeting	_
120-51	22598-22606	criteria	_
120-52	22607-22610	for	_
120-53	22611-22619	cannabis	_
120-54	22620-22625	abuse	_
120-55	22626-22628	or	_
120-56	22629-22639	dependence	_
120-57	22639-22640	.	_

#Text=The effects of current use and washout have not been adequately studied.
121-1	22641-22644	The	_
121-2	22645-22652	effects	_
121-3	22653-22655	of	_
121-4	22656-22663	current	_
121-5	22664-22667	use	_
121-6	22668-22671	and	_
121-7	22672-22679	washout	_
121-8	22680-22684	have	_
121-9	22685-22688	not	_
121-10	22689-22693	been	_
121-11	22694-22704	adequately	_
121-12	22705-22712	studied	_
121-13	22712-22713	.	_

#Text=Our subjects were at least 36 hours abstinent from cannabis use based on self-report; no biological confirmation was obtained.
122-1	22714-22717	Our	_
122-2	22718-22726	subjects	_
122-3	22727-22731	were	_
122-4	22732-22734	at	_
122-5	22735-22740	least	_
122-6	22741-22743	36	_
122-7	22744-22749	hours	_
122-8	22750-22759	abstinent	_
122-9	22760-22764	from	_
122-10	22765-22773	cannabis	_
122-11	22774-22777	use	_
122-12	22778-22783	based	_
122-13	22784-22786	on	_
122-14	22787-22798	self-report	_
122-15	22798-22799	;	_
122-16	22800-22802	no	_
122-17	22803-22813	biological	_
122-18	22814-22826	confirmation	_
122-19	22827-22830	was	_
122-20	22831-22839	obtained	_
122-21	22839-22840	.	_

#Text=We did not find a significant correlation between the frequency of use in the past month (Rmax=0.19, p >0.1) or age of onset of regular use (Rmax=−0.24, p >0.05) with regional activation within the cannabis using groups.
123-1	22841-22843	We	_
123-2	22844-22847	did	_
123-3	22848-22851	not	_
123-4	22852-22856	find	_
123-5	22857-22858	a	_
123-6	22859-22870	significant	_
123-7	22871-22882	correlation	_
123-8	22883-22890	between	_
123-9	22891-22894	the	_
123-10	22895-22904	frequency	_
123-11	22905-22907	of	_
123-12	22908-22911	use	_
123-13	22912-22914	in	_
123-14	22915-22918	the	_
123-15	22919-22923	past	_
123-16	22924-22929	month	_
123-17	22930-22931	(	_
123-18	22931-22935	Rmax	_
123-19	22935-22936	=	_
123-20	22936-22940	0.19	_
123-21	22940-22941	,	_
123-22	22942-22943	p	_
123-23	22944-22945	>	_
123-24	22945-22948	0.1	_
123-25	22948-22949	)	_
123-26	22950-22952	or	_
123-27	22953-22956	age	_
123-28	22957-22959	of	_
123-29	22960-22965	onset	_
123-30	22966-22968	of	_
123-31	22969-22976	regular	_
123-32	22977-22980	use	_
123-33	22981-22982	(	_
123-34	22982-22986	Rmax	_
123-35	22986-22987	=	_
123-36	22987-22988	−	_
123-37	22988-22992	0.24	_
123-38	22992-22993	,	_
123-39	22994-22995	p	_
123-40	22996-22997	>	_
123-41	22997-23001	0.05	_
123-42	23001-23002	)	_
123-43	23003-23007	with	_
123-44	23008-23016	regional	_
123-45	23017-23027	activation	_
123-46	23028-23034	within	_
123-47	23035-23038	the	_
123-48	23039-23047	cannabis	_
123-49	23048-23053	using	_
123-50	23054-23060	groups	_
123-51	23060-23061	.	_

#Text=It is possible that the appetitive Go/NoGo face task may have been more engaging than non-emotional versions of the tasks, resulting in greater attention and or motivation in the ADHD subjects, thereby attenuating group differences.
124-1	23062-23064	It	_
124-2	23065-23067	is	_
124-3	23068-23076	possible	_
124-4	23077-23081	that	_
124-5	23082-23085	the	_
124-6	23086-23096	appetitive	_
124-7	23097-23099	Go	_
124-8	23099-23100	/	_
124-9	23100-23104	NoGo	_
124-10	23105-23109	face	_
124-11	23110-23114	task	_
124-12	23115-23118	may	_
124-13	23119-23123	have	_
124-14	23124-23128	been	_
124-15	23129-23133	more	_
124-16	23134-23142	engaging	_
124-17	23143-23147	than	_
124-18	23148-23161	non-emotional	_
124-19	23162-23170	versions	_
124-20	23171-23173	of	_
124-21	23174-23177	the	_
124-22	23178-23183	tasks	_
124-23	23183-23184	,	_
124-24	23185-23194	resulting	_
124-25	23195-23197	in	_
124-26	23198-23205	greater	_
124-27	23206-23215	attention	_
124-28	23216-23219	and	_
124-29	23220-23222	or	_
124-30	23223-23233	motivation	_
124-31	23234-23236	in	_
124-32	23237-23240	the	_
124-33	23241-23245	ADHD	_
124-34	23246-23254	subjects	_
124-35	23254-23255	,	_
124-36	23256-23263	thereby	_
124-37	23264-23275	attenuating	_
124-38	23276-23281	group	_
124-39	23282-23293	differences	_
124-40	23293-23294	.	_

#Text=The mediation of the blood-oxygen-level dependent (BOLD) response by cannabis use within this study was limited to ADHD diagnosis by cannabis use interactions in the hippocampus and cerebellar vermis.
125-1	23295-23298	The	_
125-2	23299-23308	mediation	_
125-3	23309-23311	of	_
125-4	23312-23315	the	_
125-5	23316-23334	blood-oxygen-level	_
125-6	23335-23344	dependent	_
125-7	23345-23346	(	_
125-8	23346-23350	BOLD	_
125-9	23350-23351	)	_
125-10	23352-23360	response	_
125-11	23361-23363	by	_
125-12	23364-23372	cannabis	_
125-13	23373-23376	use	_
125-14	23377-23383	within	_
125-15	23384-23388	this	_
125-16	23389-23394	study	_
125-17	23395-23398	was	_
125-18	23399-23406	limited	_
125-19	23407-23409	to	_
125-20	23410-23414	ADHD	_
125-21	23415-23424	diagnosis	_
125-22	23425-23427	by	_
125-23	23428-23436	cannabis	_
125-24	23437-23440	use	_
125-25	23441-23453	interactions	_
125-26	23454-23456	in	_
125-27	23457-23460	the	_
125-28	23461-23472	hippocampus	_
125-29	23473-23476	and	_
125-30	23477-23487	cerebellar	_
125-31	23488-23494	vermis	_
125-32	23494-23495	.	_

#Text=The lack of a main effect of substance use is supported behaviorally within this sample and other studies.
126-1	23496-23499	The	_
126-2	23500-23504	lack	_
126-3	23505-23507	of	_
126-4	23508-23509	a	_
126-5	23510-23514	main	_
126-6	23515-23521	effect	_
126-7	23522-23524	of	_
126-8	23525-23534	substance	_
126-9	23535-23538	use	_
126-10	23539-23541	is	_
126-11	23542-23551	supported	_
126-12	23552-23564	behaviorally	_
126-13	23565-23571	within	_
126-14	23572-23576	this	_
126-15	23577-23583	sample	_
126-16	23584-23587	and	_
126-17	23588-23593	other	_
126-18	23594-23601	studies	_
126-19	23601-23602	.	_

#Text=In one study, cannabis exposure has been associated with BOLD activation during inhibition.
127-1	23603-23605	In	_
127-2	23606-23609	one	_
127-3	23610-23615	study	_
127-4	23615-23616	,	_
127-5	23617-23625	cannabis	_
127-6	23626-23634	exposure	_
127-7	23635-23638	has	_
127-8	23639-23643	been	_
127-9	23644-23654	associated	_
127-10	23655-23659	with	_
127-11	23660-23664	BOLD	_
127-12	23665-23675	activation	_
127-13	23676-23682	during	_
127-14	23683-23693	inhibition	_
127-15	23693-23694	.	_

#Text=One recent review suggests that the discordance between behavior and brain activity supports the theory of increased activation in cannabis users as compensation for altered circuitry.
128-1	23695-23698	One	_
128-2	23699-23705	recent	_
128-3	23706-23712	review	_
128-4	23713-23721	suggests	_
128-5	23722-23726	that	_
128-6	23727-23730	the	_
128-7	23731-23742	discordance	_
128-8	23743-23750	between	_
128-9	23751-23759	behavior	_
128-10	23760-23763	and	_
128-11	23764-23769	brain	_
128-12	23770-23778	activity	_
128-13	23779-23787	supports	_
128-14	23788-23791	the	_
128-15	23792-23798	theory	_
128-16	23799-23801	of	_
128-17	23802-23811	increased	_
128-18	23812-23822	activation	_
128-19	23823-23825	in	_
128-20	23826-23834	cannabis	_
128-21	23835-23840	users	_
128-22	23841-23843	as	_
128-23	23844-23856	compensation	_
128-24	23857-23860	for	_
128-25	23861-23868	altered	_
128-26	23869-23878	circuitry	_
128-27	23878-23879	.	_

#Text=Although increased activation during response inhibition in cannabis users was not shown in our ADHD participants, it was observed in the LNCG group.
129-1	23880-23888	Although	_
129-2	23889-23898	increased	_
129-3	23899-23909	activation	_
129-4	23910-23916	during	_
129-5	23917-23925	response	_
129-6	23926-23936	inhibition	_
129-7	23937-23939	in	_
129-8	23940-23948	cannabis	_
129-9	23949-23954	users	_
129-10	23955-23958	was	_
129-11	23959-23962	not	_
129-12	23963-23968	shown	_
129-13	23969-23971	in	_
129-14	23972-23975	our	_
129-15	23976-23980	ADHD	_
129-16	23981-23993	participants	_
129-17	23993-23994	,	_
129-18	23995-23997	it	_
129-19	23998-24001	was	_
129-20	24002-24010	observed	_
129-21	24011-24013	in	_
129-22	24014-24017	the	_
129-23	24018-24022	LNCG	_
129-24	24023-24028	group	_
129-25	24028-24029	.	_

#Text=The maturation of the frontal-striatal-thalamic and frontal-cerebellar networks that mediate response inhibition are a hallmark of the transition from childhood to young adulthood.
130-1	24030-24033	The	_
130-2	24034-24044	maturation	_
130-3	24045-24047	of	_
130-4	24048-24051	the	_
130-5	24052-24077	frontal-striatal-thalamic	_
130-6	24078-24081	and	_
130-7	24082-24100	frontal-cerebellar	_
130-8	24101-24109	networks	_
130-9	24110-24114	that	_
130-10	24115-24122	mediate	_
130-11	24123-24131	response	_
130-12	24132-24142	inhibition	_
130-13	24143-24146	are	_
130-14	24147-24148	a	_
130-15	24149-24157	hallmark	_
130-16	24158-24160	of	_
130-17	24161-24164	the	_
130-18	24165-24175	transition	_
130-19	24176-24180	from	_
130-20	24181-24190	childhood	_
130-21	24191-24193	to	_
130-22	24194-24199	young	_
130-23	24200-24209	adulthood	_
130-24	24209-24210	.	_

#Text=Our findings in young adults may therefore reflect a delayed maturation trajectory in ADHD participants, consistent with work by Shaw et al..
131-1	24211-24214	Our	_
131-2	24215-24223	findings	_
131-3	24224-24226	in	_
131-4	24227-24232	young	_
131-5	24233-24239	adults	_
131-6	24240-24243	may	_
131-7	24244-24253	therefore	_
131-8	24254-24261	reflect	_
131-9	24262-24263	a	_
131-10	24264-24271	delayed	_
131-11	24272-24282	maturation	_
131-12	24283-24293	trajectory	_
131-13	24294-24296	in	_
131-14	24297-24301	ADHD	_
131-15	24302-24314	participants	_
131-16	24314-24315	,	_
131-17	24316-24326	consistent	_
131-18	24327-24331	with	_
131-19	24332-24336	work	_
131-20	24337-24339	by	_
131-21	24340-24344	Shaw	_
131-22	24345-24347	et	_
131-23	24348-24350	al	_
131-24	24350-24351	.	_
131-25	24351-24352	.	_

#Text=Furthermore, the lack of a main effect of cannabis use across diagnoses may be reflective of the opposing effects of cannabis use in the ADHD and LNCG participants.
132-1	24353-24364	Furthermore	_
132-2	24364-24365	,	_
132-3	24366-24369	the	_
132-4	24370-24374	lack	_
132-5	24375-24377	of	_
132-6	24378-24379	a	_
132-7	24380-24384	main	_
132-8	24385-24391	effect	_
132-9	24392-24394	of	_
132-10	24395-24403	cannabis	_
132-11	24404-24407	use	_
132-12	24408-24414	across	_
132-13	24415-24424	diagnoses	_
132-14	24425-24428	may	_
132-15	24429-24431	be	_
132-16	24432-24442	reflective	_
132-17	24443-24445	of	_
132-18	24446-24449	the	_
132-19	24450-24458	opposing	_
132-20	24459-24466	effects	_
132-21	24467-24469	of	_
132-22	24470-24478	cannabis	_
132-23	24479-24482	use	_
132-24	24483-24485	in	_
132-25	24486-24489	the	_
132-26	24490-24494	ADHD	_
132-27	24495-24498	and	_
132-28	24499-24503	LNCG	_
132-29	24504-24516	participants	_
132-30	24516-24517	.	_

#Text=The notion that the hippocampus and cerebellum are especially plastic with respect to cannabis use may not be altogether surprising considering these two regions comprise part of the endocannabinoid system.
133-1	24518-24521	The	_
133-2	24522-24528	notion	_
133-3	24529-24533	that	_
133-4	24534-24537	the	_
133-5	24538-24549	hippocampus	_
133-6	24550-24553	and	_
133-7	24554-24564	cerebellum	_
133-8	24565-24568	are	_
133-9	24569-24579	especially	_
133-10	24580-24587	plastic	_
133-11	24588-24592	with	_
133-12	24593-24600	respect	_
133-13	24601-24603	to	_
133-14	24604-24612	cannabis	_
133-15	24613-24616	use	_
133-16	24617-24620	may	_
133-17	24621-24624	not	_
133-18	24625-24627	be	_
133-19	24628-24638	altogether	_
133-20	24639-24649	surprising	_
133-21	24650-24661	considering	_
133-22	24662-24667	these	_
133-23	24668-24671	two	_
133-24	24672-24679	regions	_
133-25	24680-24688	comprise	_
133-26	24689-24693	part	_
133-27	24694-24696	of	_
133-28	24697-24700	the	_
133-29	24701-24716	endocannabinoid	_
133-30	24717-24723	system	_
133-31	24723-24724	.	_

#Text=The cerebellum is an important structure of the response inhibition circuit.
134-1	24725-24728	The	_
134-2	24729-24739	cerebellum	_
134-3	24740-24742	is	_
134-4	24743-24745	an	_
134-5	24746-24755	important	_
134-6	24756-24765	structure	_
134-7	24766-24768	of	_
134-8	24769-24772	the	_
134-9	24773-24781	response	_
134-10	24782-24792	inhibition	_
134-11	24793-24800	circuit	_
134-12	24800-24801	.	_

#Text=The basal ganglia and cerebellum have the highest concentration of cannabinoid receptors and cannabinoids are known to produce hippocampal neurogenesis.
135-1	24802-24805	The	_
135-2	24806-24811	basal	_
135-3	24812-24819	ganglia	_
135-4	24820-24823	and	_
135-5	24824-24834	cerebellum	_
135-6	24835-24839	have	_
135-7	24840-24843	the	_
135-8	24844-24851	highest	_
135-9	24852-24865	concentration	_
135-10	24866-24868	of	_
135-11	24869-24880	cannabinoid	_
135-12	24881-24890	receptors	_
135-13	24891-24894	and	_
135-14	24895-24907	cannabinoids	_
135-15	24908-24911	are	_
135-16	24912-24917	known	_
135-17	24918-24920	to	_
135-18	24921-24928	produce	_
135-19	24929-24940	hippocampal	_
135-20	24941-24953	neurogenesis	_
135-21	24953-24954	.	_

#Text=Furthermore, cannabinoids can activate CB1 receptors in the hippocampus, effecting dopamine release and higher activation in the service of normative performance in vigilance tasks is typical of cannabis studies in youth.
136-1	24955-24966	Furthermore	_
136-2	24966-24967	,	_
136-3	24968-24980	cannabinoids	_
136-4	24981-24984	can	_
136-5	24985-24993	activate	_
136-6	24994-24997	CB1	_
136-7	24998-25007	receptors	_
136-8	25008-25010	in	_
136-9	25011-25014	the	_
136-10	25015-25026	hippocampus	_
136-11	25026-25027	,	_
136-12	25028-25037	effecting	_
136-13	25038-25046	dopamine	_
136-14	25047-25054	release	_
136-15	25055-25058	and	_
136-16	25059-25065	higher	_
136-17	25066-25076	activation	_
136-18	25077-25079	in	_
136-19	25080-25083	the	_
136-20	25084-25091	service	_
136-21	25092-25094	of	_
136-22	25095-25104	normative	_
136-23	25105-25116	performance	_
136-24	25117-25119	in	_
136-25	25120-25129	vigilance	_
136-26	25130-25135	tasks	_
136-27	25136-25138	is	_
136-28	25139-25146	typical	_
136-29	25147-25149	of	_
136-30	25150-25158	cannabis	_
136-31	25159-25166	studies	_
136-32	25167-25169	in	_
136-33	25170-25175	youth	_
136-34	25175-25176	.	_

#Text=It should be noted, however, that the response inhibition task used in this study might have assessed additional cognitive constructs.
137-1	25177-25179	It	_
137-2	25180-25186	should	_
137-3	25187-25189	be	_
137-4	25190-25195	noted	_
137-5	25195-25196	,	_
137-6	25197-25204	however	_
137-7	25204-25205	,	_
137-8	25206-25210	that	_
137-9	25211-25214	the	_
137-10	25215-25223	response	_
137-11	25224-25234	inhibition	_
137-12	25235-25239	task	_
137-13	25240-25244	used	_
137-14	25245-25247	in	_
137-15	25248-25252	this	_
137-16	25253-25258	study	_
137-17	25259-25264	might	_
137-18	25265-25269	have	_
137-19	25270-25278	assessed	_
137-20	25279-25289	additional	_
137-21	25290-25299	cognitive	_
137-22	25300-25310	constructs	_
137-23	25310-25311	.	_

#Text=For example, the task involved a low-frequency presentation which is susceptible to the oddball effect, and a switching target between runs which potentially recruited working memory networks.
138-1	25312-25315	For	_
138-2	25316-25323	example	_
138-3	25323-25324	,	_
138-4	25325-25328	the	_
138-5	25329-25333	task	_
138-6	25334-25342	involved	_
138-7	25343-25344	a	_
138-8	25345-25358	low-frequency	_
138-9	25359-25371	presentation	_
138-10	25372-25377	which	_
138-11	25378-25380	is	_
138-12	25381-25392	susceptible	_
138-13	25393-25395	to	_
138-14	25396-25399	the	_
138-15	25400-25407	oddball	_
138-16	25408-25414	effect	_
138-17	25414-25415	,	_
138-18	25416-25419	and	_
138-19	25420-25421	a	_
138-20	25422-25431	switching	_
138-21	25432-25438	target	_
138-22	25439-25446	between	_
138-23	25447-25451	runs	_
138-24	25452-25457	which	_
138-25	25458-25469	potentially	_
138-26	25470-25479	recruited	_
138-27	25480-25487	working	_
138-28	25488-25494	memory	_
138-29	25495-25503	networks	_
138-30	25503-25504	.	_

#Text=Further, the task was relatively easy for most participants and involved repetitive stimuli, which may have resulted in the task assessing attention more generally as opposed to response inhibition.
139-1	25505-25512	Further	_
139-2	25512-25513	,	_
139-3	25514-25517	the	_
139-4	25518-25522	task	_
139-5	25523-25526	was	_
139-6	25527-25537	relatively	_
139-7	25538-25542	easy	_
139-8	25543-25546	for	_
139-9	25547-25551	most	_
139-10	25552-25564	participants	_
139-11	25565-25568	and	_
139-12	25569-25577	involved	_
139-13	25578-25588	repetitive	_
139-14	25589-25596	stimuli	_
139-15	25596-25597	,	_
139-16	25598-25603	which	_
139-17	25604-25607	may	_
139-18	25608-25612	have	_
139-19	25613-25621	resulted	_
139-20	25622-25624	in	_
139-21	25625-25628	the	_
139-22	25629-25633	task	_
139-23	25634-25643	assessing	_
139-24	25644-25653	attention	_
139-25	25654-25658	more	_
139-26	25659-25668	generally	_
139-27	25669-25671	as	_
139-28	25672-25679	opposed	_
139-29	25680-25682	to	_
139-30	25683-25691	response	_
139-31	25692-25702	inhibition	_
139-32	25702-25703	.	_

#Text=The alignment of our results with meta-analysis results of attention tasks support this theory.
140-1	25704-25707	The	_
140-2	25708-25717	alignment	_
140-3	25718-25720	of	_
140-4	25721-25724	our	_
140-5	25725-25732	results	_
140-6	25733-25737	with	_
140-7	25738-25751	meta-analysis	_
140-8	25752-25759	results	_
140-9	25760-25762	of	_
140-10	25763-25772	attention	_
140-11	25773-25778	tasks	_
140-12	25779-25786	support	_
140-13	25787-25791	this	_
140-14	25792-25798	theory	_
140-15	25798-25799	.	_

#Text=While one could argue that the lack of anterior cingulate cortex differences in ADHD contradicts this, anterior cingulate activation appears to diminish with increasing age.
141-1	25800-25805	While	_
141-2	25806-25809	one	_
141-3	25810-25815	could	_
141-4	25816-25821	argue	_
141-5	25822-25826	that	_
141-6	25827-25830	the	_
141-7	25831-25835	lack	_
141-8	25836-25838	of	_
141-9	25839-25847	anterior	_
141-10	25848-25857	cingulate	_
141-11	25858-25864	cortex	_
141-12	25865-25876	differences	_
141-13	25877-25879	in	_
141-14	25880-25884	ADHD	_
141-15	25885-25896	contradicts	_
141-16	25897-25901	this	_
141-17	25901-25902	,	_
141-18	25903-25911	anterior	_
141-19	25912-25921	cingulate	_
141-20	25922-25932	activation	_
141-21	25933-25940	appears	_
141-22	25941-25943	to	_
141-23	25944-25952	diminish	_
141-24	25953-25957	with	_
141-25	25958-25968	increasing	_
141-26	25969-25972	age	_
141-27	25972-25973	.	_

#Text=Despite the robust effects of diagnosis presented in this work, there are limitations to be considered.
142-1	25974-25981	Despite	_
142-2	25982-25985	the	_
142-3	25986-25992	robust	_
142-4	25993-26000	effects	_
142-5	26001-26003	of	_
142-6	26004-26013	diagnosis	_
142-7	26014-26023	presented	_
142-8	26024-26026	in	_
142-9	26027-26031	this	_
142-10	26032-26036	work	_
142-11	26036-26037	,	_
142-12	26038-26043	there	_
142-13	26044-26047	are	_
142-14	26048-26059	limitations	_
142-15	26060-26062	to	_
142-16	26063-26065	be	_
142-17	26066-26076	considered	_
142-18	26076-26077	.	_

#Text=LNCG sample sizes were small when considering subgroups broken down by site and cannabis use status.
143-1	26078-26082	LNCG	_
143-2	26083-26089	sample	_
143-3	26090-26095	sizes	_
143-4	26096-26100	were	_
143-5	26101-26106	small	_
143-6	26107-26111	when	_
143-7	26112-26123	considering	_
143-8	26124-26133	subgroups	_
143-9	26134-26140	broken	_
143-10	26141-26145	down	_
143-11	26146-26148	by	_
143-12	26149-26153	site	_
143-13	26154-26157	and	_
143-14	26158-26166	cannabis	_
143-15	26167-26170	use	_
143-16	26171-26177	status	_
143-17	26177-26178	.	_

#Text=This is especially relevant for the lack of significant difference between smoking status in ADHD and LNCG participants, and correlations with activation and age of first use.
144-1	26179-26183	This	_
144-2	26184-26186	is	_
144-3	26187-26197	especially	_
144-4	26198-26206	relevant	_
144-5	26207-26210	for	_
144-6	26211-26214	the	_
144-7	26215-26219	lack	_
144-8	26220-26222	of	_
144-9	26223-26234	significant	_
144-10	26235-26245	difference	_
144-11	26246-26253	between	_
144-12	26254-26261	smoking	_
144-13	26262-26268	status	_
144-14	26269-26271	in	_
144-15	26272-26276	ADHD	_
144-16	26277-26280	and	_
144-17	26281-26285	LNCG	_
144-18	26286-26298	participants	_
144-19	26298-26299	,	_
144-20	26300-26303	and	_
144-21	26304-26316	correlations	_
144-22	26317-26321	with	_
144-23	26322-26332	activation	_
144-24	26333-26336	and	_
144-25	26337-26340	age	_
144-26	26341-26343	of	_
144-27	26344-26349	first	_
144-28	26350-26353	use	_
144-29	26353-26354	.	_

#Text=Further, the ADHD and LNCG groups differed in the number of correct NoGo trials, thereby potentially influencing statistical inference.
145-1	26355-26362	Further	_
145-2	26362-26363	,	_
145-3	26364-26367	the	_
145-4	26368-26372	ADHD	_
145-5	26373-26376	and	_
145-6	26377-26381	LNCG	_
145-7	26382-26388	groups	_
145-8	26389-26397	differed	_
145-9	26398-26400	in	_
145-10	26401-26404	the	_
145-11	26405-26411	number	_
145-12	26412-26414	of	_
145-13	26415-26422	correct	_
145-14	26423-26427	NoGo	_
145-15	26428-26434	trials	_
145-16	26434-26435	,	_
145-17	26436-26443	thereby	_
145-18	26444-26455	potentially	_
145-19	26456-26467	influencing	_
145-20	26468-26479	statistical	_
145-21	26480-26489	inference	_
145-22	26489-26490	.	_

#Text=In addition, our sample, especially the cannabis users, was disproportionately male.
146-1	26491-26493	In	_
146-2	26494-26502	addition	_
146-3	26502-26503	,	_
146-4	26504-26507	our	_
146-5	26508-26514	sample	_
146-6	26514-26515	,	_
146-7	26516-26526	especially	_
146-8	26527-26530	the	_
146-9	26531-26539	cannabis	_
146-10	26540-26545	users	_
146-11	26545-26546	,	_
146-12	26547-26550	was	_
146-13	26551-26569	disproportionately	_
146-14	26570-26574	male	_
146-15	26574-26575	.	_

#Text=A recent study found gender differences in right parietal and left fronto-parietal regions during motor inhibition.
147-1	26576-26577	A	_
147-2	26578-26584	recent	_
147-3	26585-26590	study	_
147-4	26591-26596	found	_
147-5	26597-26603	gender	_
147-6	26604-26615	differences	_
147-7	26616-26618	in	_
147-8	26619-26624	right	_
147-9	26625-26633	parietal	_
147-10	26634-26637	and	_
147-11	26638-26642	left	_
147-12	26643-26658	fronto-parietal	_
147-13	26659-26666	regions	_
147-14	26667-26673	during	_
147-15	26674-26679	motor	_
147-16	26680-26690	inhibition	_
147-17	26690-26691	.	_

#Text=Although our secondary analyses using gender as a covariate did not show it to significantly impact the findings, our results may not generalize to female cannabis-users.
148-1	26692-26700	Although	_
148-2	26701-26704	our	_
148-3	26705-26714	secondary	_
148-4	26715-26723	analyses	_
148-5	26724-26729	using	_
148-6	26730-26736	gender	_
148-7	26737-26739	as	_
148-8	26740-26741	a	_
148-9	26742-26751	covariate	_
148-10	26752-26755	did	_
148-11	26756-26759	not	_
148-12	26760-26764	show	_
148-13	26765-26767	it	_
148-14	26768-26770	to	_
148-15	26771-26784	significantly	_
148-16	26785-26791	impact	_
148-17	26792-26795	the	_
148-18	26796-26804	findings	_
148-19	26804-26805	,	_
148-20	26806-26809	our	_
148-21	26810-26817	results	_
148-22	26818-26821	may	_
148-23	26822-26825	not	_
148-24	26826-26836	generalize	_
148-25	26837-26839	to	_
148-26	26840-26846	female	_
148-27	26847-26861	cannabis-users	_
148-28	26861-26862	.	_

#Text=We also excluded adults who reported binge-drinking alcohol more than once a week.
149-1	26863-26865	We	_
149-2	26866-26870	also	_
149-3	26871-26879	excluded	_
149-4	26880-26886	adults	_
149-5	26887-26890	who	_
149-6	26891-26899	reported	_
149-7	26900-26914	binge-drinking	_
149-8	26915-26922	alcohol	_
149-9	26923-26927	more	_
149-10	26928-26932	than	_
149-11	26933-26937	once	_
149-12	26938-26939	a	_
149-13	26940-26944	week	_
149-14	26944-26945	.	_

#Text=Heavy drinking, often co-occurring with frequent cannabis use, may have contributed to results in prior studies.
150-1	26946-26951	Heavy	_
150-2	26952-26960	drinking	_
150-3	26960-26961	,	_
150-4	26962-26967	often	_
150-5	26968-26980	co-occurring	_
150-6	26981-26985	with	_
150-7	26986-26994	frequent	_
150-8	26995-27003	cannabis	_
150-9	27004-27007	use	_
150-10	27007-27008	,	_
150-11	27009-27012	may	_
150-12	27013-27017	have	_
150-13	27018-27029	contributed	_
150-14	27030-27032	to	_
150-15	27033-27040	results	_
150-16	27041-27043	in	_
150-17	27044-27049	prior	_
150-18	27050-27057	studies	_
150-19	27057-27058	.	_

#Text=We did not assess brain-based activity prior to cannabis use; longitudinal studies with both behavioral and imaging measures are needed to disentangle a temporal ordering of constructs.
151-1	27059-27061	We	_
151-2	27062-27065	did	_
151-3	27066-27069	not	_
151-4	27070-27076	assess	_
151-5	27077-27088	brain-based	_
151-6	27089-27097	activity	_
151-7	27098-27103	prior	_
151-8	27104-27106	to	_
151-9	27107-27115	cannabis	_
151-10	27116-27119	use	_
151-11	27119-27120	;	_
151-12	27121-27133	longitudinal	_
151-13	27134-27141	studies	_
151-14	27142-27146	with	_
151-15	27147-27151	both	_
151-16	27152-27162	behavioral	_
151-17	27163-27166	and	_
151-18	27167-27174	imaging	_
151-19	27175-27183	measures	_
151-20	27184-27187	are	_
151-21	27188-27194	needed	_
151-22	27195-27197	to	_
151-23	27198-27209	disentangle	_
151-24	27210-27211	a	_
151-25	27212-27220	temporal	_
151-26	27221-27229	ordering	_
151-27	27230-27232	of	_
151-28	27233-27243	constructs	_
151-29	27243-27244	.	_

#Text=Regardless, to our knowledge, this study is the largest to date investigating the association between ADHD and cannabis use, and, as a multisite study encompassing a heterogeneous sample, increases the generalizability of results.
152-1	27245-27255	Regardless	_
152-2	27255-27256	,	_
152-3	27257-27259	to	_
152-4	27260-27263	our	_
152-5	27264-27273	knowledge	_
152-6	27273-27274	,	_
152-7	27275-27279	this	_
152-8	27280-27285	study	_
152-9	27286-27288	is	_
152-10	27289-27292	the	_
152-11	27293-27300	largest	_
152-12	27301-27303	to	_
152-13	27304-27308	date	_
152-14	27309-27322	investigating	_
152-15	27323-27326	the	_
152-16	27327-27338	association	_
152-17	27339-27346	between	_
152-18	27347-27351	ADHD	_
152-19	27352-27355	and	_
152-20	27356-27364	cannabis	_
152-21	27365-27368	use	_
152-22	27368-27369	,	_
152-23	27370-27373	and	_
152-24	27373-27374	,	_
152-25	27375-27377	as	_
152-26	27378-27379	a	_
152-27	27380-27389	multisite	_
152-28	27390-27395	study	_
152-29	27396-27408	encompassing	_
152-30	27409-27410	a	_
152-31	27411-27424	heterogeneous	_
152-32	27425-27431	sample	_
152-33	27431-27432	,	_
152-34	27433-27442	increases	_
152-35	27443-27446	the	_
152-36	27447-27463	generalizability	_
152-37	27464-27466	of	_
152-38	27467-27474	results	_
152-39	27474-27475	.	_

#Text=We caution that the absence of behavioral decrements in regular light cannabis users does not necessarily indicate that chronic cannabis exerts minimal effects on the non-intoxicated brain.
153-1	27476-27478	We	_
153-2	27479-27486	caution	_
153-3	27487-27491	that	_
153-4	27492-27495	the	_
153-5	27496-27503	absence	_
153-6	27504-27506	of	_
153-7	27507-27517	behavioral	_
153-8	27518-27528	decrements	_
153-9	27529-27531	in	_
153-10	27532-27539	regular	_
153-11	27540-27545	light	_
153-12	27546-27554	cannabis	_
153-13	27555-27560	users	_
153-14	27561-27565	does	_
153-15	27566-27569	not	_
153-16	27570-27581	necessarily	_
153-17	27582-27590	indicate	_
153-18	27591-27595	that	_
153-19	27596-27603	chronic	_
153-20	27604-27612	cannabis	_
153-21	27613-27619	exerts	_
153-22	27620-27627	minimal	_
153-23	27628-27635	effects	_
153-24	27636-27638	on	_
153-25	27639-27642	the	_
153-26	27643-27658	non-intoxicated	_
153-27	27659-27664	brain	_
153-28	27664-27665	.	_

#Text=We detected a cannabis-by-ADHD interaction in hippocampus and cerebellar vermis, where activation during inhibition was higher in cannabis users compared to non-users, but only within the non-ADHD subject groups.
154-1	27666-27668	We	_
154-2	27669-27677	detected	_
154-3	27678-27679	a	_
154-4	27680-27696	cannabis-by-ADHD	_
154-5	27697-27708	interaction	_
154-6	27709-27711	in	_
154-7	27712-27723	hippocampus	_
154-8	27724-27727	and	_
154-9	27728-27738	cerebellar	_
154-10	27739-27745	vermis	_
154-11	27745-27746	,	_
154-12	27747-27752	where	_
154-13	27753-27763	activation	_
154-14	27764-27770	during	_
154-15	27771-27781	inhibition	_
154-16	27782-27785	was	_
154-17	27786-27792	higher	_
154-18	27793-27795	in	_
154-19	27796-27804	cannabis	_
154-20	27805-27810	users	_
154-21	27811-27819	compared	_
154-22	27820-27822	to	_
154-23	27823-27832	non-users	_
154-24	27832-27833	,	_
154-25	27834-27837	but	_
154-26	27838-27842	only	_
154-27	27843-27849	within	_
154-28	27850-27853	the	_
154-29	27854-27862	non-ADHD	_
154-30	27863-27870	subject	_
154-31	27871-27877	groups	_
154-32	27877-27878	.	_

#Text=Altered gray matter volume in right parahippocampal gyrus, right hippocampus, and cerebellar vermis has been found in cannabis-using subjects.
155-1	27879-27886	Altered	_
155-2	27887-27891	gray	_
155-3	27892-27898	matter	_
155-4	27899-27905	volume	_
155-5	27906-27908	in	_
155-6	27909-27914	right	_
155-7	27915-27930	parahippocampal	_
155-8	27931-27936	gyrus	_
155-9	27936-27937	,	_
155-10	27938-27943	right	_
155-11	27944-27955	hippocampus	_
155-12	27955-27956	,	_
155-13	27957-27960	and	_
155-14	27961-27971	cerebellar	_
155-15	27972-27978	vermis	_
155-16	27979-27982	has	_
155-17	27983-27987	been	_
155-18	27988-27993	found	_
155-19	27994-27996	in	_
155-20	27997-28011	cannabis-using	_
155-21	28012-28020	subjects	_
155-22	28020-28021	.	_

#Text=Moreover, greater right parahippocampal recruitment during a face-naming task was also found in cannabis users.
156-1	28022-28030	Moreover	_
156-2	28030-28031	,	_
156-3	28032-28039	greater	_
156-4	28040-28045	right	_
156-5	28046-28061	parahippocampal	_
156-6	28062-28073	recruitment	_
156-7	28074-28080	during	_
156-8	28081-28082	a	_
156-9	28083-28094	face-naming	_
156-10	28095-28099	task	_
156-11	28100-28103	was	_
156-12	28104-28108	also	_
156-13	28109-28114	found	_
156-14	28115-28117	in	_
156-15	28118-28126	cannabis	_
156-16	28127-28132	users	_
156-17	28132-28133	.	_

#Text=Therefore, it is possible that altered patterns of activation to Go/NoGo faces in these structures among non-ADHD cannabis users stem from these morphological abnormalities, where the ADHD neurodevelopmental phenotype avoids this regional brain effect by engaging different neurocircuitry to inhibit non-target behavior.
157-1	28134-28143	Therefore	_
157-2	28143-28144	,	_
157-3	28145-28147	it	_
157-4	28148-28150	is	_
157-5	28151-28159	possible	_
157-6	28160-28164	that	_
157-7	28165-28172	altered	_
157-8	28173-28181	patterns	_
157-9	28182-28184	of	_
157-10	28185-28195	activation	_
157-11	28196-28198	to	_
157-12	28199-28201	Go	_
157-13	28201-28202	/	_
157-14	28202-28206	NoGo	_
157-15	28207-28212	faces	_
157-16	28213-28215	in	_
157-17	28216-28221	these	_
157-18	28222-28232	structures	_
157-19	28233-28238	among	_
157-20	28239-28247	non-ADHD	_
157-21	28248-28256	cannabis	_
157-22	28257-28262	users	_
157-23	28263-28267	stem	_
157-24	28268-28272	from	_
157-25	28273-28278	these	_
157-26	28279-28292	morphological	_
157-27	28293-28306	abnormalities	_
157-28	28306-28307	,	_
157-29	28308-28313	where	_
157-30	28314-28317	the	_
157-31	28318-28322	ADHD	_
157-32	28323-28341	neurodevelopmental	_
157-33	28342-28351	phenotype	_
157-34	28352-28358	avoids	_
157-35	28359-28363	this	_
157-36	28364-28372	regional	_
157-37	28373-28378	brain	_
157-38	28379-28385	effect	_
157-39	28386-28388	by	_
157-40	28389-28397	engaging	_
157-41	28398-28407	different	_
157-42	28408-28422	neurocircuitry	_
157-43	28423-28425	to	_
157-44	28426-28433	inhibit	_
157-45	28434-28444	non-target	_
157-46	28445-28453	behavior	_
157-47	28453-28454	.	_

#Text=Indeed, a recent comprehensive review of 43 studies examining structural and functional brain differences between chronic cannabis users and controls indicates numerous altered patterns (usually increases) of brain activation in the service of normal behavioral performance in cannabis users.
158-1	28455-28461	Indeed	_
158-2	28461-28462	,	_
158-3	28463-28464	a	_
158-4	28465-28471	recent	_
158-5	28472-28485	comprehensive	_
158-6	28486-28492	review	_
158-7	28493-28495	of	_
158-8	28496-28498	43	_
158-9	28499-28506	studies	_
158-10	28507-28516	examining	_
158-11	28517-28527	structural	_
158-12	28528-28531	and	_
158-13	28532-28542	functional	_
158-14	28543-28548	brain	_
158-15	28549-28560	differences	_
158-16	28561-28568	between	_
158-17	28569-28576	chronic	_
158-18	28577-28585	cannabis	_
158-19	28586-28591	users	_
158-20	28592-28595	and	_
158-21	28596-28604	controls	_
158-22	28605-28614	indicates	_
158-23	28615-28623	numerous	_
158-24	28624-28631	altered	_
158-25	28632-28640	patterns	_
158-26	28641-28642	(	_
158-27	28642-28649	usually	_
158-28	28650-28659	increases	_
158-29	28659-28660	)	_
158-30	28661-28663	of	_
158-31	28664-28669	brain	_
158-32	28670-28680	activation	_
158-33	28681-28683	in	_
158-34	28684-28687	the	_
158-35	28688-28695	service	_
158-36	28696-28698	of	_
158-37	28699-28705	normal	_
158-38	28706-28716	behavioral	_
158-39	28717-28728	performance	_
158-40	28729-28731	in	_
158-41	28732-28740	cannabis	_
158-42	28741-28746	users	_
158-43	28746-28747	.	_

#Text=Such activation increases in cortical executive control regions are typically interpreted as evidence of less efficient cortical processing and where, in contrast, reduced activation in response to impulsive errors can be interpreted as blunted awareness of errors in drug users.
159-1	28748-28752	Such	_
159-2	28753-28763	activation	_
159-3	28764-28773	increases	_
159-4	28774-28776	in	_
159-5	28777-28785	cortical	_
159-6	28786-28795	executive	_
159-7	28796-28803	control	_
159-8	28804-28811	regions	_
159-9	28812-28815	are	_
159-10	28816-28825	typically	_
159-11	28826-28837	interpreted	_
159-12	28838-28840	as	_
159-13	28841-28849	evidence	_
159-14	28850-28852	of	_
159-15	28853-28857	less	_
159-16	28858-28867	efficient	_
159-17	28868-28876	cortical	_
159-18	28877-28887	processing	_
159-19	28888-28891	and	_
159-20	28892-28897	where	_
159-21	28897-28898	,	_
159-22	28899-28901	in	_
159-23	28902-28910	contrast	_
159-24	28910-28911	,	_
159-25	28912-28919	reduced	_
159-26	28920-28930	activation	_
159-27	28931-28933	in	_
159-28	28934-28942	response	_
159-29	28943-28945	to	_
159-30	28946-28955	impulsive	_
159-31	28956-28962	errors	_
159-32	28963-28966	can	_
159-33	28967-28969	be	_
159-34	28970-28981	interpreted	_
159-35	28982-28984	as	_
159-36	28985-28992	blunted	_
159-37	28993-29002	awareness	_
159-38	29003-29005	of	_
159-39	29006-29012	errors	_
159-40	29013-29015	in	_
159-41	29016-29020	drug	_
159-42	29021-29026	users	_
159-43	29026-29027	.	_

#Text=Therefore, the lack of behavioral and brain main effects of regular light cannabis use may not generalize beyond young adult light-to-moderate users and may not apply to older cannabis users following decades of use.
160-1	29028-29037	Therefore	_
160-2	29037-29038	,	_
160-3	29039-29042	the	_
160-4	29043-29047	lack	_
160-5	29048-29050	of	_
160-6	29051-29061	behavioral	_
160-7	29062-29065	and	_
160-8	29066-29071	brain	_
160-9	29072-29076	main	_
160-10	29077-29084	effects	_
160-11	29085-29087	of	_
160-12	29088-29095	regular	_
160-13	29096-29101	light	_
160-14	29102-29110	cannabis	_
160-15	29111-29114	use	_
160-16	29115-29118	may	_
160-17	29119-29122	not	_
160-18	29123-29133	generalize	_
160-19	29134-29140	beyond	_
160-20	29141-29146	young	_
160-21	29147-29152	adult	_
160-22	29153-29170	light-to-moderate	_
160-23	29171-29176	users	_
160-24	29177-29180	and	_
160-25	29181-29184	may	_
160-26	29185-29188	not	_
160-27	29189-29194	apply	_
160-28	29195-29197	to	_
160-29	29198-29203	older	_
160-30	29204-29212	cannabis	_
160-31	29213-29218	users	_
160-32	29219-29228	following	_
160-33	29229-29236	decades	_
160-34	29237-29239	of	_
160-35	29240-29243	use	_
160-36	29243-29244	.	_

#Text=Finally, behavioral impairments from chronic cannabis use might be more evident in real-world situations that do not elicit unusual vigilance or attention.
#Text=5 Conclusions
#Text=This work has demonstrated clear inhibitory network differences between participants diagnosed during childhood with ADHD and a Local Normative Comparison Group.
161-1	29245-29252	Finally	_
161-2	29252-29253	,	_
161-3	29254-29264	behavioral	_
161-4	29265-29276	impairments	_
161-5	29277-29281	from	_
161-6	29282-29289	chronic	_
161-7	29290-29298	cannabis	_
161-8	29299-29302	use	_
161-9	29303-29308	might	_
161-10	29309-29311	be	_
161-11	29312-29316	more	_
161-12	29317-29324	evident	_
161-13	29325-29327	in	_
161-14	29328-29338	real-world	_
161-15	29339-29349	situations	_
161-16	29350-29354	that	_
161-17	29355-29357	do	_
161-18	29358-29361	not	_
161-19	29362-29368	elicit	_
161-20	29369-29376	unusual	_
161-21	29377-29386	vigilance	_
161-22	29387-29389	or	_
161-23	29390-29399	attention	_
161-24	29399-29400	.	_
161-25	29401-29402	5	_
161-26	29403-29414	Conclusions	_
161-27	29415-29419	This	_
161-28	29420-29424	work	_
161-29	29425-29428	has	_
161-30	29429-29441	demonstrated	_
161-31	29442-29447	clear	_
161-32	29448-29458	inhibitory	_
161-33	29459-29466	network	_
161-34	29467-29478	differences	_
161-35	29479-29486	between	_
161-36	29487-29499	participants	_
161-37	29500-29509	diagnosed	_
161-38	29510-29516	during	_
161-39	29517-29526	childhood	_
161-40	29527-29531	with	_
161-41	29532-29536	ADHD	_
161-42	29537-29540	and	_
161-43	29541-29542	a	_
161-44	29543-29548	Local	_
161-45	29549-29558	Normative	_
161-46	29559-29569	Comparison	_
161-47	29570-29575	Group	_
161-48	29575-29576	.	_

#Text=Two regions of the endocannabinoid system, the hippocampus and cerebellar vermis, have been identified as being uniquely influenced by an interaction between cannabis use and the altered brain circuitry of ADHD diagnosed individuals.
162-1	29577-29580	Two	_
162-2	29581-29588	regions	_
162-3	29589-29591	of	_
162-4	29592-29595	the	_
162-5	29596-29611	endocannabinoid	_
162-6	29612-29618	system	_
162-7	29618-29619	,	_
162-8	29620-29623	the	_
162-9	29624-29635	hippocampus	_
162-10	29636-29639	and	_
162-11	29640-29650	cerebellar	_
162-12	29651-29657	vermis	_
162-13	29657-29658	,	_
162-14	29659-29663	have	_
162-15	29664-29668	been	_
162-16	29669-29679	identified	_
162-17	29680-29682	as	_
162-18	29683-29688	being	_
162-19	29689-29697	uniquely	_
162-20	29698-29708	influenced	_
162-21	29709-29711	by	_
162-22	29712-29714	an	_
162-23	29715-29726	interaction	_
162-24	29727-29734	between	_
162-25	29735-29743	cannabis	_
162-26	29744-29747	use	_
162-27	29748-29751	and	_
162-28	29752-29755	the	_
162-29	29756-29763	altered	_
162-30	29764-29769	brain	_
162-31	29770-29779	circuitry	_
162-32	29780-29782	of	_
162-33	29783-29787	ADHD	_
162-34	29788-29797	diagnosed	_
162-35	29798-29809	individuals	_
162-36	29809-29810	.	_

#Text=Future studies targeting hippocampal and cerebellar-dependent function in these groups may provide further insight into how this circuitry is altered by comorbid ADHD and cannabis use.
163-1	29811-29817	Future	_
163-2	29818-29825	studies	_
163-3	29826-29835	targeting	_
163-4	29836-29847	hippocampal	_
163-5	29848-29851	and	_
163-6	29852-29872	cerebellar-dependent	_
163-7	29873-29881	function	_
163-8	29882-29884	in	_
163-9	29885-29890	these	_
163-10	29891-29897	groups	_
163-11	29898-29901	may	_
163-12	29902-29909	provide	_
163-13	29910-29917	further	_
163-14	29918-29925	insight	_
163-15	29926-29930	into	_
163-16	29931-29934	how	_
163-17	29935-29939	this	_
163-18	29940-29949	circuitry	_
163-19	29950-29952	is	_
163-20	29953-29960	altered	_
163-21	29961-29963	by	_
163-22	29964-29972	comorbid	_
163-23	29973-29977	ADHD	_
163-24	29978-29981	and	_
163-25	29982-29990	cannabis	_
163-26	29991-29994	use	_
163-27	29994-29995	.	_

#Text=Supplementary Material
#Text=Portions of this work were presented as a poster at the International Society for Magnetic Resonance Imaging in Medicine, Salt Lake City, USA 2013.
164-1	29996-30009	Supplementary	_
164-2	30010-30018	Material	_
164-3	30019-30027	Portions	_
164-4	30028-30030	of	_
164-5	30031-30035	this	_
164-6	30036-30040	work	_
164-7	30041-30045	were	_
164-8	30046-30055	presented	_
164-9	30056-30058	as	_
164-10	30059-30060	a	_
164-11	30061-30067	poster	_
164-12	30068-30070	at	_
164-13	30071-30074	the	_
164-14	30075-30088	International	_
164-15	30089-30096	Society	_
164-16	30097-30100	for	_
164-17	30101-30109	Magnetic	_
164-18	30110-30119	Resonance	_
164-19	30120-30127	Imaging	_
164-20	30128-30130	in	_
164-21	30131-30139	Medicine	_
164-22	30139-30140	,	_
164-23	30141-30145	Salt	_
164-24	30146-30150	Lake	_
164-25	30151-30155	City	_
164-26	30155-30156	,	_
164-27	30157-30160	USA	_
164-28	30161-30165	2013	_
164-29	30165-30166	.	_

#Text=Informed Consent         
#Text=All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, and the applicable revisions at the time of the investigation.
165-1	30178-30186	Informed	_
165-2	30187-30194	Consent	_
165-3	30204-30207	All	_
165-4	30208-30218	procedures	_
165-5	30219-30227	followed	_
165-6	30228-30232	were	_
165-7	30233-30235	in	_
165-8	30236-30246	accordance	_
165-9	30247-30251	with	_
165-10	30252-30255	the	_
165-11	30256-30263	ethical	_
165-12	30264-30273	standards	_
165-13	30274-30276	of	_
165-14	30277-30280	the	_
165-15	30281-30292	responsible	_
165-16	30293-30302	committee	_
165-17	30303-30305	on	_
165-18	30306-30311	human	_
165-19	30312-30327	experimentation	_
165-20	30328-30329	(	_
165-21	30329-30342	institutional	_
165-22	30343-30346	and	_
165-23	30347-30355	national	_
165-24	30355-30356	)	_
165-25	30357-30360	and	_
165-26	30361-30365	with	_
165-27	30366-30369	the	_
165-28	30370-30378	Helsinki	_
165-29	30379-30390	Declaration	_
165-30	30391-30393	of	_
165-31	30394-30398	1975	_
165-32	30398-30399	,	_
165-33	30400-30403	and	_
165-34	30404-30407	the	_
165-35	30408-30418	applicable	_
165-36	30419-30428	revisions	_
165-37	30429-30431	at	_
165-38	30432-30435	the	_
165-39	30436-30440	time	_
165-40	30441-30443	of	_
165-41	30444-30447	the	_
165-42	30448-30461	investigation	_
165-43	30461-30462	.	_

#Text=Informed consent was obtained from all patients for being included in the study.
166-1	30463-30471	Informed	_
166-2	30472-30479	consent	_
166-3	30480-30483	was	_
166-4	30484-30492	obtained	_
166-5	30493-30497	from	_
166-6	30498-30501	all	_
166-7	30502-30510	patients	_
166-8	30511-30514	for	_
166-9	30515-30520	being	_
166-10	30521-30529	included	_
166-11	30530-30532	in	_
166-12	30533-30536	the	_
166-13	30537-30542	study	_
166-14	30542-30543	.	_

#Text=Financial Disclosures         
#Text=Dr.
167-1	30555-30564	Financial	_
167-2	30565-30576	Disclosures	_
167-3	30586-30588	Dr	_
167-4	30588-30589	.	_

#Text=Arnold has received research funding from CureMark, Fore-str, Lilly, and Shire, advisory board honoraria from Biomarin, Novartis, Noven, Roche, Seaside Therapeutics, and Shire, consulting fees from Tris Pharma, and travel support from Noven.
168-1	30590-30596	Arnold	_
168-2	30597-30600	has	_
168-3	30601-30609	received	_
168-4	30610-30618	research	_
168-5	30619-30626	funding	_
168-6	30627-30631	from	_
168-7	30632-30640	CureMark	_
168-8	30640-30641	,	_
168-9	30642-30650	Fore-str	_
168-10	30650-30651	,	_
168-11	30652-30657	Lilly	_
168-12	30657-30658	,	_
168-13	30659-30662	and	_
168-14	30663-30668	Shire	_
168-15	30668-30669	,	_
168-16	30670-30678	advisory	_
168-17	30679-30684	board	_
168-18	30685-30694	honoraria	_
168-19	30695-30699	from	_
168-20	30700-30708	Biomarin	_
168-21	30708-30709	,	_
168-22	30710-30718	Novartis	_
168-23	30718-30719	,	_
168-24	30720-30725	Noven	_
168-25	30725-30726	,	_
168-26	30727-30732	Roche	_
168-27	30732-30733	,	_
168-28	30734-30741	Seaside	_
168-29	30742-30754	Therapeutics	_
168-30	30754-30755	,	_
168-31	30756-30759	and	_
168-32	30760-30765	Shire	_
168-33	30765-30766	,	_
168-34	30767-30777	consulting	_
168-35	30778-30782	fees	_
168-36	30783-30787	from	_
168-37	30788-30792	Tris	_
168-38	30793-30799	Pharma	_
168-39	30799-30800	,	_
168-40	30801-30804	and	_
168-41	30805-30811	travel	_
168-42	30812-30819	support	_
168-43	30820-30824	from	_
168-44	30825-30830	Noven	_
168-45	30830-30831	.	_

#Text=Dr.
169-1	30832-30834	Dr	_
169-2	30834-30835	.	_

#Text=Swanson has received research support from Alza, Richwood, Shire, Celgene, Novartis, Celltech, Gliatech, Cephalon, Watson, CIBA, Janssen, and McNeil; has been on the advisory board for Alza, Rich-wood, Shire, Celgene, Novartis, Celltech, UCB, Gliatech, Cephalon, McNeil, and Lilly; has been on speaker’s bureau for Alza, Shire, Novartis, Celltech, UCB, Cephalon, CIBA, Janssen, and McNeil; and has consulted to Alza, Richwood, Shire, Celgene, Novartis, Celltech, UCB, Gliatech, Cephalon, Watson, CIBA, Janssen, McNeil, and Lilly.
170-1	30836-30843	Swanson	_
170-2	30844-30847	has	_
170-3	30848-30856	received	_
170-4	30857-30865	research	_
170-5	30866-30873	support	_
170-6	30874-30878	from	_
170-7	30879-30883	Alza	_
170-8	30883-30884	,	_
170-9	30885-30893	Richwood	_
170-10	30893-30894	,	_
170-11	30895-30900	Shire	_
170-12	30900-30901	,	_
170-13	30902-30909	Celgene	_
170-14	30909-30910	,	_
170-15	30911-30919	Novartis	_
170-16	30919-30920	,	_
170-17	30921-30929	Celltech	_
170-18	30929-30930	,	_
170-19	30931-30939	Gliatech	_
170-20	30939-30940	,	_
170-21	30941-30949	Cephalon	_
170-22	30949-30950	,	_
170-23	30951-30957	Watson	_
170-24	30957-30958	,	_
170-25	30959-30963	CIBA	_
170-26	30963-30964	,	_
170-27	30965-30972	Janssen	_
170-28	30972-30973	,	_
170-29	30974-30977	and	_
170-30	30978-30984	McNeil	_
170-31	30984-30985	;	_
170-32	30986-30989	has	_
170-33	30990-30994	been	_
170-34	30995-30997	on	_
170-35	30998-31001	the	_
170-36	31002-31010	advisory	_
170-37	31011-31016	board	_
170-38	31017-31020	for	_
170-39	31021-31025	Alza	_
170-40	31025-31026	,	_
170-41	31027-31036	Rich-wood	_
170-42	31036-31037	,	_
170-43	31038-31043	Shire	_
170-44	31043-31044	,	_
170-45	31045-31052	Celgene	_
170-46	31052-31053	,	_
170-47	31054-31062	Novartis	_
170-48	31062-31063	,	_
170-49	31064-31072	Celltech	_
170-50	31072-31073	,	_
170-51	31074-31077	UCB	_
170-52	31077-31078	,	_
170-53	31079-31087	Gliatech	_
170-54	31087-31088	,	_
170-55	31089-31097	Cephalon	_
170-56	31097-31098	,	_
170-57	31099-31105	McNeil	_
170-58	31105-31106	,	_
170-59	31107-31110	and	_
170-60	31111-31116	Lilly	_
170-61	31116-31117	;	_
170-62	31118-31121	has	_
170-63	31122-31126	been	_
170-64	31127-31129	on	_
170-65	31130-31137	speaker	_
170-66	31137-31138	’	_
170-67	31138-31139	s	_
170-68	31140-31146	bureau	_
170-69	31147-31150	for	_
170-70	31151-31155	Alza	_
170-71	31155-31156	,	_
170-72	31157-31162	Shire	_
170-73	31162-31163	,	_
170-74	31164-31172	Novartis	_
170-75	31172-31173	,	_
170-76	31174-31182	Celltech	_
170-77	31182-31183	,	_
170-78	31184-31187	UCB	_
170-79	31187-31188	,	_
170-80	31189-31197	Cephalon	_
170-81	31197-31198	,	_
170-82	31199-31203	CIBA	_
170-83	31203-31204	,	_
170-84	31205-31212	Janssen	_
170-85	31212-31213	,	_
170-86	31214-31217	and	_
170-87	31218-31224	McNeil	_
170-88	31224-31225	;	_
170-89	31226-31229	and	_
170-90	31230-31233	has	_
170-91	31234-31243	consulted	_
170-92	31244-31246	to	_
170-93	31247-31251	Alza	_
170-94	31251-31252	,	_
170-95	31253-31261	Richwood	_
170-96	31261-31262	,	_
170-97	31263-31268	Shire	_
170-98	31268-31269	,	_
170-99	31270-31277	Celgene	_
170-100	31277-31278	,	_
170-101	31279-31287	Novartis	_
170-102	31287-31288	,	_
170-103	31289-31297	Celltech	_
170-104	31297-31298	,	_
170-105	31299-31302	UCB	_
170-106	31302-31303	,	_
170-107	31304-31312	Gliatech	_
170-108	31312-31313	,	_
170-109	31314-31322	Cephalon	_
170-110	31322-31323	,	_
170-111	31324-31330	Watson	_
170-112	31330-31331	,	_
170-113	31332-31336	CIBA	_
170-114	31336-31337	,	_
170-115	31338-31345	Janssen	_
170-116	31345-31346	,	_
170-117	31347-31353	McNeil	_
170-118	31353-31354	,	_
170-119	31355-31358	and	_
170-120	31359-31364	Lilly	_
170-121	31364-31365	.	_

#Text=Dr. van Erp has been a consultant for Roche Pharmaceuticals.
171-1	31366-31368	Dr	_
171-2	31368-31369	.	_
171-3	31370-31373	van	_
171-4	31374-31377	Erp	_
171-5	31378-31381	has	_
171-6	31382-31386	been	_
171-7	31387-31388	a	_
171-8	31389-31399	consultant	_
171-9	31400-31403	for	_
171-10	31404-31409	Roche	_
171-11	31410-31425	Pharmaceuticals	_
171-12	31425-31426	.	_

#Text=Dr.
172-1	31427-31429	Dr	_
172-2	31429-31430	.	_

#Text=Mathalon is a consultant for Bristol-Myers Squibb and has consulted for Roche Pharmaceuticals.
173-1	31431-31439	Mathalon	_
173-2	31440-31442	is	_
173-3	31443-31444	a	_
173-4	31445-31455	consultant	_
173-5	31456-31459	for	_
173-6	31460-31473	Bristol-Myers	_
173-7	31474-31480	Squibb	_
173-8	31481-31484	and	_
173-9	31485-31488	has	_
173-10	31489-31498	consulted	_
173-11	31499-31502	for	_
173-12	31503-31508	Roche	_
173-13	31509-31524	Pharmaceuticals	_
173-14	31524-31525	.	_

#Text=Dr.
174-1	31526-31528	Dr	_
174-2	31528-31529	.	_

#Text=Potkin’s work has been funded by the NIH.
175-1	31530-31536	Potkin	_
175-2	31536-31537	’	_
175-3	31537-31538	s	_
175-4	31539-31543	work	_
175-5	31544-31547	has	_
175-6	31548-31552	been	_
175-7	31553-31559	funded	_
175-8	31560-31562	by	_
175-9	31563-31566	the	_
175-10	31567-31570	NIH	_
175-11	31570-31571	.	_

#Text=Dr.
176-1	31572-31574	Dr	_
176-2	31574-31575	.	_

#Text=Potkin has received grant support, funding, honoraria, or has been a paid consultant to the following companies that conducted scientific or medical research and/or marketed medications related to psychiatric and neurodegenerative disorders: Alkermes, Eli Lilly, FORUM, Genentech, Janssen, Lundbeck, Merck, Novartis, Otsuka, Roche, Sunovion, Takeda, Toyama, and Vanda.
177-1	31576-31582	Potkin	_
177-2	31583-31586	has	_
177-3	31587-31595	received	_
177-4	31596-31601	grant	_
177-5	31602-31609	support	_
177-6	31609-31610	,	_
177-7	31611-31618	funding	_
177-8	31618-31619	,	_
177-9	31620-31629	honoraria	_
177-10	31629-31630	,	_
177-11	31631-31633	or	_
177-12	31634-31637	has	_
177-13	31638-31642	been	_
177-14	31643-31644	a	_
177-15	31645-31649	paid	_
177-16	31650-31660	consultant	_
177-17	31661-31663	to	_
177-18	31664-31667	the	_
177-19	31668-31677	following	_
177-20	31678-31687	companies	_
177-21	31688-31692	that	_
177-22	31693-31702	conducted	_
177-23	31703-31713	scientific	_
177-24	31714-31716	or	_
177-25	31717-31724	medical	_
177-26	31725-31733	research	_
177-27	31734-31737	and	_
177-28	31737-31738	/	_
177-29	31738-31740	or	_
177-30	31741-31749	marketed	_
177-31	31750-31761	medications	_
177-32	31762-31769	related	_
177-33	31770-31772	to	_
177-34	31773-31784	psychiatric	_
177-35	31785-31788	and	_
177-36	31789-31806	neurodegenerative	_
177-37	31807-31816	disorders	_
177-38	31816-31817	:	_
177-39	31818-31826	Alkermes	_
177-40	31826-31827	,	_
177-41	31828-31831	Eli	_
177-42	31832-31837	Lilly	_
177-43	31837-31838	,	_
177-44	31839-31844	FORUM	_
177-45	31844-31845	,	_
177-46	31846-31855	Genentech	_
177-47	31855-31856	,	_
177-48	31857-31864	Janssen	_
177-49	31864-31865	,	_
177-50	31866-31874	Lundbeck	_
177-51	31874-31875	,	_
177-52	31876-31881	Merck	_
177-53	31881-31882	,	_
177-54	31883-31891	Novartis	_
177-55	31891-31892	,	_
177-56	31893-31899	Otsuka	_
177-57	31899-31900	,	_
177-58	31901-31906	Roche	_
177-59	31906-31907	,	_
177-60	31908-31916	Sunovion	_
177-61	31916-31917	,	_
177-62	31918-31924	Takeda	_
177-63	31924-31925	,	_
177-64	31926-31932	Toyama	_
177-65	31932-31933	,	_
177-66	31934-31937	and	_
177-67	31938-31943	Vanda	_
177-68	31943-31944	.	_

#Text=The remaining authors report no biomedical financial interests or potential conflicts of interest.
178-1	31945-31948	The	_
178-2	31949-31958	remaining	_
178-3	31959-31966	authors	_
178-4	31967-31973	report	_
178-5	31974-31976	no	_
178-6	31977-31987	biomedical	_
178-7	31988-31997	financial	_
178-8	31998-32007	interests	_
178-9	32008-32010	or	_
178-10	32011-32020	potential	_
178-11	32021-32030	conflicts	_
178-12	32031-32033	of	_
178-13	32034-32042	interest	_
178-14	32042-32043	.	_

#Text=Medial temporal structures and memory functions in adolescents with heavy cannabis use
#Text=
#Text=Structural and functional imaging studies in chronic cannabis users: A systematic review of adolescent and adult findings
#Text=Chronic cannabis users show altered neurophysiological functioning on Stroop task conflict resolution
#Text=The functional neuroanatomical correlates of response variability: evidence from a response inhibition task
#Text=Dopaminergic function in cannabis users and its relationship to cannabis-induced psychotic symptoms
#Text=Neural basis of Δ-9-Tetrahydrocannabinol and Cannabidiol: Effects during response inhibition
#Text=Anterior Cingulate Cortex and Response Conflict: Effects of Frequency, Inhibition and Errors
#Text=Review of the validity and significance of cannabis withdrawal syndrome
#Text=From behavior to cognition to the brain and back: what have we learned from functional imaging studies of attention deficit hyperactivity disorder?
179-1	32044-32050	Medial	_
179-2	32051-32059	temporal	_
179-3	32060-32070	structures	_
179-4	32071-32074	and	_
179-5	32075-32081	memory	_
179-6	32082-32091	functions	_
179-7	32092-32094	in	_
179-8	32095-32106	adolescents	_
179-9	32107-32111	with	_
179-10	32112-32117	heavy	_
179-11	32118-32126	cannabis	_
179-12	32127-32130	use	_
179-13	32132-32142	Structural	_
179-14	32143-32146	and	_
179-15	32147-32157	functional	_
179-16	32158-32165	imaging	_
179-17	32166-32173	studies	_
179-18	32174-32176	in	_
179-19	32177-32184	chronic	_
179-20	32185-32193	cannabis	_
179-21	32194-32199	users	_
179-22	32199-32200	:	_
179-23	32201-32202	A	_
179-24	32203-32213	systematic	_
179-25	32214-32220	review	_
179-26	32221-32223	of	_
179-27	32224-32234	adolescent	_
179-28	32235-32238	and	_
179-29	32239-32244	adult	_
179-30	32245-32253	findings	_
179-31	32254-32261	Chronic	_
179-32	32262-32270	cannabis	_
179-33	32271-32276	users	_
179-34	32277-32281	show	_
179-35	32282-32289	altered	_
179-36	32290-32308	neurophysiological	_
179-37	32309-32320	functioning	_
179-38	32321-32323	on	_
179-39	32324-32330	Stroop	_
179-40	32331-32335	task	_
179-41	32336-32344	conflict	_
179-42	32345-32355	resolution	_
179-43	32356-32359	The	_
179-44	32360-32370	functional	_
179-45	32371-32386	neuroanatomical	_
179-46	32387-32397	correlates	_
179-47	32398-32400	of	_
179-48	32401-32409	response	_
179-49	32410-32421	variability	_
179-50	32421-32422	:	_
179-51	32423-32431	evidence	_
179-52	32432-32436	from	_
179-53	32437-32438	a	_
179-54	32439-32447	response	_
179-55	32448-32458	inhibition	_
179-56	32459-32463	task	_
179-57	32464-32476	Dopaminergic	_
179-58	32477-32485	function	_
179-59	32486-32488	in	_
179-60	32489-32497	cannabis	_
179-61	32498-32503	users	_
179-62	32504-32507	and	_
179-63	32508-32511	its	_
179-64	32512-32524	relationship	_
179-65	32525-32527	to	_
179-66	32528-32544	cannabis-induced	_
179-67	32545-32554	psychotic	_
179-68	32555-32563	symptoms	_
179-69	32564-32570	Neural	_
179-70	32571-32576	basis	_
179-71	32577-32579	of	_
179-72	32580-32581	Δ	_
179-73	32581-32582	-	_
179-74	32582-32583	9	_
179-75	32583-32584	-	_
179-76	32584-32604	Tetrahydrocannabinol	_
179-77	32605-32608	and	_
179-78	32609-32620	Cannabidiol	_
179-79	32620-32621	:	_
179-80	32622-32629	Effects	_
179-81	32630-32636	during	_
179-82	32637-32645	response	_
179-83	32646-32656	inhibition	_
179-84	32657-32665	Anterior	_
179-85	32666-32675	Cingulate	_
179-86	32676-32682	Cortex	_
179-87	32683-32686	and	_
179-88	32687-32695	Response	_
179-89	32696-32704	Conflict	_
179-90	32704-32705	:	_
179-91	32706-32713	Effects	_
179-92	32714-32716	of	_
179-93	32717-32726	Frequency	_
179-94	32726-32727	,	_
179-95	32728-32738	Inhibition	_
179-96	32739-32742	and	_
179-97	32743-32749	Errors	_
179-98	32750-32756	Review	_
179-99	32757-32759	of	_
179-100	32760-32763	the	_
179-101	32764-32772	validity	_
179-102	32773-32776	and	_
179-103	32777-32789	significance	_
179-104	32790-32792	of	_
179-105	32793-32801	cannabis	_
179-106	32802-32812	withdrawal	_
179-107	32813-32821	syndrome	_
179-108	32822-32826	From	_
179-109	32827-32835	behavior	_
179-110	32836-32838	to	_
179-111	32839-32848	cognition	_
179-112	32849-32851	to	_
179-113	32852-32855	the	_
179-114	32856-32861	brain	_
179-115	32862-32865	and	_
179-116	32866-32870	back	_
179-117	32870-32871	:	_
179-118	32872-32876	what	_
179-119	32877-32881	have	_
179-120	32882-32884	we	_
179-121	32885-32892	learned	_
179-122	32893-32897	from	_
179-123	32898-32908	functional	_
179-124	32909-32916	imaging	_
179-125	32917-32924	studies	_
179-126	32925-32927	of	_
179-127	32928-32937	attention	_
179-128	32938-32945	deficit	_
179-129	32946-32959	hyperactivity	_
179-130	32960-32968	disorder	_
179-131	32968-32969	?	_

#Text=Large-scale brain systems in ADHD: beyond the prefrontal–striatal model
#Text=Disrupted ‘reflection’ impulsivity in cannabis users but not current or former ecstasy users
#Text=Grey matter alterations associated with cannabis use: Results of a VBM study in heavy cannabis users and healthy controls
#Text=Have we been asking the right questions when assessing response inhibition in go/no-go tasks with fMRI?
180-1	32970-32981	Large-scale	_
180-2	32982-32987	brain	_
180-3	32988-32995	systems	_
180-4	32996-32998	in	_
180-5	32999-33003	ADHD	_
180-6	33003-33004	:	_
180-7	33005-33011	beyond	_
180-8	33012-33015	the	_
180-9	33016-33035	prefrontal–striatal	_
180-10	33036-33041	model	_
180-11	33042-33051	Disrupted	_
180-12	33052-33053	‘	_
180-13	33053-33063	reflection	_
180-14	33063-33064	’	_
180-15	33065-33076	impulsivity	_
180-16	33077-33079	in	_
180-17	33080-33088	cannabis	_
180-18	33089-33094	users	_
180-19	33095-33098	but	_
180-20	33099-33102	not	_
180-21	33103-33110	current	_
180-22	33111-33113	or	_
180-23	33114-33120	former	_
180-24	33121-33128	ecstasy	_
180-25	33129-33134	users	_
180-26	33135-33139	Grey	_
180-27	33140-33146	matter	_
180-28	33147-33158	alterations	_
180-29	33159-33169	associated	_
180-30	33170-33174	with	_
180-31	33175-33183	cannabis	_
180-32	33184-33187	use	_
180-33	33187-33188	:	_
180-34	33189-33196	Results	_
180-35	33197-33199	of	_
180-36	33200-33201	a	_
180-37	33202-33205	VBM	_
180-38	33206-33211	study	_
180-39	33212-33214	in	_
180-40	33215-33220	heavy	_
180-41	33221-33229	cannabis	_
180-42	33230-33235	users	_
180-43	33236-33239	and	_
180-44	33240-33247	healthy	_
180-45	33248-33256	controls	_
180-46	33257-33261	Have	_
180-47	33262-33264	we	_
180-48	33265-33269	been	_
180-49	33270-33276	asking	_
180-50	33277-33280	the	_
180-51	33281-33286	right	_
180-52	33287-33296	questions	_
180-53	33297-33301	when	_
180-54	33302-33311	assessing	_
180-55	33312-33320	response	_
180-56	33321-33331	inhibition	_
180-57	33332-33334	in	_
180-58	33335-33337	go	_
180-59	33337-33338	/	_
180-60	33338-33343	no-go	_
180-61	33344-33349	tasks	_
180-62	33350-33354	with	_
180-63	33355-33359	fMRI	_
180-64	33359-33360	?	_

#Text=A meta-analysis and critical review
#Text=Toward systems neuroscience of ADHD: A meta-analysis of 55 fMRI studies
#Text=The neural correlates of attention deficit hyperactivity disorder: an ALE meta-analysis
#Text=Impulsivity, attention, memory, and decision-making among adolescent marijuana users
#Text=Differential patterns of striatal activation in young children with and without ADHD
#Text=Function biomedical informatics research network recommendations for prospective multicenter functional MRI studies
#Text=Performance of young adult cannabis users on neurocognitive measures of impulsive behavior and their relationship to symptoms of cannabis use disorders
#Text=Meta-analysis of functional magnetic resonance imaging studies of inhibition and attention in Attention-deficit/Hyperactivity Disorder
#Text=Impaired error awareness and anterior cingulate cortex hypoactivity in chronic cannabis users
#Text=Behavioral Disinhibition and the Development of early-onset addiction: Common and specific influences
#Text=FSL
#Text=Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic- and antidepressant-like effects
#Text=Prospective association of childhood attention-deficit/hyperactivity disorder (ADHD) and substance use and abuse/dependence: A meta-analytic review
#Text=Mean response times, variability, and skew in the responding of ADHD children: a response time distributional approach
#Text=Executive functioning in adult ADHD: a meta-analytic review
#Text=Neuroimaging in cannabis use: a systematic review of the literature
#Text=Altered brain tissue composition in heavy marijuana users
#Text=Effects of THC on Behavioral Measures of Impulsivity in Humans
#Text=Brain activation, response inhibition, and increased risk for substance use disorder
#Text=The MTA at 8 years: Prospective follow-up of children treated for Combined-Type ADHD in a multisite study
#Text=Attention-Deficit/Hyperactivity Disorder and risk of substance use disorder: Developmental considerations, potential pathways, and opportunities for research
#Text=Impulsivity differences in recreational cannabis users and binge drinkers in a university population
#Text=Deficits in learning and memory: Parahippocampal hyperactivity and frontocortical hypoactivity in cannabis users
#Text=An fMRI study of the effects of psychostimulants on Default-Mode processing during Stroop task performance in youths with ADHD
#Text=Is moderate substance use associated with altered executive functioning in a population-based sample of young adults?
181-1	33361-33362	A	_
181-2	33363-33376	meta-analysis	_
181-3	33377-33380	and	_
181-4	33381-33389	critical	_
181-5	33390-33396	review	_
181-6	33397-33403	Toward	_
181-7	33404-33411	systems	_
181-8	33412-33424	neuroscience	_
181-9	33425-33427	of	_
181-10	33428-33432	ADHD	_
181-11	33432-33433	:	_
181-12	33434-33435	A	_
181-13	33436-33449	meta-analysis	_
181-14	33450-33452	of	_
181-15	33453-33455	55	_
181-16	33456-33460	fMRI	_
181-17	33461-33468	studies	_
181-18	33469-33472	The	_
181-19	33473-33479	neural	_
181-20	33480-33490	correlates	_
181-21	33491-33493	of	_
181-22	33494-33503	attention	_
181-23	33504-33511	deficit	_
181-24	33512-33525	hyperactivity	_
181-25	33526-33534	disorder	_
181-26	33534-33535	:	_
181-27	33536-33538	an	_
181-28	33539-33542	ALE	_
181-29	33543-33556	meta-analysis	_
181-30	33557-33568	Impulsivity	_
181-31	33568-33569	,	_
181-32	33570-33579	attention	_
181-33	33579-33580	,	_
181-34	33581-33587	memory	_
181-35	33587-33588	,	_
181-36	33589-33592	and	_
181-37	33593-33608	decision-making	_
181-38	33609-33614	among	_
181-39	33615-33625	adolescent	_
181-40	33626-33635	marijuana	_
181-41	33636-33641	users	_
181-42	33642-33654	Differential	_
181-43	33655-33663	patterns	_
181-44	33664-33666	of	_
181-45	33667-33675	striatal	_
181-46	33676-33686	activation	_
181-47	33687-33689	in	_
181-48	33690-33695	young	_
181-49	33696-33704	children	_
181-50	33705-33709	with	_
181-51	33710-33713	and	_
181-52	33714-33721	without	_
181-53	33722-33726	ADHD	_
181-54	33727-33735	Function	_
181-55	33736-33746	biomedical	_
181-56	33747-33758	informatics	_
181-57	33759-33767	research	_
181-58	33768-33775	network	_
181-59	33776-33791	recommendations	_
181-60	33792-33795	for	_
181-61	33796-33807	prospective	_
181-62	33808-33819	multicenter	_
181-63	33820-33830	functional	_
181-64	33831-33834	MRI	_
181-65	33835-33842	studies	_
181-66	33843-33854	Performance	_
181-67	33855-33857	of	_
181-68	33858-33863	young	_
181-69	33864-33869	adult	_
181-70	33870-33878	cannabis	_
181-71	33879-33884	users	_
181-72	33885-33887	on	_
181-73	33888-33902	neurocognitive	_
181-74	33903-33911	measures	_
181-75	33912-33914	of	_
181-76	33915-33924	impulsive	_
181-77	33925-33933	behavior	_
181-78	33934-33937	and	_
181-79	33938-33943	their	_
181-80	33944-33956	relationship	_
181-81	33957-33959	to	_
181-82	33960-33968	symptoms	_
181-83	33969-33971	of	_
181-84	33972-33980	cannabis	_
181-85	33981-33984	use	_
181-86	33985-33994	disorders	_
181-87	33995-34008	Meta-analysis	_
181-88	34009-34011	of	_
181-89	34012-34022	functional	_
181-90	34023-34031	magnetic	_
181-91	34032-34041	resonance	_
181-92	34042-34049	imaging	_
181-93	34050-34057	studies	_
181-94	34058-34060	of	_
181-95	34061-34071	inhibition	_
181-96	34072-34075	and	_
181-97	34076-34085	attention	_
181-98	34086-34088	in	_
181-99	34089-34106	Attention-deficit	_
181-100	34106-34107	/	_
181-101	34107-34120	Hyperactivity	_
181-102	34121-34129	Disorder	_
181-103	34130-34138	Impaired	_
181-104	34139-34144	error	_
181-105	34145-34154	awareness	_
181-106	34155-34158	and	_
181-107	34159-34167	anterior	_
181-108	34168-34177	cingulate	_
181-109	34178-34184	cortex	_
181-110	34185-34197	hypoactivity	_
181-111	34198-34200	in	_
181-112	34201-34208	chronic	_
181-113	34209-34217	cannabis	_
181-114	34218-34223	users	_
181-115	34224-34234	Behavioral	_
181-116	34235-34248	Disinhibition	_
181-117	34249-34252	and	_
181-118	34253-34256	the	_
181-119	34257-34268	Development	_
181-120	34269-34271	of	_
181-121	34272-34283	early-onset	_
181-122	34284-34293	addiction	_
181-123	34293-34294	:	_
181-124	34295-34301	Common	_
181-125	34302-34305	and	_
181-126	34306-34314	specific	_
181-127	34315-34325	influences	_
181-128	34326-34329	FSL	_
181-129	34330-34342	Cannabinoids	_
181-130	34343-34350	promote	_
181-131	34351-34360	embryonic	_
181-132	34361-34364	and	_
181-133	34365-34370	adult	_
181-134	34371-34382	hippocampus	_
181-135	34383-34395	neurogenesis	_
181-136	34396-34399	and	_
181-137	34400-34407	produce	_
181-138	34408-34418	anxiolytic	_
181-139	34418-34419	-	_
181-140	34420-34423	and	_
181-141	34424-34443	antidepressant-like	_
181-142	34444-34451	effects	_
181-143	34452-34463	Prospective	_
181-144	34464-34475	association	_
181-145	34476-34478	of	_
181-146	34479-34488	childhood	_
181-147	34489-34506	attention-deficit	_
181-148	34506-34507	/	_
181-149	34507-34520	hyperactivity	_
181-150	34521-34529	disorder	_
181-151	34530-34531	(	_
181-152	34531-34535	ADHD	_
181-153	34535-34536	)	_
181-154	34537-34540	and	_
181-155	34541-34550	substance	_
181-156	34551-34554	use	_
181-157	34555-34558	and	_
181-158	34559-34564	abuse	_
181-159	34564-34565	/	_
181-160	34565-34575	dependence	_
181-161	34575-34576	:	_
181-162	34577-34578	A	_
181-163	34579-34592	meta-analytic	_
181-164	34593-34599	review	_
181-165	34600-34604	Mean	_
181-166	34605-34613	response	_
181-167	34614-34619	times	_
181-168	34619-34620	,	_
181-169	34621-34632	variability	_
181-170	34632-34633	,	_
181-171	34634-34637	and	_
181-172	34638-34642	skew	_
181-173	34643-34645	in	_
181-174	34646-34649	the	_
181-175	34650-34660	responding	_
181-176	34661-34663	of	_
181-177	34664-34668	ADHD	_
181-178	34669-34677	children	_
181-179	34677-34678	:	_
181-180	34679-34680	a	_
181-181	34681-34689	response	_
181-182	34690-34694	time	_
181-183	34695-34709	distributional	_
181-184	34710-34718	approach	_
181-185	34719-34728	Executive	_
181-186	34729-34740	functioning	_
181-187	34741-34743	in	_
181-188	34744-34749	adult	_
181-189	34750-34754	ADHD	_
181-190	34754-34755	:	_
181-191	34756-34757	a	_
181-192	34758-34771	meta-analytic	_
181-193	34772-34778	review	_
181-194	34779-34791	Neuroimaging	_
181-195	34792-34794	in	_
181-196	34795-34803	cannabis	_
181-197	34804-34807	use	_
181-198	34807-34808	:	_
181-199	34809-34810	a	_
181-200	34811-34821	systematic	_
181-201	34822-34828	review	_
181-202	34829-34831	of	_
181-203	34832-34835	the	_
181-204	34836-34846	literature	_
181-205	34847-34854	Altered	_
181-206	34855-34860	brain	_
181-207	34861-34867	tissue	_
181-208	34868-34879	composition	_
181-209	34880-34882	in	_
181-210	34883-34888	heavy	_
181-211	34889-34898	marijuana	_
181-212	34899-34904	users	_
181-213	34905-34912	Effects	_
181-214	34913-34915	of	_
181-215	34916-34919	THC	_
181-216	34920-34922	on	_
181-217	34923-34933	Behavioral	_
181-218	34934-34942	Measures	_
181-219	34943-34945	of	_
181-220	34946-34957	Impulsivity	_
181-221	34958-34960	in	_
181-222	34961-34967	Humans	_
181-223	34968-34973	Brain	_
181-224	34974-34984	activation	_
181-225	34984-34985	,	_
181-226	34986-34994	response	_
181-227	34995-35005	inhibition	_
181-228	35005-35006	,	_
181-229	35007-35010	and	_
181-230	35011-35020	increased	_
181-231	35021-35025	risk	_
181-232	35026-35029	for	_
181-233	35030-35039	substance	_
181-234	35040-35043	use	_
181-235	35044-35052	disorder	_
181-236	35053-35056	The	_
181-237	35057-35060	MTA	_
181-238	35061-35063	at	_
181-239	35064-35065	8	_
181-240	35066-35071	years	_
181-241	35071-35072	:	_
181-242	35073-35084	Prospective	_
181-243	35085-35094	follow-up	_
181-244	35095-35097	of	_
181-245	35098-35106	children	_
181-246	35107-35114	treated	_
181-247	35115-35118	for	_
181-248	35119-35132	Combined-Type	_
181-249	35133-35137	ADHD	_
181-250	35138-35140	in	_
181-251	35141-35142	a	_
181-252	35143-35152	multisite	_
181-253	35153-35158	study	_
181-254	35159-35176	Attention-Deficit	_
181-255	35176-35177	/	_
181-256	35177-35190	Hyperactivity	_
181-257	35191-35199	Disorder	_
181-258	35200-35203	and	_
181-259	35204-35208	risk	_
181-260	35209-35211	of	_
181-261	35212-35221	substance	_
181-262	35222-35225	use	_
181-263	35226-35234	disorder	_
181-264	35234-35235	:	_
181-265	35236-35249	Developmental	_
181-266	35250-35264	considerations	_
181-267	35264-35265	,	_
181-268	35266-35275	potential	_
181-269	35276-35284	pathways	_
181-270	35284-35285	,	_
181-271	35286-35289	and	_
181-272	35290-35303	opportunities	_
181-273	35304-35307	for	_
181-274	35308-35316	research	_
181-275	35317-35328	Impulsivity	_
181-276	35329-35340	differences	_
181-277	35341-35343	in	_
181-278	35344-35356	recreational	_
181-279	35357-35365	cannabis	_
181-280	35366-35371	users	_
181-281	35372-35375	and	_
181-282	35376-35381	binge	_
181-283	35382-35390	drinkers	_
181-284	35391-35393	in	_
181-285	35394-35395	a	_
181-286	35396-35406	university	_
181-287	35407-35417	population	_
181-288	35418-35426	Deficits	_
181-289	35427-35429	in	_
181-290	35430-35438	learning	_
181-291	35439-35442	and	_
181-292	35443-35449	memory	_
181-293	35449-35450	:	_
181-294	35451-35466	Parahippocampal	_
181-295	35467-35480	hyperactivity	_
181-296	35481-35484	and	_
181-297	35485-35499	frontocortical	_
181-298	35500-35512	hypoactivity	_
181-299	35513-35515	in	_
181-300	35516-35524	cannabis	_
181-301	35525-35530	users	_
181-302	35531-35533	An	_
181-303	35534-35538	fMRI	_
181-304	35539-35544	study	_
181-305	35545-35547	of	_
181-306	35548-35551	the	_
181-307	35552-35559	effects	_
181-308	35560-35562	of	_
181-309	35563-35579	psychostimulants	_
181-310	35580-35582	on	_
181-311	35583-35595	Default-Mode	_
181-312	35596-35606	processing	_
181-313	35607-35613	during	_
181-314	35614-35620	Stroop	_
181-315	35621-35625	task	_
181-316	35626-35637	performance	_
181-317	35638-35640	in	_
181-318	35641-35647	youths	_
181-319	35648-35652	with	_
181-320	35653-35657	ADHD	_
181-321	35658-35660	Is	_
181-322	35661-35669	moderate	_
181-323	35670-35679	substance	_
181-324	35680-35683	use	_
181-325	35684-35694	associated	_
181-326	35695-35699	with	_
181-327	35700-35707	altered	_
181-328	35708-35717	executive	_
181-329	35718-35729	functioning	_
181-330	35730-35732	in	_
181-331	35733-35734	a	_
181-332	35735-35751	population-based	_
181-333	35752-35758	sample	_
181-334	35759-35761	of	_
181-335	35762-35767	young	_
181-336	35768-35774	adults	_
181-337	35774-35775	?	_

#Text=Evidence of increased activation underlying cognitive control in ecstasy and cannabis users
#Text=Linear age-correlated functional development of right inferior fronto-striato-cerebellar networks during response inhibition and anterior cingulate during error-related processes
#Text=Effects of age and gender on neural networks of motor response inhibition: From adolescence to mid-adulthood
#Text=Attention-deficit/hyperactivity disorder is characterized by a delay in cortical maturation
#Text=Deficient response inhibition as a cognitive endophenotype of ADHD
#Text=Impact of marijuana on response inhibition: An fMRI study in young adults
#Text=Frontostriatal maturation predicts cognitive control failure to appetitive cues in adolescents
#Text=Impact of ADHD and cannabis use on executive functioning in young adults
#Text=Functional MRI of inhibitory processing in abstinent adolescent marijuana users
#Text=The dopamine and cannabinoid interaction in the modulation of emotions and cognition: assessing the role of cannabinoid CB1 receptor in neurons expressing dopamine D1 receptors
#Text=The NimStim set of facial expressions: Judgments from untrained research participants
#Text=Behavioural and biochemical evidence for interactions between h9-tetrahydrocannabinol and nicotine
#Text=Drug-related decrease in neuropsychological functions of abstinent drug users
#Text=A general statistical analysis for fMRI data
#Text=The organization of the human cerebral cortex estimated by intrinsic functional connectivity
#Text=In-scanner behavioral performance
#Text=A main effect of ADHD diagnosis was observed with a higher likelihood of false positives associated with ADHD (left, p<.05), irrespective of cannabis use history.
182-1	35776-35784	Evidence	_
182-2	35785-35787	of	_
182-3	35788-35797	increased	_
182-4	35798-35808	activation	_
182-5	35809-35819	underlying	_
182-6	35820-35829	cognitive	_
182-7	35830-35837	control	_
182-8	35838-35840	in	_
182-9	35841-35848	ecstasy	_
182-10	35849-35852	and	_
182-11	35853-35861	cannabis	_
182-12	35862-35867	users	_
182-13	35868-35874	Linear	_
182-14	35875-35889	age-correlated	_
182-15	35890-35900	functional	_
182-16	35901-35912	development	_
182-17	35913-35915	of	_
182-18	35916-35921	right	_
182-19	35922-35930	inferior	_
182-20	35931-35956	fronto-striato-cerebellar	_
182-21	35957-35965	networks	_
182-22	35966-35972	during	_
182-23	35973-35981	response	_
182-24	35982-35992	inhibition	_
182-25	35993-35996	and	_
182-26	35997-36005	anterior	_
182-27	36006-36015	cingulate	_
182-28	36016-36022	during	_
182-29	36023-36036	error-related	_
182-30	36037-36046	processes	_
182-31	36047-36054	Effects	_
182-32	36055-36057	of	_
182-33	36058-36061	age	_
182-34	36062-36065	and	_
182-35	36066-36072	gender	_
182-36	36073-36075	on	_
182-37	36076-36082	neural	_
182-38	36083-36091	networks	_
182-39	36092-36094	of	_
182-40	36095-36100	motor	_
182-41	36101-36109	response	_
182-42	36110-36120	inhibition	_
182-43	36120-36121	:	_
182-44	36122-36126	From	_
182-45	36127-36138	adolescence	_
182-46	36139-36141	to	_
182-47	36142-36155	mid-adulthood	_
182-48	36156-36173	Attention-deficit	_
182-49	36173-36174	/	_
182-50	36174-36187	hyperactivity	_
182-51	36188-36196	disorder	_
182-52	36197-36199	is	_
182-53	36200-36213	characterized	_
182-54	36214-36216	by	_
182-55	36217-36218	a	_
182-56	36219-36224	delay	_
182-57	36225-36227	in	_
182-58	36228-36236	cortical	_
182-59	36237-36247	maturation	_
182-60	36248-36257	Deficient	_
182-61	36258-36266	response	_
182-62	36267-36277	inhibition	_
182-63	36278-36280	as	_
182-64	36281-36282	a	_
182-65	36283-36292	cognitive	_
182-66	36293-36306	endophenotype	_
182-67	36307-36309	of	_
182-68	36310-36314	ADHD	_
182-69	36315-36321	Impact	_
182-70	36322-36324	of	_
182-71	36325-36334	marijuana	_
182-72	36335-36337	on	_
182-73	36338-36346	response	_
182-74	36347-36357	inhibition	_
182-75	36357-36358	:	_
182-76	36359-36361	An	_
182-77	36362-36366	fMRI	_
182-78	36367-36372	study	_
182-79	36373-36375	in	_
182-80	36376-36381	young	_
182-81	36382-36388	adults	_
182-82	36389-36403	Frontostriatal	_
182-83	36404-36414	maturation	_
182-84	36415-36423	predicts	_
182-85	36424-36433	cognitive	_
182-86	36434-36441	control	_
182-87	36442-36449	failure	_
182-88	36450-36452	to	_
182-89	36453-36463	appetitive	_
182-90	36464-36468	cues	_
182-91	36469-36471	in	_
182-92	36472-36483	adolescents	_
182-93	36484-36490	Impact	_
182-94	36491-36493	of	_
182-95	36494-36498	ADHD	_
182-96	36499-36502	and	_
182-97	36503-36511	cannabis	_
182-98	36512-36515	use	_
182-99	36516-36518	on	_
182-100	36519-36528	executive	_
182-101	36529-36540	functioning	_
182-102	36541-36543	in	_
182-103	36544-36549	young	_
182-104	36550-36556	adults	_
182-105	36557-36567	Functional	_
182-106	36568-36571	MRI	_
182-107	36572-36574	of	_
182-108	36575-36585	inhibitory	_
182-109	36586-36596	processing	_
182-110	36597-36599	in	_
182-111	36600-36609	abstinent	_
182-112	36610-36620	adolescent	_
182-113	36621-36630	marijuana	_
182-114	36631-36636	users	_
182-115	36637-36640	The	_
182-116	36641-36649	dopamine	_
182-117	36650-36653	and	_
182-118	36654-36665	cannabinoid	_
182-119	36666-36677	interaction	_
182-120	36678-36680	in	_
182-121	36681-36684	the	_
182-122	36685-36695	modulation	_
182-123	36696-36698	of	_
182-124	36699-36707	emotions	_
182-125	36708-36711	and	_
182-126	36712-36721	cognition	_
182-127	36721-36722	:	_
182-128	36723-36732	assessing	_
182-129	36733-36736	the	_
182-130	36737-36741	role	_
182-131	36742-36744	of	_
182-132	36745-36756	cannabinoid	_
182-133	36757-36760	CB1	_
182-134	36761-36769	receptor	_
182-135	36770-36772	in	_
182-136	36773-36780	neurons	_
182-137	36781-36791	expressing	_
182-138	36792-36800	dopamine	_
182-139	36801-36803	D1	_
182-140	36804-36813	receptors	_
182-141	36814-36817	The	_
182-142	36818-36825	NimStim	_
182-143	36826-36829	set	_
182-144	36830-36832	of	_
182-145	36833-36839	facial	_
182-146	36840-36851	expressions	_
182-147	36851-36852	:	_
182-148	36853-36862	Judgments	_
182-149	36863-36867	from	_
182-150	36868-36877	untrained	_
182-151	36878-36886	research	_
182-152	36887-36899	participants	_
182-153	36900-36911	Behavioural	_
182-154	36912-36915	and	_
182-155	36916-36927	biochemical	_
182-156	36928-36936	evidence	_
182-157	36937-36940	for	_
182-158	36941-36953	interactions	_
182-159	36954-36961	between	_
182-160	36962-36964	h9	_
182-161	36964-36965	-	_
182-162	36965-36985	tetrahydrocannabinol	_
182-163	36986-36989	and	_
182-164	36990-36998	nicotine	_
182-165	36999-37011	Drug-related	_
182-166	37012-37020	decrease	_
182-167	37021-37023	in	_
182-168	37024-37042	neuropsychological	_
182-169	37043-37052	functions	_
182-170	37053-37055	of	_
182-171	37056-37065	abstinent	_
182-172	37066-37070	drug	_
182-173	37071-37076	users	_
182-174	37077-37078	A	_
182-175	37079-37086	general	_
182-176	37087-37098	statistical	_
182-177	37099-37107	analysis	_
182-178	37108-37111	for	_
182-179	37112-37116	fMRI	_
182-180	37117-37121	data	_
182-181	37122-37125	The	_
182-182	37126-37138	organization	_
182-183	37139-37141	of	_
182-184	37142-37145	the	_
182-185	37146-37151	human	_
182-186	37152-37160	cerebral	_
182-187	37161-37167	cortex	_
182-188	37168-37177	estimated	_
182-189	37178-37180	by	_
182-190	37181-37190	intrinsic	_
182-191	37191-37201	functional	_
182-192	37202-37214	connectivity	_
182-193	37215-37225	In-scanner	_
182-194	37226-37236	behavioral	_
182-195	37237-37248	performance	_
182-196	37249-37250	A	_
182-197	37251-37255	main	_
182-198	37256-37262	effect	_
182-199	37263-37265	of	_
182-200	37266-37270	ADHD	_
182-201	37271-37280	diagnosis	_
182-202	37281-37284	was	_
182-203	37285-37293	observed	_
182-204	37294-37298	with	_
182-205	37299-37300	a	_
182-206	37301-37307	higher	_
182-207	37308-37318	likelihood	_
182-208	37319-37321	of	_
182-209	37322-37327	false	_
182-210	37328-37337	positives	_
182-211	37338-37348	associated	_
182-212	37349-37353	with	_
182-213	37354-37358	ADHD	_
182-214	37359-37360	(	_
182-215	37360-37364	left	_
182-216	37364-37365	,	_
182-217	37366-37367	p	_
182-218	37367-37368	<	_
182-219	37368-37371	.05	_
182-220	37371-37372	)	_
182-221	37372-37373	,	_
182-222	37374-37386	irrespective	_
182-223	37387-37389	of	_
182-224	37390-37398	cannabis	_
182-225	37399-37402	use	_
182-226	37403-37410	history	_
182-227	37410-37411	.	_

#Text=Main effect of ADHD diagnosis during an inhibition (NoGo>Go) task
#Text=Cortical network differences are primarily right lateralized and include frontal and parietal regions, which are reduced in subjects with history of childhood ADHD.
183-1	37412-37416	Main	_
183-2	37417-37423	effect	_
183-3	37424-37426	of	_
183-4	37427-37431	ADHD	_
183-5	37432-37441	diagnosis	_
183-6	37442-37448	during	_
183-7	37449-37451	an	_
183-8	37452-37462	inhibition	_
183-9	37463-37464	(	_
183-10	37464-37468	NoGo	_
183-11	37468-37469	>	_
183-12	37469-37471	Go	_
183-13	37471-37472	)	_
183-14	37473-37477	task	_
183-15	37478-37486	Cortical	_
183-16	37487-37494	network	_
183-17	37495-37506	differences	_
183-18	37507-37510	are	_
183-19	37511-37520	primarily	_
183-20	37521-37526	right	_
183-21	37527-37538	lateralized	_
183-22	37539-37542	and	_
183-23	37543-37550	include	_
183-24	37551-37558	frontal	_
183-25	37559-37562	and	_
183-26	37563-37571	parietal	_
183-27	37572-37579	regions	_
183-28	37579-37580	,	_
183-29	37581-37586	which	_
183-30	37587-37590	are	_
183-31	37591-37598	reduced	_
183-32	37599-37601	in	_
183-33	37602-37610	subjects	_
183-34	37611-37615	with	_
183-35	37616-37623	history	_
183-36	37624-37626	of	_
183-37	37627-37636	childhood	_
183-38	37637-37641	ADHD	_
183-39	37641-37642	.	_

#Text=No regions of activation were significantly greater in ADHD than LNCG subjects.
184-1	37643-37645	No	_
184-2	37646-37653	regions	_
184-3	37654-37656	of	_
184-4	37657-37667	activation	_
184-5	37668-37672	were	_
184-6	37673-37686	significantly	_
184-7	37687-37694	greater	_
184-8	37695-37697	in	_
184-9	37698-37702	ADHD	_
184-10	37703-37707	than	_
184-11	37708-37712	LNCG	_
184-12	37713-37721	subjects	_
184-13	37721-37722	.	_

#Text=Main effect of ADHD diagnosis: group map and anatomically defined subcortical ROI boxplot
#Text=Significant clusters of hypoactivation in ADHD subcortical cortices include right caudate, thalamus and accumbens (left).
185-1	37723-37727	Main	_
185-2	37728-37734	effect	_
185-3	37735-37737	of	_
185-4	37738-37742	ADHD	_
185-5	37743-37752	diagnosis	_
185-6	37752-37753	:	_
185-7	37754-37759	group	_
185-8	37760-37763	map	_
185-9	37764-37767	and	_
185-10	37768-37780	anatomically	_
185-11	37781-37788	defined	_
185-12	37789-37800	subcortical	_
185-13	37801-37804	ROI	_
185-14	37805-37812	boxplot	_
185-15	37813-37824	Significant	_
185-16	37825-37833	clusters	_
185-17	37834-37836	of	_
185-18	37837-37851	hypoactivation	_
185-19	37852-37854	in	_
185-20	37855-37859	ADHD	_
185-21	37860-37871	subcortical	_
185-22	37872-37880	cortices	_
185-23	37881-37888	include	_
185-24	37889-37894	right	_
185-25	37895-37902	caudate	_
185-26	37902-37903	,	_
185-27	37904-37912	thalamus	_
185-28	37913-37916	and	_
185-29	37917-37926	accumbens	_
185-30	37927-37928	(	_
185-31	37928-37932	left	_
185-32	37932-37933	)	_
185-33	37933-37934	.	_

#Text=Further native space analyses confirmed right caudate hypoactivation in ADHD (right) participants along with right putamen and left pallidum.
186-1	37935-37942	Further	_
186-2	37943-37949	native	_
186-3	37950-37955	space	_
186-4	37956-37964	analyses	_
186-5	37965-37974	confirmed	_
186-6	37975-37980	right	_
186-7	37981-37988	caudate	_
186-8	37989-38003	hypoactivation	_
186-9	38004-38006	in	_
186-10	38007-38011	ADHD	_
186-11	38012-38013	(	_
186-12	38013-38018	right	_
186-13	38018-38019	)	_
186-14	38020-38032	participants	_
186-15	38033-38038	along	_
186-16	38039-38043	with	_
186-17	38044-38049	right	_
186-18	38050-38057	putamen	_
186-19	38058-38061	and	_
186-20	38062-38066	left	_
186-21	38067-38075	pallidum	_
186-22	38075-38076	.	_

#Text=Interaction effects of cannabis use and ADHD diagnosis
#Text=Significant regions of marijuana use by ADHD diagnosis interaction effects included right hippocampus, right cerebellum/vermis and lingual gyrus.
187-1	38077-38088	Interaction	_
187-2	38089-38096	effects	_
187-3	38097-38099	of	_
187-4	38100-38108	cannabis	_
187-5	38109-38112	use	_
187-6	38113-38116	and	_
187-7	38117-38121	ADHD	_
187-8	38122-38131	diagnosis	_
187-9	38132-38143	Significant	_
187-10	38144-38151	regions	_
187-11	38152-38154	of	_
187-12	38155-38164	marijuana	_
187-13	38165-38168	use	_
187-14	38169-38171	by	_
187-15	38172-38176	ADHD	_
187-16	38177-38186	diagnosis	_
187-17	38187-38198	interaction	_
187-18	38199-38206	effects	_
187-19	38207-38215	included	_
187-20	38216-38221	right	_
187-21	38222-38233	hippocampus	_
187-22	38233-38234	,	_
187-23	38235-38240	right	_
187-24	38241-38251	cerebellum	_
187-25	38251-38252	/	_
187-26	38252-38258	vermis	_
187-27	38259-38262	and	_
187-28	38263-38270	lingual	_
187-29	38271-38276	gyrus	_
187-30	38276-38277	.	_

#Text=Task Breakdown of Interaction Effects
#Text=Individually, ADHD and cannabis use both attenuate hippocampal and cerebellar deactivation NoGo>Go seen in “normal” controls (LNCG, non-users), but in combination, do not effect NoGo>Go activation.
188-1	38278-38282	Task	_
188-2	38283-38292	Breakdown	_
188-3	38293-38295	of	_
188-4	38296-38307	Interaction	_
188-5	38308-38315	Effects	_
188-6	38316-38328	Individually	_
188-7	38328-38329	,	_
188-8	38330-38334	ADHD	_
188-9	38335-38338	and	_
188-10	38339-38347	cannabis	_
188-11	38348-38351	use	_
188-12	38352-38356	both	_
188-13	38357-38366	attenuate	_
188-14	38367-38378	hippocampal	_
188-15	38379-38382	and	_
188-16	38383-38393	cerebellar	_
188-17	38394-38406	deactivation	_
188-18	38407-38411	NoGo	_
188-19	38411-38412	>	_
188-20	38412-38414	Go	_
188-21	38415-38419	seen	_
188-22	38420-38422	in	_
188-23	38423-38424	“	_
188-24	38424-38430	normal	_
188-25	38430-38431	”	_
188-26	38432-38440	controls	_
188-27	38441-38442	(	_
188-28	38442-38446	LNCG	_
188-29	38446-38447	,	_
188-30	38448-38457	non-users	_
188-31	38457-38458	)	_
188-32	38458-38459	,	_
188-33	38460-38463	but	_
188-34	38464-38466	in	_
188-35	38467-38478	combination	_
188-36	38478-38479	,	_
188-37	38480-38482	do	_
188-38	38483-38486	not	_
188-39	38487-38493	effect	_
188-40	38494-38498	NoGo	_
188-41	38498-38499	>	_
188-42	38499-38501	Go	_
188-43	38502-38512	activation	_
188-44	38512-38513	.	_

#Text=Interaction effects during inhibition are dominated by the NoGo condition.
189-1	38514-38525	Interaction	_
189-2	38526-38533	effects	_
189-3	38534-38540	during	_
189-4	38541-38551	inhibition	_
189-5	38552-38555	are	_
189-6	38556-38565	dominated	_
189-7	38566-38568	by	_
189-8	38569-38572	the	_
189-9	38573-38577	NoGo	_
189-10	38578-38587	condition	_
189-11	38587-38588	.	_

#Text=Baseline Demographics and Characteristics
#Text=\tADHDCannabis User (n=25)\tADHDCannabis Non- user (n=25)\tLNCGCannabis User (n=11)\tLNCGCannabis Non- user (n=12)\tOverall (n=73)\t \tGender\t \t Male, n (%)\t24 (96%)\t17 (68%)\t10 (91%)\t6 (50%)\t57 (78%)\t \tAge (yr)\t \t Mean (SD)\t24.6 (1.4)\t25 (1.2)\t24.2 (1.5)\t24.1 (1.0)\t24.6 (1.3)\t \tIQ\t \t Mean (SD)\t97.9 (11.5)\t106.3 (16.4)\t111.5 (21.2)\t107.1 (28.8)\t104.2 (18.6)\t \tSmoker\t \t Yes (>1/day), n (%)\t11 (44%)\t7 (28%)\t2 (18%)\t2 (17%)\t22 (30%)\t \tMedication Status\t \t On Medication, n (%)\t2 (8%)\t0 (0%)\tNA\tNA\tNA\t \tAge of First Cannabis Use (years)\t\t\t\t\t\t \t Mean (SD)\t15.8 (3.2)\tNA\t17.8 (3.0)\tNA\tNA\t \tCurrent Cannabis Use\t \t (≥ 1/day), n (%)\t14 (56%)\tNA\t5 (20%)\tNA\tNA\t \tDSM Diagnosis of Cannabis\t \t Abuse/Dependence, n (%)\t6/5 (24/20%)\tNA\t6/3 (55/27%)\tNA\tNA\t \tDSM Diagnosis of Alcohol\t \t Dependence, n (%)\t1 (4%)\t0 (0%)\t0 (0%)\t0 (0%)\t1 (1%)\t \tDSM Diagnosis of Nicotine\t\t\t\t\t\t \t Dependence, n (%)\t2 (8%)\t2 (8%)\t2 (18%)\t0 (0%)\t6 (8%)\t \t
#Text=Note: ADHD = Attention-deficit/hyperactivity disorder, LNCG = local normative control group, SD = standard deviation, NA = not applicable
#Text=Significant NoGo>Go Voxelwise Clusters of Activation
#Text=Region\tSide\tMNI Coordinates\tMaximum Z\t \tMain Effect LNCG>ADHD\t \t Supramarginal Gyrus, Superior Parietal, Angular Gyrus\tR\t(52,−40,54)\t4.73\t \t Middle Frontal Gyrus, Frontal Pole\tR\t(42,34,22)\t4.4\t \t Superior Parietal Lobe\tR\t(30,−46,42)\t4.39\t \t Middle Frontal Gyrus, Inferior Frontal Gyrus\tR\t(40,16,48)\t4.36\t \t Postcentral, Precentral Gyrus\tL\t(−18,−32,56)\t4.28\t \t Middle Frontal Gyrus, Precentral Gyrus\tR\t(40,2,56)\t4.16\t \t Posterior supramarginal gyrus\tR\t(52,−40,22)\t4.09\t \t Caudate/Accumbens\tR\t(12,22,−2)\t3.72\t \t Precuneus\tL\t(−4,−52,46)\t3.69\t \t Frontal Orbital Cortex, Frontal Pole\tR\t(24,32,−14)\t3.68\t \t Postcentral, Precentral Gyrus\tR\t(22,−32,70)\t3.63\t \t Superior Parietal Lobule\tL\t(−34,−54,46)\t3.61\t \t Precuneus\tR\t(8,−48,42)\t3.58\t \t Posterior Cingulate Gyrus\tR\t(2,−36,42)\t3.46\t \t Postcentral, Precentral Gyrus\tL\t(−42,−18,46)\t3.44\t \t Middle Frontal Gyrus, Inferior Frontal Gyrus\tL\t(−32,28,42)\t3.38\t \t Insula, Frontal Orbital Cortex\tR\t(32,24,−2)\t3.36\t \t Thalamus\tR\t(8,−6,8)\t3.32\t \tInteraction Effect Cannabis by Diagnosis\t \t Vermis VI, Cerebellum Vermis\tR\t(10,−58,−12)\t4.00\t \t Right Hippocampus\tR\t(32,−30,−8)\t3.60\t \t
#Text=Note: ADHD = Attention-deficit/hyperactivity disorder, LNCG = local normative control group, R = right, L = left
190-1	38589-38597	Baseline	_
190-2	38598-38610	Demographics	_
190-3	38611-38614	and	_
190-4	38615-38630	Characteristics	_
190-5	38632-38644	ADHDCannabis	_
190-6	38645-38649	User	_
190-7	38650-38651	(	_
190-8	38651-38652	n	_
190-9	38652-38653	=	_
190-10	38653-38655	25	_
190-11	38655-38656	)	_
190-12	38657-38669	ADHDCannabis	_
190-13	38670-38673	Non	_
190-14	38673-38674	-	_
190-15	38675-38679	user	_
190-16	38680-38681	(	_
190-17	38681-38682	n	_
190-18	38682-38683	=	_
190-19	38683-38685	25	_
190-20	38685-38686	)	_
190-21	38687-38699	LNCGCannabis	_
190-22	38700-38704	User	_
190-23	38705-38706	(	_
190-24	38706-38707	n	_
190-25	38707-38708	=	_
190-26	38708-38710	11	_
190-27	38710-38711	)	_
190-28	38712-38724	LNCGCannabis	_
190-29	38725-38728	Non	_
190-30	38728-38729	-	_
190-31	38730-38734	user	_
190-32	38735-38736	(	_
190-33	38736-38737	n	_
190-34	38737-38738	=	_
190-35	38738-38740	12	_
190-36	38740-38741	)	_
190-37	38742-38749	Overall	_
190-38	38750-38751	(	_
190-39	38751-38752	n	_
190-40	38752-38753	=	_
190-41	38753-38755	73	_
190-42	38755-38756	)	_
190-43	38759-38765	Gender	_
190-44	38769-38773	Male	_
190-45	38773-38774	,	_
190-46	38775-38776	n	_
190-47	38777-38778	(	_
190-48	38778-38779	%	_
190-49	38779-38780	)	_
190-50	38781-38783	24	_
190-51	38784-38785	(	_
190-52	38785-38788	96%	_
190-53	38788-38789	)	_
190-54	38790-38792	17	_
190-55	38793-38794	(	_
190-56	38794-38797	68%	_
190-57	38797-38798	)	_
190-58	38799-38801	10	_
190-59	38802-38803	(	_
190-60	38803-38806	91%	_
190-61	38806-38807	)	_
190-62	38808-38809	6	_
190-63	38810-38811	(	_
190-64	38811-38814	50%	_
190-65	38814-38815	)	_
190-66	38816-38818	57	_
190-67	38819-38820	(	_
190-68	38820-38823	78%	_
190-69	38823-38824	)	_
190-70	38827-38830	Age	_
190-71	38831-38832	(	_
190-72	38832-38834	yr	_
190-73	38834-38835	)	_
190-74	38839-38843	Mean	_
190-75	38844-38845	(	_
190-76	38845-38847	SD	_
190-77	38847-38848	)	_
190-78	38849-38853	24.6	_
190-79	38854-38855	(	_
190-80	38855-38858	1.4	_
190-81	38858-38859	)	_
190-82	38860-38862	25	_
190-83	38863-38864	(	_
190-84	38864-38867	1.2	_
190-85	38867-38868	)	_
190-86	38869-38873	24.2	_
190-87	38874-38875	(	_
190-88	38875-38878	1.5	_
190-89	38878-38879	)	_
190-90	38880-38884	24.1	_
190-91	38885-38886	(	_
190-92	38886-38889	1.0	_
190-93	38889-38890	)	_
190-94	38891-38895	24.6	_
190-95	38896-38897	(	_
190-96	38897-38900	1.3	_
190-97	38900-38901	)	_
190-98	38904-38906	IQ	_
190-99	38910-38914	Mean	_
190-100	38915-38916	(	_
190-101	38916-38918	SD	_
190-102	38918-38919	)	_
190-103	38920-38924	97.9	_
190-104	38925-38926	(	_
190-105	38926-38930	11.5	_
190-106	38930-38931	)	_
190-107	38932-38937	106.3	_
190-108	38938-38939	(	_
190-109	38939-38943	16.4	_
190-110	38943-38944	)	_
190-111	38945-38950	111.5	_
190-112	38951-38952	(	_
190-113	38952-38956	21.2	_
190-114	38956-38957	)	_
190-115	38958-38963	107.1	_
190-116	38964-38965	(	_
190-117	38965-38969	28.8	_
190-118	38969-38970	)	_
190-119	38971-38976	104.2	_
190-120	38977-38978	(	_
190-121	38978-38982	18.6	_
190-122	38982-38983	)	_
190-123	38986-38992	Smoker	_
190-124	38996-38999	Yes	_
190-125	39000-39001	(	_
190-126	39001-39002	>	_
190-127	39002-39003	1	_
190-128	39003-39004	/	_
190-129	39004-39007	day	_
190-130	39007-39008	)	_
190-131	39008-39009	,	_
190-132	39010-39011	n	_
190-133	39012-39013	(	_
190-134	39013-39014	%	_
190-135	39014-39015	)	_
190-136	39016-39018	11	_
190-137	39019-39020	(	_
190-138	39020-39023	44%	_
190-139	39023-39024	)	_
190-140	39025-39026	7	_
190-141	39027-39028	(	_
190-142	39028-39031	28%	_
190-143	39031-39032	)	_
190-144	39033-39034	2	_
190-145	39035-39036	(	_
190-146	39036-39039	18%	_
190-147	39039-39040	)	_
190-148	39041-39042	2	_
190-149	39043-39044	(	_
190-150	39044-39047	17%	_
190-151	39047-39048	)	_
190-152	39049-39051	22	_
190-153	39052-39053	(	_
190-154	39053-39056	30%	_
190-155	39056-39057	)	_
190-156	39060-39070	Medication	_
190-157	39071-39077	Status	_
190-158	39081-39083	On	_
190-159	39084-39094	Medication	_
190-160	39094-39095	,	_
190-161	39096-39097	n	_
190-162	39098-39099	(	_
190-163	39099-39100	%	_
190-164	39100-39101	)	_
190-165	39102-39103	2	_
190-166	39104-39105	(	_
190-167	39105-39107	8%	_
190-168	39107-39108	)	_
190-169	39109-39110	0	_
190-170	39111-39112	(	_
190-171	39112-39114	0%	_
190-172	39114-39115	)	_
190-173	39116-39118	NA	_
190-174	39119-39121	NA	_
190-175	39122-39124	NA	_
190-176	39127-39130	Age	_
190-177	39131-39133	of	_
190-178	39134-39139	First	_
190-179	39140-39148	Cannabis	_
190-180	39149-39152	Use	_
190-181	39153-39154	(	_
190-182	39154-39159	years	_
190-183	39159-39160	)	_
190-184	39169-39173	Mean	_
190-185	39174-39175	(	_
190-186	39175-39177	SD	_
190-187	39177-39178	)	_
190-188	39179-39183	15.8	_
190-189	39184-39185	(	_
190-190	39185-39188	3.2	_
190-191	39188-39189	)	_
190-192	39190-39192	NA	_
190-193	39193-39197	17.8	_
190-194	39198-39199	(	_
190-195	39199-39202	3.0	_
190-196	39202-39203	)	_
190-197	39204-39206	NA	_
190-198	39207-39209	NA	_
190-199	39212-39219	Current	_
190-200	39220-39228	Cannabis	_
190-201	39229-39232	Use	_
190-202	39236-39237	(	_
190-203	39237-39238	≥	_
190-204	39239-39240	1	_
190-205	39240-39241	/	_
190-206	39241-39244	day	_
190-207	39244-39245	)	_
190-208	39245-39246	,	_
190-209	39247-39248	n	_
190-210	39249-39250	(	_
190-211	39250-39251	%	_
190-212	39251-39252	)	_
190-213	39253-39255	14	_
190-214	39256-39257	(	_
190-215	39257-39260	56%	_
190-216	39260-39261	)	_
190-217	39262-39264	NA	_
190-218	39265-39266	5	_
190-219	39267-39268	(	_
190-220	39268-39271	20%	_
190-221	39271-39272	)	_
190-222	39273-39275	NA	_
190-223	39276-39278	NA	_
190-224	39281-39284	DSM	_
190-225	39285-39294	Diagnosis	_
190-226	39295-39297	of	_
190-227	39298-39306	Cannabis	_
190-228	39310-39315	Abuse	_
190-229	39315-39316	/	_
190-230	39316-39326	Dependence	_
190-231	39326-39327	,	_
190-232	39328-39329	n	_
190-233	39330-39331	(	_
190-234	39331-39332	%	_
190-235	39332-39333	)	_
190-236	39334-39335	6	_
190-237	39335-39336	/	_
190-238	39336-39337	5	_
190-239	39338-39339	(	_
190-240	39339-39341	24	_
190-241	39341-39342	/	_
190-242	39342-39345	20%	_
190-243	39345-39346	)	_
190-244	39347-39349	NA	_
190-245	39350-39351	6	_
190-246	39351-39352	/	_
190-247	39352-39353	3	_
190-248	39354-39355	(	_
190-249	39355-39357	55	_
190-250	39357-39358	/	_
190-251	39358-39361	27%	_
190-252	39361-39362	)	_
190-253	39363-39365	NA	_
190-254	39366-39368	NA	_
190-255	39371-39374	DSM	_
190-256	39375-39384	Diagnosis	_
190-257	39385-39387	of	_
190-258	39388-39395	Alcohol	_
190-259	39399-39409	Dependence	_
190-260	39409-39410	,	_
190-261	39411-39412	n	_
190-262	39413-39414	(	_
190-263	39414-39415	%	_
190-264	39415-39416	)	_
190-265	39417-39418	1	_
190-266	39419-39420	(	_
190-267	39420-39422	4%	_
190-268	39422-39423	)	_
190-269	39424-39425	0	_
190-270	39426-39427	(	_
190-271	39427-39429	0%	_
190-272	39429-39430	)	_
190-273	39431-39432	0	_
190-274	39433-39434	(	_
190-275	39434-39436	0%	_
190-276	39436-39437	)	_
190-277	39438-39439	0	_
190-278	39440-39441	(	_
190-279	39441-39443	0%	_
190-280	39443-39444	)	_
190-281	39445-39446	1	_
190-282	39447-39448	(	_
190-283	39448-39450	1%	_
190-284	39450-39451	)	_
190-285	39454-39457	DSM	_
190-286	39458-39467	Diagnosis	_
190-287	39468-39470	of	_
190-288	39471-39479	Nicotine	_
190-289	39488-39498	Dependence	_
190-290	39498-39499	,	_
190-291	39500-39501	n	_
190-292	39502-39503	(	_
190-293	39503-39504	%	_
190-294	39504-39505	)	_
190-295	39506-39507	2	_
190-296	39508-39509	(	_
190-297	39509-39511	8%	_
190-298	39511-39512	)	_
190-299	39513-39514	2	_
190-300	39515-39516	(	_
190-301	39516-39518	8%	_
190-302	39518-39519	)	_
190-303	39520-39521	2	_
190-304	39522-39523	(	_
190-305	39523-39526	18%	_
190-306	39526-39527	)	_
190-307	39528-39529	0	_
190-308	39530-39531	(	_
190-309	39531-39533	0%	_
190-310	39533-39534	)	_
190-311	39535-39536	6	_
190-312	39537-39538	(	_
190-313	39538-39540	8%	_
190-314	39540-39541	)	_
190-315	39545-39549	Note	_
190-316	39549-39550	:	_
190-317	39551-39555	ADHD	_
190-318	39556-39557	=	_
190-319	39558-39575	Attention-deficit	_
190-320	39575-39576	/	_
190-321	39576-39589	hyperactivity	_
190-322	39590-39598	disorder	_
190-323	39598-39599	,	_
190-324	39600-39604	LNCG	_
190-325	39605-39606	=	_
190-326	39607-39612	local	_
190-327	39613-39622	normative	_
190-328	39623-39630	control	_
190-329	39631-39636	group	_
190-330	39636-39637	,	_
190-331	39638-39640	SD	_
190-332	39641-39642	=	_
190-333	39643-39651	standard	_
190-334	39652-39661	deviation	_
190-335	39661-39662	,	_
190-336	39663-39665	NA	_
190-337	39666-39667	=	_
190-338	39668-39671	not	_
190-339	39672-39682	applicable	_
190-340	39683-39694	Significant	_
190-341	39695-39699	NoGo	_
190-342	39699-39700	>	_
190-343	39700-39702	Go	_
190-344	39703-39712	Voxelwise	_
190-345	39713-39721	Clusters	_
190-346	39722-39724	of	_
190-347	39725-39735	Activation	_
190-348	39736-39742	Region	_
190-349	39743-39747	Side	_
190-350	39748-39751	MNI	_
190-351	39752-39763	Coordinates	_
190-352	39764-39771	Maximum	_
190-353	39772-39773	Z	_
190-354	39776-39780	Main	_
190-355	39781-39787	Effect	_
190-356	39788-39792	LNCG	_
190-357	39792-39793	>	_
190-358	39793-39797	ADHD	_
190-359	39801-39814	Supramarginal	_
190-360	39815-39820	Gyrus	_
190-361	39820-39821	,	_
190-362	39822-39830	Superior	_
190-363	39831-39839	Parietal	_
190-364	39839-39840	,	_
190-365	39841-39848	Angular	_
190-366	39849-39854	Gyrus	_
190-367	39855-39856	R	_
190-368	39857-39858	(	_
190-369	39858-39860	52	_
190-370	39860-39861	,	_
190-371	39861-39862	−	_
190-372	39862-39867	40,54	_
190-373	39867-39868	)	_
190-374	39869-39873	4.73	_
190-375	39877-39883	Middle	_
190-376	39884-39891	Frontal	_
190-377	39892-39897	Gyrus	_
190-378	39897-39898	,	_
190-379	39899-39906	Frontal	_
190-380	39907-39911	Pole	_
190-381	39912-39913	R	_
190-382	39914-39915	(	_
190-383	39915-39923	42,34,22	_
190-384	39923-39924	)	_
190-385	39925-39928	4.4	_
190-386	39932-39940	Superior	_
190-387	39941-39949	Parietal	_
190-388	39950-39954	Lobe	_
190-389	39955-39956	R	_
190-390	39957-39958	(	_
190-391	39958-39960	30	_
190-392	39960-39961	,	_
190-393	39961-39962	−	_
190-394	39962-39967	46,42	_
190-395	39967-39968	)	_
190-396	39969-39973	4.39	_
190-397	39977-39983	Middle	_
190-398	39984-39991	Frontal	_
190-399	39992-39997	Gyrus	_
190-400	39997-39998	,	_
190-401	39999-40007	Inferior	_
190-402	40008-40015	Frontal	_
190-403	40016-40021	Gyrus	_
190-404	40022-40023	R	_
190-405	40024-40025	(	_
190-406	40025-40033	40,16,48	_
190-407	40033-40034	)	_
190-408	40035-40039	4.36	_
190-409	40043-40054	Postcentral	_
190-410	40054-40055	,	_
190-411	40056-40066	Precentral	_
190-412	40067-40072	Gyrus	_
190-413	40073-40074	L	_
190-414	40075-40076	(	_
190-415	40076-40077	−	_
190-416	40077-40079	18	_
190-417	40079-40080	,	_
190-418	40080-40081	−	_
190-419	40081-40086	32,56	_
190-420	40086-40087	)	_
190-421	40088-40092	4.28	_
190-422	40096-40102	Middle	_
190-423	40103-40110	Frontal	_
190-424	40111-40116	Gyrus	_
190-425	40116-40117	,	_
190-426	40118-40128	Precentral	_
190-427	40129-40134	Gyrus	_
190-428	40135-40136	R	_
190-429	40137-40138	(	_
190-430	40138-40145	40,2,56	_
190-431	40145-40146	)	_
190-432	40147-40151	4.16	_
190-433	40155-40164	Posterior	_
190-434	40165-40178	supramarginal	_
190-435	40179-40184	gyrus	_
190-436	40185-40186	R	_
190-437	40187-40188	(	_
190-438	40188-40190	52	_
190-439	40190-40191	,	_
190-440	40191-40192	−	_
190-441	40192-40197	40,22	_
190-442	40197-40198	)	_
190-443	40199-40203	4.09	_
190-444	40207-40214	Caudate	_
190-445	40214-40215	/	_
190-446	40215-40224	Accumbens	_
190-447	40225-40226	R	_
190-448	40227-40228	(	_
190-449	40228-40233	12,22	_
190-450	40233-40234	,	_
190-451	40234-40235	−	_
190-452	40235-40236	2	_
190-453	40236-40237	)	_
190-454	40238-40242	3.72	_
190-455	40246-40255	Precuneus	_
190-456	40256-40257	L	_
190-457	40258-40259	(	_
190-458	40259-40260	−	_
190-459	40260-40261	4	_
190-460	40261-40262	,	_
190-461	40262-40263	−	_
190-462	40263-40268	52,46	_
190-463	40268-40269	)	_
190-464	40270-40274	3.69	_
190-465	40278-40285	Frontal	_
190-466	40286-40293	Orbital	_
190-467	40294-40300	Cortex	_
190-468	40300-40301	,	_
190-469	40302-40309	Frontal	_
190-470	40310-40314	Pole	_
190-471	40315-40316	R	_
190-472	40317-40318	(	_
190-473	40318-40323	24,32	_
190-474	40323-40324	,	_
190-475	40324-40325	−	_
190-476	40325-40327	14	_
190-477	40327-40328	)	_
190-478	40329-40333	3.68	_
190-479	40337-40348	Postcentral	_
190-480	40348-40349	,	_
190-481	40350-40360	Precentral	_
190-482	40361-40366	Gyrus	_
190-483	40367-40368	R	_
190-484	40369-40370	(	_
190-485	40370-40372	22	_
190-486	40372-40373	,	_
190-487	40373-40374	−	_
190-488	40374-40379	32,70	_
190-489	40379-40380	)	_
190-490	40381-40385	3.63	_
190-491	40389-40397	Superior	_
190-492	40398-40406	Parietal	_
190-493	40407-40413	Lobule	_
190-494	40414-40415	L	_
190-495	40416-40417	(	_
190-496	40417-40418	−	_
190-497	40418-40420	34	_
190-498	40420-40421	,	_
190-499	40421-40422	−	_
190-500	40422-40427	54,46	_
190-501	40427-40428	)	_
190-502	40429-40433	3.61	_
190-503	40437-40446	Precuneus	_
190-504	40447-40448	R	_
190-505	40449-40450	(	_
190-506	40450-40451	8	_
190-507	40451-40452	,	_
190-508	40452-40453	−	_
190-509	40453-40458	48,42	_
190-510	40458-40459	)	_
190-511	40460-40464	3.58	_
190-512	40468-40477	Posterior	_
190-513	40478-40487	Cingulate	_
190-514	40488-40493	Gyrus	_
190-515	40494-40495	R	_
190-516	40496-40497	(	_
190-517	40497-40498	2	_
190-518	40498-40499	,	_
190-519	40499-40500	−	_
190-520	40500-40505	36,42	_
190-521	40505-40506	)	_
190-522	40507-40511	3.46	_
190-523	40515-40526	Postcentral	_
190-524	40526-40527	,	_
190-525	40528-40538	Precentral	_
190-526	40539-40544	Gyrus	_
190-527	40545-40546	L	_
190-528	40547-40548	(	_
190-529	40548-40549	−	_
190-530	40549-40551	42	_
190-531	40551-40552	,	_
190-532	40552-40553	−	_
190-533	40553-40558	18,46	_
190-534	40558-40559	)	_
190-535	40560-40564	3.44	_
190-536	40568-40574	Middle	_
190-537	40575-40582	Frontal	_
190-538	40583-40588	Gyrus	_
190-539	40588-40589	,	_
190-540	40590-40598	Inferior	_
190-541	40599-40606	Frontal	_
190-542	40607-40612	Gyrus	_
190-543	40613-40614	L	_
190-544	40615-40616	(	_
190-545	40616-40617	−	_
190-546	40617-40625	32,28,42	_
190-547	40625-40626	)	_
190-548	40627-40631	3.38	_
190-549	40635-40641	Insula	_
190-550	40641-40642	,	_
190-551	40643-40650	Frontal	_
190-552	40651-40658	Orbital	_
190-553	40659-40665	Cortex	_
190-554	40666-40667	R	_
190-555	40668-40669	(	_
190-556	40669-40674	32,24	_
190-557	40674-40675	,	_
190-558	40675-40676	−	_
190-559	40676-40677	2	_
190-560	40677-40678	)	_
190-561	40679-40683	3.36	_
190-562	40687-40695	Thalamus	_
190-563	40696-40697	R	_
190-564	40698-40699	(	_
190-565	40699-40700	8	_
190-566	40700-40701	,	_
190-567	40701-40702	−	_
190-568	40702-40705	6,8	_
190-569	40705-40706	)	_
190-570	40707-40711	3.32	_
190-571	40714-40725	Interaction	_
190-572	40726-40732	Effect	_
190-573	40733-40741	Cannabis	_
190-574	40742-40744	by	_
190-575	40745-40754	Diagnosis	_
190-576	40758-40764	Vermis	_
190-577	40765-40767	VI	_
190-578	40767-40768	,	_
190-579	40769-40779	Cerebellum	_
190-580	40780-40786	Vermis	_
190-581	40787-40788	R	_
190-582	40789-40790	(	_
190-583	40790-40792	10	_
190-584	40792-40793	,	_
190-585	40793-40794	−	_
190-586	40794-40796	58	_
190-587	40796-40797	,	_
190-588	40797-40798	−	_
190-589	40798-40800	12	_
190-590	40800-40801	)	_
190-591	40802-40806	4.00	_
190-592	40810-40815	Right	_
190-593	40816-40827	Hippocampus	_
190-594	40828-40829	R	_
190-595	40830-40831	(	_
190-596	40831-40833	32	_
190-597	40833-40834	,	_
190-598	40834-40835	−	_
190-599	40835-40837	30	_
190-600	40837-40838	,	_
190-601	40838-40839	−	_
190-602	40839-40840	8	_
190-603	40840-40841	)	_
190-604	40842-40846	3.60	_
190-605	40850-40854	Note	_
190-606	40854-40855	:	_
190-607	40856-40860	ADHD	_
190-608	40861-40862	=	_
190-609	40863-40880	Attention-deficit	_
190-610	40880-40881	/	_
190-611	40881-40894	hyperactivity	_
190-612	40895-40903	disorder	_
190-613	40903-40904	,	_
190-614	40905-40909	LNCG	_
190-615	40910-40911	=	_
190-616	40912-40917	local	_
190-617	40918-40927	normative	_
190-618	40928-40935	control	_
190-619	40936-40941	group	_
190-620	40941-40942	,	_
190-621	40943-40944	R	_
190-622	40945-40946	=	_
190-623	40947-40952	right	_
190-624	40952-40953	,	_
190-625	40954-40955	L	_
190-626	40956-40957	=	_
190-627	40958-40962	left	_
